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Abstract
Recognizing the cell-instructive capacity of tissue-specific extracellular matrix (ECM) to
direct cell attachment, proliferation and differentiation, there is a need for the development of
in vitro cell culture models that reflect the complexity of the ECM to improve
stem/progenitor cell expansion and lineage-commitment. This thesis focused on the
development and characterization of ECM-derived microcarriers for the in vitro dynamic
culture and expansion of stromal cells for cell therapy and tissue engineering applications.
To develop novel platforms for use in dynamic culture systems, initial work focused on
applying electrospraying techniques to fabricate microcarriers from decellularized dermal
tissue (DDT) and decellularized myocardial tissue (DMT) and compare their properties to
our previously-established decellularized adipose tissue (DAT) microcarriers. The soft and
compliant microcarriers comprised exclusively of ECM were stable over a range of
concentrations without the need for chemical crosslinking. The microcarriers were well
tolerated in vivo and supported the growth of tissue-specific stromal cell populations within
spinner flasks.
Recognizing the multilineage differentiation capacity of human adipose-derived stromal cells
(hASCs), as well as the potential for the ECM to provide cell-instructive cues that can direct
ASC differentiation, the effects of expanding hASCs on microcarriers derived from DAT
versus decellularized cartilage tissue (DCT) were explored. More specifically, novel DCT
microcarriers were fabricated and characterized. Both platforms supported hASC attachment
and growth over 2 weeks in spinner flasks under proliferation conditions, with PCR array and
global protein analyses suggesting that the DCT microcarriers may have predisposed the cells
towards the chondrogenic lineage.
Building on previous work, the final goal was to investigate the adipogenic differentiation of
hASCs cultured directly on DAT or DCT microcarriers within spinner flasks. Recognizing
that both the tissue-specific ECM composition and the dynamic culture conditions may
impact hASC differentiation, the hASC response was compared under varying stirring rates
(20 versus 40 rpm) and oxygen tensions (~20 % versus 2 % O2). While adipogenic gene
ii

expression

was

not

affected

by

the

dynamic

culture

conditions,

analysis

of

glycerol-3-phosphate dehydrogenase (GPDH) enzyme activity and intracellular lipid
accumulation supported that hASC adipogenesis was enhanced on the DAT microcarriers
cultured under ~20 % O2 and 20 rpm.
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Summary for Lay Audience
There has been increasing interest in using mesenchymal stromal cells (MSCs) for cell
therapy applications for a number of diseases and tissue regeneration strategies. The most
common MSC population can be obtained from the bone marrow but obtaining these cells
can be a painful process for patients and the frequency of these cells is low. Adipose tissue
(fat) provides an abundant and accessible alternative source of MSCs called adipose-derived
stromal cells (ASCs) that have the potential to differentiate into mature fat, cartilage and
bone cells.
In order to use these cells in human clinical therapies, it is estimated that million to billions
of cells will be needed per treatment, with the potential for multiple treatments required. This
presents a significant challenge in translating stem cell therapies because the conventional
methods used for expanding MSCs diminish their pro-regenerative properties and reduce
their capacity to differentiate. The goal of this project was to make novel platforms for
expanding cells within stirred bioreactor systems as an alternative approach that may better
preserve the regenerative capacity of the cells.
More specifically, proteins isolated from tissues discarded as surgical waste were used to
generate three-dimensional (3D) microcarriers that can support cell attachment and growth,
and potentially serve as injectable cell delivery platforms. Each tissue in our body has its own
unique protein composition and emerging research suggests that this tissue-specific
composition can direct the differentiation of MSC populations in culture. To explore this, the
work in this thesis aimed to develop and characterize novel microcarriers using proteins
isolated from fat, cartilage, heart, and skin, and explore their potential as platforms for cell
expansion or differentiation within a stirred bioreactor system. Long-term, this project aims
to develop a strategy to expand cell populations from small biopsies to obtain
clinically-relevant cell populations, and potentially use them as tissue-specific platforms to
deliver regenerative cells for a wide range of applications.
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Chapter 1
1 Literature Review
1.1 In vitro cell culture models
Conventional two-dimensional (2D) cell culture models have been widely used to aid in
the understanding of complex cellular physiology and how cells function and respond to
stimuli [1]. A major criticism of these studies is an assumption that human physiology
can be accurately represented using a cellular monolayer grown on a substrate of rigid
tissue culture plastic [2]. These 2D models underestimate the importance of the
extracellular matrix (ECM) found in native tissues. The ECM is a complex and dynamic
network of macromolecules present within all tissues, which provides essential physical
scaffolding for cells, as well as biochemical and biomechanical cues required for cell
survival, proliferation, and differentiation [3], [4]. Growing evidence suggests that the
ECM can have distinct tissue-specific effects on stem or progenitor cell proliferation
and/or differentiation [5]. The incorporation of tissue-specific ECM into threedimensional (3D) culture platforms may provide a better understanding of the importance
of these cell-ECM interactions and allow for the development of strategies that harness
the innate potential of the ECM to direct cell function.
When moving towards 3D bioscaffolds for in vitro cell culture, there are inherent
limitations with nutrient diffusion and waste removal when static culture methods are
applied, especially in the inner scaffold regions, which can be improved through dynamic
culture methods utilizing bioreactor systems [6]. There are numerous bioreactor types,
ranging from simple systems such as spinner flasks to more complex perfusion reactors,
which will be discussed in more detail in Section 1.9.1. In general, bioreactors should be
designed based on their target application, considering factors such as whether the cells
will grow in suspension or are adherent, and the required scale of manufacturing [7]. The
combination of ECM-derived biomaterials and dynamic culture methods may have the
potential to enhance cell survival and maintain cell phenotype, while expanding the cells
to obtain sufficient yields for cell therapies.
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1.2 The extracellular matrix
The acellular structural component of tissues in the body is predominantly comprised of a
complex protein-rich network known as the ECM. In addition to providing tissues with
structure, the ECM is responsible for regulating cell behaviour, affecting survival,
proliferation, migration and other functions including differentiation and protein secretion
[8]. The ECM also provides a reserve of sequestered growth factors that can be activated
or released upon specific stimuli, and subsequently, interact with cell-surface receptors to
modulate intracellular signaling [9]. Cells sense and respond to the ECM by secreting
and remodeling the environment, demonstrating the dynamic interrelationship between
cells and their surroundings [4]. The ECM consists of a large variety of matrix
macromolecules whose precise composition and specific organization varies from tissue
to tissue. The major constituents of the ECM include structural proteins such as collagens
and elastin, glycosaminoglycans and proteoglycans, and glycoproteins such as fibronectin
and laminins [10].

1.2.1

Collagens

Collagen is the most abundant protein in mammals and provides structural integrity,
strength, and stability to the ECM [11]. Collagen also plays an important role in
biological functions by influencing cellular activities such as attachment, viability,
growth and differentiation through receptor-mediated signaling [12]. A defining feature
of all collagens is a common structural motif: the right-handed triple helical structure
comprised of three α-chain subunits stabilized by hydrogen bonds [13]. The typical
primary structure of each α-chain consists of the repeated amino acid sequences glycineX-Y, where X and Y are most commonly proline and hydroxyproline residues,
respectively, possessing a left-handed coiled conformation [13]. Structurally, the small
glycine residues are positioned in the inner coil, while the larger proline and
hydroxyproline residues are positioned in the outer portions of the triple helix [14]. As a
result, steric repulsion between the pyrrolidine rings on the proline and hydroxyproline
residues enable stability by allowing tight twists in the molecule [15].
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A total of 28 different collagens have been identified to date and can be classified into
several subtypes: fibrillar (e.g. type I, II, III, V), network-forming or basement membrane
(e.g. type IV), fibril-associated collagens with interruptions in their triple helices
(FACIT) (e.g. type IX, XII, XIV), short chain collagens (e.g. type VIII, X), anchoring
fibrils (e.g. type VII), and membrane-type collagens [16]. Each type of collagen
possesses a unique amino acid sequence, structure, and functional features within specific
tissues [17]. For example, the fibrillar collagens are arranged in highly organized
aggregates crosslinked at the telopeptide regions by the enzyme lysyl oxidase [18]. Under
electron microscopy, the fibrils are defined by a characteristic banding pattern with a
periodicity of ~ 64-67 nm, based on the staggered arrangement of individual collagen
monomers [16]. This fibril formation imparts tensile strength to connective tissues that
are required to withstand mechanical stresses including tension, shear, and pressure [16].
The fibrillar collagen type I is the most abundant collagen in the body, as it forms more
than 90 % of the organic mass of bone and is the major collagen of tendons, skin,
ligaments, and cornea [16]. FACIT collagens closely interact with fibril-forming
collagens as they modulate the surface properties of fibrils, as well as fibril packing [17].
The structure of FACIT collagens is characterized by collagenous domains interrupted by
short non-helical and non-collagenous domains [15]. Collagen IV, a network-forming
collagen found in all mammalian basement membranes, assembles into mesh-works as a
result of its flexible triple helix structures, which interact with other components
including laminins and nidogens [16].

1.2.2

Elastin

Elastin is a major component of elastic fibers, which are an integral part of the ECM as
they provide structural support and elastic recoil required for the continuous mechanical
stretching and recovery of soft force-bearing tissues [19]. Tropoelastin is the soluble
monomer precursor of elastin that is secreted as a 60 kDa mature protein by diverse
elastogenic cell types including fibroblasts, endothelial cells, smooth muscle cells, airway
epithelial cells, and auricular chondrocytes [20]–[23]. A dominant feature of the
tropoelastin amino acid sequence is its well characterized alternating hydrophobic and
hydrophilic domain structure, with the hydrophobic regions featuring non-polar amino
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acids such as glycine, valine, proline, and leucine [24], [25]. The hydrophilic domains are
rich in lysine and alanine, which participate in cross-linking [25]. Upon excretion into the
extracellular space, tropoelastin is deposited onto fibrillin microfibrils and crosslinked by
lysyl oxidase to form elastic fibers [23].

1.2.3

Glycosaminoglycans

Glycosaminoglycans (GAGs) are linear, negatively-charged polysaccharides, which can
bind large amounts of water giving them their distinctive viscous, lubricating, and shock
absorbing properties [26]. GAGs can also modulate cell adhesion, growth, differentiation,
and signaling, directly through interactions with cell-surface receptors and indirectly
through the action of sequestered growth factors and cytokines [27]. The disaccharide
building blocks that make up GAGs consist of an amino sugar (glucosamine that is
N-acetylated, or N-sulfated, or N-acetylgalactosamine) that is linked by a glycosidic bond
to a uronic acid (glucuronic acid or iduronic acid) or galactose [28]. GAGs can be
classified into two main types: sulphated GAGs (e.g. chondroitin sulphate (CS), dermatan
sulphate (DS), keratan sulphate (KS), heparin and heparan sulphate (HS)) and nonsulphated GAGs (e.g. hyaluronic acid) [27]–[29]. Although each of these GAGs has a
predominant disaccharide component, the biosynthesis in which they are produced can be
modified at multiple positions through sulphation, acetylation, and/or epimerization,
creating heterogeneity in any particular class of GAGs [30]. In tissue-engineering
applications, GAGs are often immobilized on different material surfaces or integrated
into various scaffold or hydrogel systems. The rationale behind their use as biomaterials
is justified by their potential function as a matrix component and/or as a binding partner
for cell receptors, as well as growth factors and cytokines [31].

1.2.4

Proteoglycans

Proteoglycans consist of a core protein to which one or more glycosaminoglycan chains
are covalently attached. In addition to their presence within the ECM, proteoglycans are
found within the pericellular matrix of many cell types and are involved in a variety of
functions such as providing structural support, controlling enzymatic activity, and some
serve as cell surface receptors [32]. ECM proteoglycans can be divided into two major
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groups: (1) hyaluronan- and lectin-binding proteoglycans (hyalectans) and (2) small
leucine-rich proteoglycans (SLRPs) [33]. Hyalectans such as aggrecan, versican,
brevican, and neurocan, have a tridomain structure consisting of a central domain that
incorporates most of the GAGs, flanked by unique N-terminal domain that binds
hyaluronic acid and a C-terminal domain that binds lectins [34].

Aggrecan is

predominantly found in cartilage and the intervertebral discs, but also in the perineuronal
nets of the brain, whereas versican is mainly found in interstitial ECMs [33]. Brevican
and neurocan are expressed throughout the central nervous system [35]. A major
biological function of these proteoglycans derives from the physicochemical
characteristics of their GAG side chains, which provide hydration and swell to enable
tissues to resist compression [31]. For example, the loss of proteoglycans in cartilage
tissue is a sign of dysfunction that is observed in various forms of arthritis [36]. SLRPs
(e.g. decorin and byglycan) constitute a family of widely-expressed proteoglycans found
in most ECMs and tissues, which are defined by their low molecular weight and presence
of leucine-rich repeats [37]. SLRPs influence cell behaviours including differentiation,
apoptosis, proliferation, and migration.

1.2.5

Glycoproteins

Adhesive glycoproteins possess multiple binding domains capable of binding collagen
and proteoglycans, as well as binding to cell surface receptors [9] such as integrins that
mediate cell adhesion to the ECM [38]. Within the ECM, two commonly studied
cell-adhesive glycoproteins are fibronectin and laminin, which have been used in
biomaterial synthesis for enhanced cell attachment and survival [39], [40].
Fibronectin is a ubiquitous ECM glycoprotein that is assembled into a fibrillar matrix in
all tissues throughout all stages of life, and plays important roles in cell adhesion,
migration, growth and differentiation [41]. Many different cell types synthesize
fibronectin and secrete it as a disulfide-bonded dimer composed of 230-270 kDa subunits
[42], [43]. Each subunit contains three types of repeating modules, types I, II, and III, and
these modules comprise functional domains that mediate interactions with other ECM
components, with cell surface receptors and with fibronectin itself [42], [43].
Specifically, type I regions bind to heparin, fibrin, or collagen, type II regions bind to

6

collagen, and type III regions bind to cell surface receptors. Within the type III regions,
there are 20 different isoforms in humans that result from alternative splicing of the
primary transcript [44]. The major cell binding region of fibronectin is the RGD motif,
located in the third module repeat, which binds to α5β1 and αv-class integrins and controls
fibronectin fibril assembly [45]. Synthetic peptides with this sequence have been
successfully used to promote cell attachment, spreading, and migration within a variety of
biomaterial substrates for many different cell types [39], [40], [46], [47].
Laminin has a characteristic structure comprised of three polypeptide chains, an α-chain,
β-chain, and γ-chain. These three chains assemble to form an asymmetrical cross-shaped
structure through disulfide bonds [48]. More specifically, the three short arms are located
on the N-terminus with three globular domains on the α-chain and two globular domains
for the β-chain and γ-chain [49]. On the opposite end, the long arm possess a coiled-coil
conformation with a large globular domain at the C-terminus [49]. Notably, laminin
forms a web-like structural network that is an integral part of the basement membrane
[48]. The basement membrane provides an adhesive substrate for cells and it is linked
functionally to the actin cytoskeleton via integrins or other ECM receptors to mediate cell
attachment and migration, as well as modulate intracellular signaling pathways [19], [50].
Similar to the RGD sequence in fibronectin, the isoleucine-lysine-valine-alanine-valine
motif (IKVAV), derived from the laminin-α1 chain has been indicated to interact with
integrins, modulating cell attachment, proliferation, and enabling the maintenance of cells
in the differentiated state [51]. Several studies have indicated that the use of this and
other laminin-derived motifs positively regulate mesenchymal stromal cell (MSC)
attachment, proliferation, differentiation [52]–[54].

1.3 Adipose tissue function and ECM composition
Since the discovery of adipsin and the characterization of leptin in 1987, adipose tissue
has been established as an endocrine organ [55], [56]. Most adipose tissue is made up of
lipid-filled cells called adipocytes, which are held in a framework of collagen fibers [57].
In humans, there are at least two functionally distinct types of fat: white and brown [58].
White adipose tissue is the primary site of energy storage and the release of hormones
and cytokines that modulate whole-body metabolism and insulin resistance [58].
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Additionally, white adipose tissue can act as a thermal insulator and protect other organs
from mechanical damage [58]. Brown adipose tissue uses the chemical energy in lipids
and glucose to produce heat through non-shivering thermogenesis via mitochondrial
uncoupling of oxidative phosphorylation of free fatty acids, mediated by uncoupling
protein 1 (UCP1) [57], [59]. In 2007, brown adipose tissue was reported to exist in the
neck and trunk of some human adults, which overturned the belief that brown adipose
tissue was only found in infants [55], [60], [61]. This research also led to the discovery of
beige fat cells, which are UCP1-expressing and mitochondrial-rich adipocytes found
interspersed throughout white adipose tissue [59].
Adipose tissue ECM shares a lot of similarities with other soft connective tissues in the
body, such as dermis, tendons and ligaments, fibrous connective tissues, and fascia. It
was shown through immunohistochemistry that the ECM within adipose tissue is
enriched with collagenous proteins, including collagen types I-VI, with collagens type I
and IV being the most prevalent [62]. In addition to collagens, the ECM of adipose tissue
contains fibronectin, laminin, GAGs, and proteoglycans such as biglycan and decorin
[63], [64]. Notably, a basement membrane is present surrounding individual adipocytes,
providing structure and shape to the tissue and is comprised of laminins, collagen type
IV, V, and VI [64].
Adipose tissue releases a wide array of protein factors and signaling molecules called
adipokines, which influence energy balance, angiogenesis, blood pressure, lipid
metabolism, glucose homeostasis, and vascular hemostasis [65]. All adipose tissue depots
express adiponectin, which is an adipocyte-specific hormone with systemic
insulin-sensitizing and anti-inflammatory properties [66]. Leptin is another adipokine
secreted by adipocytes that plays an essential role in suppressing appetite and promoting
energy expenditure through interactions with receptors in the central nervous system [66].

1.4 Dermal ECM composition
Skin is a complex organ covering the entire surface of the body that is composed of the
epidermis, dermis, and subcutaneous tissues. Focusing on the dermis, the main ECM
components are collagens, elastin, proteoglycans, and glycoproteins [67]. Collagens
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impart tensile strength to the skin, with the major types being collagen type I, III, and V
[67]. Proteoglycans such as decorin and biglycan are found throughout the dermis, with
decorin being found in higher abundance [68]. It is thought that decorin may have direct
tissue stabilizing function by linking collagen type I-fibrils [68]. Fibrillin microfibrils are
fundamental structural components of the dermis and together with elastic fibers, they
provide the skin with elasticity. In addition, fibrillin microfibrils also assist in anchoring
the epidermal basement membrane to the interstitial matrix by directly binding perlecan
[69].

1.5 Myocardial ECM composition
The mammalian myocardium comprises cardiomyocytes and large populations of
interstitial cells enmeshed within the ECM [70]. Similar to many other tissues, the
cardiac ECM can be divided into proteins that reside in the interstitial matrix and proteins
that reside in the basement membrane. Within the interstitial matrix, collagen type I
provides structural support and imparts tensile properties, whereas collagen type III
provides elasticity along with low levels of elastin [70]. Proteoglycans such as decorin
and versican are found in the interstitial matrix. Decorin regulates the assembly of
collagen type I and III fibrils, whereas versican is found in the left ventricle and mediates
inflammatory cell-cell and cell-matrix interactions [71], [72]. Fibronectin is found within
the interstitial matrix, while laminin is found within the basement membrane [70]. Lastly,
many matricellular proteins are found within the interstitial matrix including osteopontin,
galectin-3, periostin, secreted protein acidic and rich in cysteine (SPARC),
thrombospondin, and tenascins [73]. Matricellular proteins do not contribute to the
organization or physical properties of the ECM, but mediate processes such as cell
adhesion, migration, growth and differentiation [74].

1.6 Cartilage tissue function and ECM composition
Depending on its composition, cartilage is either classified as hyaline cartilage,
fibrocartilage, or elastic cartilage. Hyaline cartilage (also known as articular cartilage) is
most known for its load bearing capacity that permits smooth motion between adjoining
bones within articulating joints (e.g. hip, knee, or elbow) [75]. Elastic cartilage is similar
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to hyaline cartilage, except it contains a dense network of elastic fibers and provides
flexible support to structures such as the ear or trachea [75]. Lastly, fibrocartilage has
thick layers of large collagen fibers providing a unique combination of tensile strength,
compressive strength, and deformability [76]. Table 1.1 outlines the main ECM
components, cell types, location, and functions of each cartilage type.
Table 1.1 Overview of the three different cartilage types [77]–[80]

Main ECM
Components

Cell Types

Locations

Hyaline Cartilage
• Type II collagen
• Aggrecan

Elastic Cartilage
• Type II
collagen
• Elastic fibers
• Aggrecan

•
•
•

•
•
•
•
•

•
•
•
•
•

Functions

•

Chondrocytes
Chondroblasts
Ephiphyseal
plates of long
bones
Fetal skeleton
Articular ends
of long bones
Throughout the
upper
respiratory tract
Provides low
friction in joints
Shock
absorption
Structural and
biological
barrier between
bone surfaces

•
•
•

•
•

Fibrocartilage
Type I collagen
Type II collagen in
varying amounts

Chondrocytes
Chondroblasts
External ear
Auditory tube
External
acoustin
meatus
Epiglottis
Laryngeal
cartilage

•

Fibrochondrocytes

•
•
•
•
•

Intervertebral disc
Symphysis pubis
Menisci
Tendinous insertions
Glenohumeral/acetabular
labra
Temporomandibular joint

Structural
support

•
•

•

Weight bearing
Compression/shear force
resistance

1.7 ECM-derived bio-scaffolds
As mentioned previously, the ECM provides a structurally and functionally specialized
environment for each tissue type, serving as a mechanical framework that facilitates cell
adhesion and migration, as well as a bioactive substrate for cell signaling and mediating
intracellular processes such as proliferation and differentiation [81], [82]. Recognizing
the intricacy of the ECM, decoupling the unique constituents and properties within
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different tissues is important for rational biomaterials development. Specifically,
cell-ECM interactions may be used to help facilitate ex vivo MSC culture, as well as to
regulate MSC differentiation [83]. Various bottom-up strategies using materials modified
with mechanical reinforcements, growth factors, cell adhesive peptides and ECM-derived
molecules have been meticulously designed [84]–[89]. As this approach has proven to be
challenging, the use of decellularized tissue bio-scaffolds has emerged as a promising
option to exploit the innate functions of the ECM and will be discussed more in Section
1.7.2.

1.7.1

Cell-instructive effects of the ECM

Many research groups have shown that ECM-derived scaffolds are capable of regulating
cell behaviors including cell survival and differentiation, through the presence of
biochemical factors and biomechanical properties. There have been several studies that
have outlined the tissue-specific effects of the biochemical composition on cellular
processes such as differentiation [5]. For example, one study performed by Duan et al.
encapsulated human embryonic stem cells (ESCs) as embryoid bodies into hydrogels
with varying percentages of porcine heart ECM and observed that higher percentages of
ECM correlated with increased cardiac marker expression and increased numbers of
contracting cells with larger contraction amplitudes, without the addition of soluble
factors [90]. A different study by Shojaie et al. demonstrated that mouse ESC-derived
endoderm differentiated into multiple mature lung epithelial cell types with no additional
growth factors or serum in the culture medium when cultured on sections of
decellularized rat lung [91]. This studied also concluded that this differentiation was
dependent on heparan sulphate proteoglycans and its bound factors remaining on the
decellularized scaffolds [91]. Another mechanism through which the biochemical
composition of the ECM may also function to direct cellular processes is through
degradation products generated by matrix metalloproteinases (MMPs) and ADAMs (a
disintegrin and metalloproteinase) family members, which have been shown to modulate
host immune response and recruit and differentiate endogenous stem/progenitor cells
[81], [92].
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In addition to biochemical composition, physical properties of biomaterial substrates are
also important mediators of cell function [93]. For example, when MSCs are cultured on
stiffer matrices in 2D configurations, cell spreading occurs causing well-aligned stress
fibers and enhanced focal adhesion assembly, all of which contribute to a high tension
state that promotes osteogenic differentiation [87]. A study performed by Huebsch et al.
encapsulated clonally-derived murine MSCs in 3D alginate hydrogels functionalized with
RGD of varying stiffness and demonstrated that softer hydrogels (2.5–5 kPa) promoted
adipogenic differentiation, whereas stiffer hydrogels (11–30 kPa) promoted osteogenesis
[94]. An interesting finding from this work was that in 3D systems, these changes were
not due to cell morphological differences, which is contrast to work performed on 2D
matrices of varying stiffness, where elasticity causes alterations in cell shape that alter the
lineage commitment of MSCs [94]–[96].

1.7.2

Decellularized tissue bioscaffolds

Within the scope of ECM-derived biomaterials, the production of decellularized tissue
scaffolds has been a promising strategy in regenerative medicine applications. This
approach offers several advantages over biomaterials generated from more purified ECM
components such as collagen, in that it allows for the generation of scaffolds with greater
complexity that can potentially retain ultrastructural features, mechanical properties, and
ECM constituents unique to the tissue of interest [97]. Virtually every tissue in the body,
including small intestinal submucosa (SIS), urinary bladder, dermal tissue, adipose tissue,
bone, and blood vessels, has been decellularized [98]–[101]. Furthermore, a number of
off-the-shelf products are commercially available and have received FDA approval for
clinical use including decellularized human dermis (AlloDerm® Regenerative Tissue
Matrix, LifeCell®), porcine mesothelium (Meso BioMatrix® Surgical Mesh, DSM),
porcine heart valves (Synergraft®, CryoLife), and porcine urinary bladder (ACell, Inc)
[102], [103].

1.7.3

Decellularization techniques

Decellularization techniques involve a combination of mechanical, chemical, and
enzymatic treatments that can be tailored to the tissue of interest (e.g., cellularity, density,
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and lipid content). Depending on the downstream requirements, decellularization can be
performed by whole organ perfusion utilizing intact vasculature or by dissecting the
tissue into smaller sections and agitating in respective reagents [104]. The goal of tissue
decellularization is to remove the immunogenic cellular components while conserving the
complex composition and ultrastructure of the ECM [82]. However, it is important to
recognize that decellularization will invariably alter the ECM composition and cause
some degree of change to the ultrastructure depending on the methods and reagents used
[102].
Physical methods that can be used to facilitate decellularization include freeze-thaw
cycles, hypertonic/hypotonic solutions to promote osmotic cell lysis, direct pressure,
sonication or agitation [102]. These methods are effective at lysing cells, but must be
followed up with methods to remove the cellular material from the tissue [102].
Enzymatic digestion is also used in many decellularization protocols in combination with
physical methods. These methods can involve the use of trypsin, lipase, and/or nucleases
that disrupt cell-ECM adhesions, lipids, and nucleic acids respectively [103]. Chemical
methods, such as the use of acids or bases, can also be used to cause or catalyze
hydrolytic degradation of biomolecules [97]. Peracetic acid is often utilized as both a
disinfectant and decellularization agent to remove residual nucleic acids with reportedly
minimal effects on ECM composition and structure [105]. Interestingly, acetic acid
damages collagens, but it does not affect sulphated GAGs [106].
Ionic detergents such as sodium dodecyl sulphate (SDS) or sodium deoxycholate have
been utilized in many decellularization protocols and are effective at removing nuclear
remnants, but can be quite harsh and reports of changes in ultrastructure and losses of
soluble proteins and GAGs, including fibronectin and laminin, have been made [102].
Triton X-100 is a non-ionic detergent that has been widely used in many decellularization
protocols, though mixed results have been observed in terms of DNA extraction,
retaining GAGs and maintaining the tissue ultrastructure [102]. Detergents are commonly
used on tissues that have a dense ECM, such as myocardium, cartilage and dermis, in
which enzymatic and osmotic methods are insufficient to remove cellular components
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[107], [108]. Moreover, residual detergent trapped within the decellularized tissue may
have cytotoxic effects both in vitro and in vivo [102].
To investigate the quality of decellularization protocols, investigators utilize a range of
biochemical assays and histology. Cell remnants can be assessed qualitatively through
4’-6-diamidino-2-phenylindole (DAPI) staining, coupled quantitatively with the QuantiT™ PicoGreen® dsDNA assay [109], [110]. To assess the composition of the
decellularized material, immunohistochemistry and biochemical assays such as the
hydroxyproline, dimethylmethylene blue (DMMB), and Fastin™ Elastin assays can be
used to assess collagen, sGAG, and elastin content respectively [111], [112]. More
recently,

methods

have

been

developed

to

apply

high

throughput

mass

spectrometry-based proteomics approaches as another tool for the in-depth analysis of
ECM composition [113]. Further, staining for collagen through Mason’s trichrome or
picrosirius red staining, along with scanning electron microscopy (SEM) can be utilized
to more closely examine the remaining ultrastructure of the ECM [109]. A final step to
assess cytocompatibility can be performed through in vitro cell culture and in vivo
implantation to probe the host response and tissue remodeling [114]. In general, the final
decellularized product is highly dependent on the methods chosen and the time frame
over which the decellularization is performed.

1.7.4

Adipose tissue decellularization

Decellularized adipose tissue (DAT) has been used by many groups as a bioactive
template for treating soft tissue defects, both as a construct that promotes fat regeneration
and in combination with human adipose-derived stromal cells (hASCs) [5], [115].
Adipose tissue is routinely discarded as surgical waste and is an abundant source of
ECM, which makes it a convenient alternative to xenogenically-sourced and synthetic
materials. The decellularization of adipose tissue typically involves a combination of
physical, chemical, and enzymatic treatment steps. The Flynn lab pioneered a detergentfree adipose tissue decellularization protocol that uses a combination of freeze/thaw
cycles,

and

washes

in

hypotonic

solutions,

enzymatic

digestion

with

trypsin/ethylenediaminetetraacetic acid (trypsin/EDTA), isopropanol extraction of lipids,
and DNase and RNase treatments to yield an intact bio-scaffold with preserved ECM
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architecture [100]. Alternatively, detergents such as SDS, and sodium deoxycholate have
been utilized by various groups in combination with a freeze/thaw cycle in order to
destabilize cellular membranes and lyse cells [116], [117]. Choi et al. homogenized
lipoaspirate waste to increase surface area followed by incubation in SDS and
RNase/DNase digestion to eliminate nucleic acids [118]. Wang et al. performed three
freeze/thaw cycles to aid in cell lysis followed by incubations in trypsin/EDTA to release
cells, isopropanol to remove lipids, and finally 1 % Triton X-100 extraction as a means to
remove the cellular components [119].

1.7.5

Cartilage tissue decellularization

Similar to adipose tissue decellularization, cartilage decellularization protocols typically
involve the use of multiple freeze/thaw cycles, rinses in hypotonic buffers, enzymatic
digestion, and washes in detergent (SDS and Triton X-100) [120]. Although cartilage has
a low abundance of cells present, the dense nature of the tissue poses challenges when
attempting to extract the cellular material. Some ways to overcome this challenge are to
use higher agitation rates and mincing or milling the tissue prior to decellularization in
order to increase the surface area to aid in the decellularization process [120]. There is a
delicate balance between removing the cellular components and retaining the chondroprotective components of the ECM, specifically GAGs, type II collagen, laminin and
collagen VI [120].
Numerous protocols have been developed for the decellularization of cartilage. A
common limitation of the protocols to date is the levels of GAG reduction postdecellularization. Although sufficient extraction of cellular material is achieved, it is
often associated with a 40-80 % loss of GAG content depending on the protocol used.
Benders et al. developed a protocol that subjected equine articular cartilage particles to 6
cycles of incubation in trypsin/EDTA, followed by a nuclease solution and Triton X-100
to obtain a decellularized scaffold [121]. While the scaffold qualitatively retained most of
the collagen type II based on immunohistochemistry, the DMMB assay revealed that the
majority of the GAG content was lost during the trypsin steps. Tavassoli et al. generated
a protocol for bovine articular cartilage decellularization that involved both physical and
chemical methods. The tissue was first maintained at -4 ℃ for one week, freeze-thaw
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cycles in liquid nitrogen for 5 cycles, and then treated with 2.5 % SDS for 4 hours [122].
Collagen content assessed through picrosirius red staining appeared qualitatively similar,
however the protocol resulted in a substantial loss in GAG content as evident through
toluidine blue staining. In another study, Rothrauff et al. suspended milled bovine
articular cartilage in a solution of Triton X-100 at 4 ℃ for 24 hours, followed by
incubation in a solution of DNase and RNase for 24 hours, reporting similar results to the
previous protocols [123]. While there have been improvements in decellularization
protocols, there remains a need for further methods development to enable effective
removal of DNA content while retaining GAGs to obtain ECM that more closely mimics
the native tissue composition, which may be important for directing cell function.

1.7.6

Methods for fabricating bioscaffolds from decellularized
tissues

In addition to being used in their intact form as 3D scaffolds, techniques have been
developed to incorporate the complex ECM from decellularized tissues into more
customizable formats. In order to diversify the use of decellularized scaffolds, it is
important to be able to manipulate properties such as stiffness, porosity, and architecture.
As a result, many studies have investigated incorporating decellularized ECM within
hydrogels, porous foams, microcarriers, and sheets [103]. Technologies like
electrospraying, electrospinning, and 3D printing have also been utilized [103]. In these
approaches the decellularized ECM is further processed through mechanical and/or
enzymatic digestion to achieve its desired form.
The most common methods of processing ECM involve mechanical (e.g. mincing or
milling) or enzymatic (e.g. pepsin) means to allow it to be incorporated within other
materials as a bioactive component or applied on its own as an injectable material [123].
In order to mill the decellularized ECM, the material is first flash frozen and then milled
using a cryo-milling apparatus. The parameters in this system (e.g. time, speed, and
sieving) may be adjusted to produce particles of different size ranges, which has been
shown to affect downstream cellular processes. For example, Brown et al. compared the
effect of decellularized adipose tissue particle size on the adipogenic differentiation of
hASCs when incorporated within methacrylated chondroitin sulphate (MCS) hydrogels
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and found a significant increase in glycerol-3-phosphate dehydrogenase (GPDH) enzyme
activity, as well as oil red O and perilipin staining of intracellular lipid accumulation
when using small particles, consistent with an enhanced adipogenic response [124].
Further demonstrating the tissue-specific instructive effects of the ECM, Pati et al. 3D
printed a porcine cartilage bioink prepared from pepsin-digested milled particles
incorporated within a polycaprolactone (PCL) framework and observed higher levels of
chondrocyte-specific gene expression in human inferior turbinate-tissue derived MSCs
compared to collagen-based bioinks [125]. An important parameter for pepsin-digested
ECM gels is the digestion time as this has been shown to impact protein solubilization,
gelation potential, and the downstream biochemical composition, as well as mechanical
properties [126].
The Flynn lab has focused on the decellularization of various types of tissues such as
adipose tissue, cartilage, bone, myocardium, and dermis (see Figure 1.1) [127]. A
common method of post decellularization processing developed in the Flynn lab involves
the use of α-amylase to digest the ECM sourced from decellularized tissues and generate
3D foams and microcarriers [127]–[130]. In our approach, collagen fibrils are preserved
following the glycosidic cleavage of carbohydrate groups in the telopeptide regions of the
collagen, as opposed to the non-specific proteolytic cleavage that occurs when using
pepsin [131]. DAT processed with α-amylase and fabricated into foams has been shown
to promote the adipogenic differentiation of hASCs in vitro and have adipo-inductive
effects in vivo [130]. In addition to DAT foams, the Flynn lab has also developed foams
derived from decellularized porcine ventricular myocardium tissue (DMT). When seeded
with human pericardial fat ASCs and cultured in myocardium differentiation medium in
comparison to collagen type I gels, expression of cardiac troponin T type II, myosin
heavy chain 6, and atrial natriuretic peptide were significantly enhanced [129].
The Flynn lab has also fabricated microcarriers from α-amylase-digested DAT through
the method of electrospraying [128]. An overview of the electrospraying process is
outlined in Figure 1.2. In this process, the α-amylase digested ECM-suspensions are
pumped through an infusion needle through to which a high voltage (15–20 kV) is
applied. The applied electrical field causes a build-up of electrical forces within the
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suspension, which overcomes the liquid surface tension forces, causing fine liquid
droplets to form. These liquid droplets fall directly into liquid nitrogen, collecting at a
grounded aluminum foil piece, and can then be lyophilized. It is important to note that
optimization may be required depending on the properties of each specific ECM source,
in particular in selecting the concentration range that will generate stable bioscaffolds.
Another key factor is the decellularization protocol that is used to generate the starting
material, as decellularization methods that degrade the ECM or the presence of residual
reagents such as surfactants may negatively impact the stability of the resultant foams
and microcarriers.
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Figure 1.1: Overview of the method of production of the tissue-specific ECMderived foams and microcarriers. (1) Decellularized tissues, prepared following
established decellularization protocols, can be used for tissue-specific ECM-derived
bioscaffold fabrication. Macroscopic images are shown of representative examples of
ECM sources that can be used as starting materials. Scale bar = 3 cm. (2) The
decellularized tissues are lyophilized, and then (3) mechanically minced. Scale bar =
1 cm. (4) The minced ECM can then be cryomilled, which is optional for the synthesis of
foams and microcarriers. Scale bar = 3 mm. (5) The minced or cyromilled ECM is then
digested with α-amylase and homogenized to create a homogenous ECM suspension.
Scale bar = 1 cm. (6a) For foam fabrication, the ECM suspension is transferred into a
user-defined mold, frozen, and lyophilized to generate a porous 3D scaffold with welldefined geometry. Scale bar = 1 cm. (6b) For microcarrier fabrication, the cryomilled
ECM suspension is electrosprayed to generate discrete spherical microcarriers. Scale bar
= 2 mm. (7) The foams and microcarriers can then be gradually rehydrated and seeded
with cells. Representative images are shown of hASCs (viable cells = green) seeded on
DAT foam (left) and DAT microcarriers (right). Scale bars = 100 μm. Figure reprinted
with permission from [127].
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Figure 1.2: Overview of the electrospraying apparatus used for microcarrier
fabrication. (A) Shows a picture of the set up including the high voltage power supply,
syringe pump, liquid nitrogen, infusion needle, ECM suspension and aluminum foil
collector. (B) Shows a schematic of the electrospraying set up including a recommended
range for the voltage, infusion rate and distance between the infusion needle tip and
liquid nitrogen. Figure reprinted with permission from [127].
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1.8 Regenerative cell sources
The goal of regenerative medicine is to replace or restore normal function of cells,
tissues, and organs that are damaged by applying one of three main strategies: cell-based
therapies, biomaterials alone, or the combination of cells and biomaterials [132]. The
development of in vitro platforms is critical for effective cell-based therapies and
designing a microenvironment through which biomaterials can aid in the regenerative
potential of these cells. In the context of cell choice for therapies, one key requirement is
the availability of a high yield of cells for therapeutic efficacy [133]. Depending on the
disease, the number of cells required for therapy has been estimated to range between
tens of millions to billions [134]. Therefore, cells should be isolated from an abundant
and accessible source [135]. If cell expansion is required, it is important that the cells
maintain their regenerative capacity, especially in the context of expanding MSCs, as
their capacity to proliferate and differentiate has been shown to diminish through serial
passaging on TCPS [136]. MSCs are multipotent adult stem cell populations that have a
differentiation potential typically associated with their mesodermal lineage (adipogenic,
chondrogenic, osteogenic, myogenic) [137]. Notably, MSCs have been shown to exhibit
immunomodulatory properties in vitro [138]. When sourcing cells for therapy, sources
can either be autologous (same donor) or allogeneic (same species). Allogeneic sources
can raise concerns with immune rejection and patients may be subjected to harsh side
effects if required to take immunosuppressive medications, however, they have the
potential to be used as off-the-shelf therapies [139]. Additionally, allogeneic cells
sourced from young, healthy donors could circumvent the fact that the regenerative
capacity of autologously sourced cells can be impaired in patients with co-morbidities or
advanced age [139]. MSCs are currently being studied for potential use as an allogeneic
cell source [140]
Stem cell sources also explored in the development of cell-based therapies to date include
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) [141], [142].
Embryonic stem cells are pluripotent cells that are derived from the inner cell mass of
blastocysts and their capability to differentiate into any cells from the endoderm,
mesoderm, or ectoderm makes them attractive for use in a wide range of applications
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[141], [143]. However, ESCs demonstrate immunological incompatibility, may form
teratomas, and are associated with ethical concerns [142]. iPSCs on the other hand, are
an alternative to ESCs, as they can be obtained through genetic reprogramming of adult
somatic cells [144], [145]. This process involves the de-differentiation of cells such as
fibroblasts to produce patient-specific pluripotent stem cells that exhibit similar
properties to ESCs [144]. The original reprogramming techniques involved the use of
viral transfection and new techniques are being developed that may have reduced risks
(e.g. synthetic messenger RNA), but teratomas are still a possibility [145].

1.8.1

Mesenchymal stromal cell (MSCs) sources

MSCs were originally identified in 1966 by Friedenstein et al. from mouse bone marrow
and were characterized based on their multilineage differentiation potential [146]–[148].
These cells were then referred to as mesenchymal stem cells by Caplan [149]. However,
to date in vivo demonstration of their self-renewal capacity or ability to differentiate has
not been conclusively shown, resulting in many scientists now referring to these cells as
mesenchymal stromal cells (MSCs) [150]. MSCs have been shown to be found in nearly
all adult tissues in the body and the most common and longest utilized source tissues are
adipose tissue and bone marrow [151].

1.8.2

Adipose-derived stromal cells (ASCs)

MSCs from lipoaspirates have gained significant attention since they were first identified
by Zuk et al., in 2001 [152]. Adipose tissue contains a higher frequency of MSCs than
bone marrow, with one gram of tissue yielding ~500 times more MSCs compared to the
same amount of bone marrow aspirate [153]. In addition, adipose tissue is highly
abundant and easy to collect as it is sourced from accessible subcutaneous fat stores in
the body. Typically, hASCs are harvested using minimally invasive techniques such as
liposuction, or they can be obtained from en bloc tissues collected following breast or
abdominal reduction surgeries. Common protocols for extracting hASCs involve
enzymatic digestion and separation steps via centrifugation to yield a heterogenous
population of cells called the stromal vascular fraction (SVF), which contains
pre-adipocytes, fibroblasts, pericytes, smooth muscle cells (SMCs), and MSCs [154],
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[155]. The SVF is purified by selecting for the adherent hASC population via expansion
on tissue culture plastic.

1.8.3

ASC origin and immunophenotype

Currently, it is believed that ASCs in vivo are situated in proximity to the vasculature
within adipose tissue, known as the perivascular niche [156]–[158]. The perivascular
origin was visually identified through immunohistochemical staining; however, due to
the lack of a definitive ASC marker, the exact location and the cellular identity of ASCs
remains elusive [159]. To provide clarity about the identity of ASC populations, the
International Federation for Adipose Therapeutics and Science (IFATS) in collaboration
with the ISCT have defined a set of criteria to define ASCs: (1) plastic-adherent; (2)
express the standard immunophenotypic profile (Table 1.2); (3) maintain multipotency
towards the adipogenic, osteogenic, and chondrogenic lineages in culture [160].
In terms of the immunophenotype, the guidelines require at least two primary positive
(expressed by > 80 % of cells) and two primary negative (expressed by < 2 % of cells)
markers, with additional markers aimed at strengthening the characterization [160]. In the
undifferentiated state, the ASC immunophenotype exhibits very similar markers to
bmMSCs (e.g. CD29, CD44, CD73, and CD90), with the exception of abundant CD34
expression in ASCs at early passages, which diminishes over time [161]–[164]. Though
these surface antigens are well defined, the ASC population is inherently heterogenous,
possessing different morphologies (e.g. small rapidly self-renewing cells, spindle-like
cells, and large flattened cells) and varying ratios of uni-, bi-, and tri-potent cells, more
committed progenitor cells, and more differentiated subpopulations [165]–[167].
Variability in ASC populations can also be attributed to the diverse tissue-harvesting
sites, isolation procedures, and growth conditions used among different laboratories
[168]–[170].
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Table 1.2: ASC immunophenotype [170]
Cell surface antigens

Primary positive markers (> 80 %)

Secondary positive markers

Primary negative markers (< 2 %)

Secondary negative markers

1.8.4

CD90 (Thy-1)
CD105 (endoglin)
CD73 (ecto-5’-nucleotidase)
CD44 (hyaluronic acid receptor)
CD29 (β1-integrin)
CD13 (aminopeptidase-N)
CD34 (progenitor associated marker)*
CD146 (melanoma cell adhesion molecule,
MCAM)*
CD10 (neprilysin)
CD26 (dipeptidyl peptidase-4)
CD49d (α4-integrin)*
CD49e (α5-integrin)
CD36 (fatty acid translocase)
CD31 (platelet endothelial cell adhesion
molecule, PECAM)
CD45 (leukocyte-common antigen, LCA)
CD235a (glycophorin A)
HLA-DR (human leukocyte antigenantigen D related)
CD3 (T-cell co-receptor)
CD11b (αM-integrin)
CD49f (α6-integrin)
CD106 (vascular cell adhesion molecule 1,
VCAM-1)
PODXL (podacalyxin-like)

Paracrine mechanisms of regeneration

As mentioned, ASCs secrete a variety of beneficial paracrine factors that exhibit
multifaceted functions including immunomodulation, angiogenesis, anti-apoptosis, antiscarring, chemoattraction, and modulating stem and progenitor cells [83]. At sites of
injury, ASCs can secrete a wide range of growth factors involved in angiogenesis and
anti-apoptosis such as platelet-derived growth factor (PDGF), basic fibroblast growth
factor (bFGF), hepatocyte growth factor (HGF), vascular endothelial growth factor
(VEGF), and angiopoietins (Ang-1 and Ang-2), as well as anti-inflammatory cytokines of
the interleukin family (e.g. IL-10, IL-13) and prostaglandin E2 (PGE2). The ASC
secretome includes a large number of potential immunoregulatory factors that are capable
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of modulating innate and adaptive immune responses [41]. Key cytokines involved in
modulating the immune response are indoleamine-2,3-dioxygenase (IDO), tumor necrosis
factor alpha (TNF-α), interferon gamma (IFN-γ), and interleukin-17 (IL-17). IDO can
lead to T cell depletion and in vitro has been shown to induce Treg cells [171]. TNF-α
increases the production of PGE2, which in turns has an immunosuppressive effect [13],
[42]. IFN-γ contributes to the immunomodulatory effects of ASCs by directly inducing
the production of IDO. Finally, monocyte chemoattractant protein-1 (MCP-1), also
known as CCL2, is a chemokine secreted by ASCs that is a potent attractant factor for
monocytes [172].

1.8.5

Transcriptional control of ASC differentiation

ASCs have the capacity to differentiate in vitro along the adipogenic, osteogenic, and
chondrogenic lineages [170]. Understanding the transcriptional factors and signaling
pathways involved in ASC differentiation is critical for the design of culture systems for
expanding these cells for regenerative applications. Based on the areas of interest in this
thesis, a description of the adipogenic and chondrogenic pathways is provided below.

1.8.5.1

Adipogenic differentiation

In vitro adipogenesis of ASCs can be promoted by seeding the cells at high densities to
undergo growth arrest as a result of contact inhibition [173]. This initial growth arrest is
followed by one or two additional rounds of cell division known as clonal expansion
[173]. The induction of ASCs towards the adipogenic cascade begins with the presence of
hormonal inducers such as glucocorticoid agonists (e.g. hydrocortisone and
dexamethasone (DEX)), used to increase cellular cyclic adenosine monophosphate
(cAMP), and supra-physiological concentrations of insulin to stimulate insulin-likegrowth factor-I receptors (IGF-IR) [55], [173], [174]. The added supplements provided in
cell culture activate the transcription factors CCAAT/enhancer-binding protein-β
(C/EBPβ) and C/EBPδ in ASCs which in turn activate C/EBPα and peroxisome
proliferator-activated receptor gamma (PPARγ), the main transcription factors of
adipogenesis [175], [176]. PPARγ can stimulate adipogenesis in the absence of C/EBPα,
but not vice versa [173], [174]. C/EBPα and PPARγ then work in a positive feedback
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loop to maintain elevated levels of both genes to drive maturation and terminal
differentiation [176]. Following this, enhanced expression of genes that characterize the
adipocyte phenotype and enable triglyceride accumulation is observed including
lipoprotein lipase (LPL), fatty acid synthase (FAS), malic enzyme, acetyl CoA
carboxylase, insulin receptor, and GPDH [173], [176].
Adipocyte gene expression can also be directly stimulated in culture with synthetic
PPARγ ligands called thiazolidinediones (TZDs) (e.g. rosiglitazone, pioglitazone, and
troglitazone), which are antidiabetic drugs used to increase insulin sensitivity [177].
Upon ligand binding, PPARγ undergoes a conformational change to form a heterodimer
with retinoid x receptor alpha (RXRα) to allow binding to target DNA regions of
particular genes called peroxisome proliferator response elements (PPREs), thus
influencing gene transcription [177]. In addition, sterol regulatory element binding
protein-1/adipocyte determination and differentiation factor-1 (SREBP1/ADD1) can also
directly upregulate PPARγ expression, as well as the production of endogenous PPARγ
ligands such as fatty acids and prostaglandins [55], [177].
A summary of the adipogenic transcriptional cascade is illustrated in Figure 1.3. Overall,
adipogenesis is mediated by a balance between pro-adipogenic and anti-adipogenic
factors along various points in the transcriptional cascade.

Figure 1.3: Transcriptional control of adipogenesis
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1.8.5.2

Chondrogenic differentiation

Chondrogenesis of mesenchymal cells is initiated by condensation, which in vitro is
mimicked by the formation of micromass pellets [176]. These pellets are cultured in
serum-containing chondrogenic media formulations supplemented with factors including
insulin,

transforming

growth

factor-β3

(TGF-β3),

dexamethasone,

and

ascorbate-2-phosphate [178]. Cellular condensation promotes increased cell-cell contact
and cell-ECM interactions, which are mediated by the upregulation of N-cadherin, neural
cell adhesion molecules, and fibronectin [176], [179]. In early chondrogenesis, TGF-β
and bone morphogenetic protein (BMP) signaling promote cellular condensation, which
is important to induce commitment towards a pre-chondrocyte phenotype. BMP also acts
during later stages to control chondrocyte proliferation and hypertrophy [176].
The major transcription factor that has a key role in the differentiation of ASCs into
chondrocytes is sex-determining region Y-related high motility group box 9 transcription
factor (SOX9) [180]. SOX9 induces the transcription of the highly homologous pair
SOX5 and SOX6 [181]. SOX5 and SOX6 increase the expression of SOX9 and prevent
premature maturation into hypertrophic cells that is indicative of endochondral
ossification [181]. At this stage, the cells begin to differentiate into highly proliferative
chondroblasts with a rounded morphology, initiating the expression of collagen types II,
IX, and XI, as well as aggrecan and cartilage oligomeric matrix protein (COMP) [180].
SOX9 is also regulated by several factors including FGF, hypoxia inducible factor-1
alpha (HIF-1α), and protein kinase A (PKA), which act to upregulate the canonical Wnt
pathway, while retinoic acid downregulates expression [176].
In the late stages, proliferating chondroblasts enlarge and become pre-hypertrophic
chondrocytes, followed by terminal differentiation into hypertrophic chondrocytes, thus
marking the beginning phase of osteochondrogenesis. During this phase, runt-related
transcription factor 2 (RUNX2) expression peaks, resulting in the induction of Indian
hedgehog (IHH) and parathyroid hormone-related protein receptor (PTHrP-R)
expression, which control chondrocyte hypertrophy leading to the beginning stages of
calcification [182], [183]. Together, these processes contribute to the further upregulation
of RUNX2 and expression of collagen X in hypertrophic chondrocytes, followed by
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apoptosis prior to calcification of the cartilaginous scaffold [176]. A schematic of the
chondrogenic pathway is illustrated in Figure 1.4.

Figure 1.4: Transcriptional control of chondrogenesis

1.8.6

Donor variability of ASCs

Although ASCs are a promising cell source for regenerative therapies, they can display
significant donor heterogeneity in terms of cell yield, proliferation, and differentiation
capacities [184], which may be important to consider when using them autologously.
Donor age is of particular interest when considering factors that may impact ASC
function. The proliferation of ASCs in vitro has been shown to diminish with increasing
age, which parallels the increased expression of the cellular senescence markers p16, p21,
and SA-β-gal [185]. Adipogenic and chondrogenic differentiation potential have also
been shown to decline with age [185]–[187]. ASC donor health status and disease state
are other important factors and some studies have correlated increased body mass index
(BMI) to reduced proliferation rates, colony forming unit frequency, and differentiation
capacity [188], [189], while others have noted no differences [190], [191]. Larger more
defined studies are needed to draw tangible conclusions on the effects of donor variability
associated with age and BMI, as well as recognizing the difficulties of dissecting the
multitude of unknown patient parameters such as diabetes, smoking, and hormonal status
that could potentially affect ASC functionality.
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1.9 Ex vivo stem cell expansion strategies
1.9.1

3D bioreactor systems

A variety of bench-scale ex-vivo cell expansion bioreactors are being explored with the
goal of maintaining the proliferative and differentiation capacities of regenerative cell
populations for use in clinical cell therapies. These bioreactors aim to overcome the 2D
culture expansion limitations and maintain the pro-regenerative capacity of the cells.
Currently, stirred bioreactors, rotating wall bioreactors or perfusion configurations are the
main types of bioreactors being explored for tissue engineering applications [192]. Stirred
bioreactor systems allow for homogenous culture conditions with even distribution of
oxygen and nutrients [193]–[196]. Additionally, microcarriers or other 3D bioscaffolds
can be suspended in these mixed bioreactor systems and have shown improvements in the
expansion of ASCs and bmMSCs, as well as improved differentiation towards the
adipogenic, chondrogenic, and osteogenic lineages [197]–[203]. Rotating wall
bioreactors have also been used to expand regenerative cell populations. Within rotating
wall vessels (RWV), the culture media, cells, and scaffolds are placed between two
concentric cylinders [204]. The vessel is then placed horizontally, and the cells and
scaffolds are maintained in a constant state of suspension by the competing forces of
gravity and the stirring caused by the rotation of the outer cylindrical wall [205]. To date,
these bioreactors have shown improved expansion of bmMSCs and have been primarily
used in bone tissue applications, with several groups showing improved osteogenic
differentiation [205]–[207]. Lastly, perfusion bioreactors have been used to culture
hepatocytes, hematopoietic stem cells, and to differentiate MSCs along the osteogenic
lineage, and have the advantage of providing continuous nutrients in order to expand
dense cell layers [208]–[214].
The spinner flask bioreactor is the most common mixed bioreactor system for expanding
cells on microcarriers because of its ease of setup and the fact that parameters such as
stirring rate, oxygen tension, and pH can be well controlled and adjusted to refine the
culture conditions [192], [215]. This type of bioreactor has two commonly used
configurations for agitation; the first is using a hanging stir-bar assembly, whereas the
second configuration uses a vertical impeller [216]. The configuration will influence the
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shear forces generated within the system, in addition to the impeller stirring rate,
microcarrier density and fluid volume within the spinner flask [217], [218]. The effect of
stirring rate on shear forces is one parameter that must be considered when moving
towards refining culture conditions to further augment differentiation. Additionally, other
factors such as the microcarrier type and oxygen tension can impact cell proliferation and
function during expansion within spinner flask systems, as described in more detail
below.

1.9.2

ASC response to shear forces

Mechanical stimulation, including shear forces from fluid flow, can provide important
biomechanical cues that can affect the differentiation of ASCs and alter their secretory
behaviour [219]–[221]. These cues can activate mechanosignalling pathways through
tensegrity, integrin-mediated mechanotransduction, and membrane fluidity [222].
Tensegrity-mediated mechanosensing takes place when a mechanical force applied on the
cells leads to changes in the cytoskeleton, transmitting the signal to the nucleus [223].
Integrin-mediated signaling generally involves the activation of the extracellular domains
of integrins, which triggers the phosphorylation and activation of focal adhesion kinase
(FAK)-mediated intracellular pathways [87]. Shearing forces can also induce a change in
membrane viscosity activating mechanotransduction pathways through a process known
as membrane fluidity [222].
As mentioned previously, in addition to their well-known differentiation potential, an
intriguing characteristic of MSCs is their ability to secrete a wide range of cytokines and
growth factors that can influence paracrine signaling such as VEGF, HGF, FGF, IGF,
PDGF, ILs and MMPs [40]. It has been demonstrated that factors including substrate
stiffness, geometry, and topography, as well as biochemical stimulation with cytokines or
small molecules can drastically change the paracrine activity of MSCs [93]. Other
researchers have been interested in the culture of MSC as spheroids or aggregate cultures.
Often times these aggregates are studied in static culture, but one study found that MSCs
cultivated as aggregates in dynamic culture showed enhanced angiogenic factor secretion
of HGF, VEGF, and FGF-2 compared to MSCs cultured on tissue culture polystyrene
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(TCPS) [224]. Overall, applying shear forces through dynamic culture may be a way to
modulate the differentiation and paracrine activity of ASCs prior to their delivery.

1.9.3

Microcarrier culture on MSC expansion

Microcarriers provide a supportive matrix that can be utilized within bioreactor systems
as mentioned previously, in order to enhance the expansion of a variety of adherent cell
types in vitro. Microcarriers were first developed in 1967 by van Wezel et al., who used
Sephadex particles made up of crosslinked dextran for the culture of adherent cells in
vaccine production [225]. Since then, microcarriers have been fabricated from a variety
of natural and synthetic materials both within laboratories and commercial settings.
Some examples of commercially-available microcarriers include alginate-based carriers
(GEM, Global Cell Solutions), dextran-based carriers (Cytodex, GE Healthcare), gelatinor collagen-based carriers (Cultispher, Percell), and polystyrene-based carriers (Plastic,
SoloHill Engineering) [226]. Synthetic polymers are easy to reproduce and tune, however
there is a strong rationale for fabricating microcarriers from decellularized tissues due to
the innate cell-instructive properties of the ECM.
As mentioned previously, the Flynn lab has established protocols to fabricate
microcarriers from decellularized adipose tissue. First-generation DAT microcarriers
were fabricated by combining a pepsin-digested DAT suspension with alginate and
stabilizing the ECM through photochemical crosslinking with rose Bengal solution with
exposure to visible light for 8 h [227]. The alginate phase was then extracted with sodium
citrate to yield the porous DAT microcarriers [227]. While this approach supported
hASCs, the use of pepsin made it necessary to incorporate alginate as an intermediate
stabilizer and the microcarriers had a low porosity and poor stability below a size range
of 900 – 950 μm [128]. This led to the fabrication of second-generation DAT
microcarriers described previously using electrospraying approaches with a-amylase
digested DAT. These microcarriers supported the attachment of hASCs and were stable
in culture for 4 weeks [128]. Additionally, greater numbers of hASCs were recovered
through enzymatic extraction from the DAT microcarriers in comparison to hASCs
expanded on Cultipsher-S microcarriers after 2, 3, and 4 weeks of dynamic culture within
spinner flasks [128].
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To date, there are multiple suitable microcarriers for the expansion of MSCs. Chui et al.
utilized alginate for the fabrication of electrosprayed chitosan-coated alginate
microcarriers crosslinked with genipin [228]. These microcarriers supported higher levels
of initial attachment of green fluorescent protein-modified human MSCs, better
detachment efficiency and higher levels of proliferation over 14 days in culture in
comparison to commercially-available Cytodex 1 microcarriers [228]. An interesting
study performed by Yuan et al. utilized Cultispher-S microcarriers for the attachment and
expansion of human bmMSCs, exploring the effects of the seeding regimen (intermittent
versus continuous agitation), agitation rate, serum level, cell:bead ratio, and pH level on
initial attachment, with subsequent studies exploring the effect of agitation rate on the
proliferation phase of culture [229]. It was found that intermittent agitation at 100 rpm, a
5:1 cell:bead ratio, and medium conditions at pH 8.0 and 0 % serum best supported initial
human bmMSC attachment [229]. Subsequent studies found that 90 rpm best supported
the proliferation of human bmMSCs compared to 60 or 110 rpm after 7 days in culture
with 10 % serum [229]. Other culture conditions have also been considered when using
microcarriers for ex vivo MSC expansion. In recent years, the development of xeno-free
microenvironments has become of considerable interest. A study performed by Carmelo
et al. investigated the effects of xeno-free conditions on the attachment and expansion of
human bmMSCs on three different commercially available microcarriers: SoloHill plastic
microcarriers coated with CELLstart solution, Synthemax® II or Enhanced Attachment®
microcarriers [230]. Cell seeding efficiency was highest on the SoloHill coated
microcarriers (~ 95 %), although similar population fold changes were seen for all
conditions [230]. Immunophenotype assessed on the microcarriers was similar for the
human bmMSCs before and after dynamic culture, in addition to similar tri-lineage
differentiation potential as seen through oil red O, von Kossa, and Alcian blue staining
[230].

1.9.4

Effect of dynamic culture on adipogenic differentiation

To date little work has been done on the use of dynamic culture to enhance the
adipogenic differentiation of MSCs. A recent study by O’Donnell et al. used a perfusion
bioreactor system to dynamically culture hASCs within gelatin methacrylate hydrogels
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[231]. Adipogenic or proliferation media was perfused at a rate of 5 μL/min for 28 days
and static 3D controls as well as monolayer controls were included [231]. Human ASCs
dynamically cultured in adipogenic differentiation media had enhanced gene expression
of ADIPOQ, FABP4, PLIN1, and LPL compared to non-induced controls, however
dynamic 3D culture conditions had reduced gene expression compared to monolayer and
static 3D culture [231]. Similar trends were seen when LPL and adiponectin secretion in
the medium were assessed [231]. Another studied performed by Frith et al. cultured
human bmMSCs as aggregates within a spinner flask at 30 rpm or RWV at 15 rpm, with
static monolayer controls included [232]. Adipogenesis was enhanced within both
dynamic conditions compared to static monolayer controls, as demonstrated through oil
red O staining and enhanced gene expression of PPARγ, C/EBPα, and aP2 after 7 days in
culture [232]. Previous work in the Flynn lab cultured human ASCs on the firstgeneration DAT microcarriers synthesized with pepsin-digested ECM or gelatin
microcarriers for 14 days in spinner flask bioreactors at 15 rpm prior to induction in
adipogenic differentiation medium for an additional 14 days, with 2D TCPS controls
included [202]. GPDH activity was enhanced on the DAT beads after 72 h, 7 days, and
14 days in dynamic culture compared to the gelatin microcarriers and TCPS controls
[202]. Interestingly, lipid accumulation observed through oil red O staining was seen in
hASCs cultured on the DAT microcarriers under proliferation conditions, indicating an
adipo-inductive effect [202]. Overall, these studies support that both dynamic culture and
substrates can impact the in vitro adipogenic differentiation of ASCs.

1.9.5

Effect of oxygen tension on adipogenic differentiation

Cells that are grown in culture under atmospheric conditions are generally exposed to a
hyperoxic environment, as the oxygen tension in most tissues in the body is significantly
lower than 21 %. Within adipose tissue, the normal oxygen tension typically ranges from
3-11 % [233]. At the molecular level, the intracellular protein hypoxia inducible factor
1-alpha (HIF-1α) is degraded following the hydroxylation of oxygen-dependent prolyl
hydroxylase under physiological normoxic states [234]. Under hypoxia, this degradation
pathway is inhibited, leading to the stabilization of HIF-1α and the activation of the Akt
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and P38 mitogen-activated protein kinase (MAPK) pathways that drive cell proliferation
and differentiation [235].
Most studies to date have demonstrated that oxygen tension as low as 2 % reduces the
differentiation capacity of ASCs [236]. Choi et al. cultured hASCs on TCPS under 21 %
and 2 % oxygen conditions and induced cells with adipogenic differentiation medium or
maintained cells in proliferation medium for 21 days [237]. When cultured in adipogenic
differentiation medium, the hASC gene expression of LPL, PPARγ, and FABP4 was
reduced when cultured under 2 % oxygen tension and this was confirmed through
reduced lipid accumulation assessed by oil red O staining [238]. Schiller et al. cultured
hASCs on tissue culture plastic under 20 % or 5 % oxygen conditions in either
adipogenic differentiation medium or proliferation medium for 7, 14 and 21 days of
culture [239]. When cultured in adipogenic differentiation medium, PPARγ and FABP4
expression were reduced after 21 days in 5 % oxygen conditions and a reduction in
GPDH enzyme activity was also observed.

1.10 Project overview, hypothesis, and specific aims
1.10.1

Project overview

Recognizing the cell-instructive properties of the ECM and the flexibility of our
electrospraying platform to fabricate non-chemically crosslinked microcarriers, the first
aim (Chapter 2) of the current project was to extend the DAT microcarrier fabrication
methods to generate microcarriers from decellularized dermal tissue (DDT) and
decellularized myocardial tissue (DMT) and investigate their use as substrates for the
expansion of tissue-specific stromal cell populations under dynamic culture within a
spinner flask system.
Recognizing the multilineage differentiation capacity of hASCs towards the adipogenic
and chondrogenic lineages in culture, as well as the potential for the ECM to provide
cell-instructive cues that can direct ASC differentiation [92] the focus of the second aim
(Chapter 3) was on the comparative analysis of the response of hASCs expanded on
microcarriers derived from DAT versus decellularized cartilage tissue (DCT) within the
spinner flasks. More specifically, novel DCT microcarriers were fabricated and

35

characterized, and the effects of two-weeks of dynamic culture on the microcarriers under
proliferation conditions on hASC attachment and growth, MSC-associated gene
expression, the hASC proteome and secretome, and the adipogenic and chondrogenic
differentiation capacity of the cells post-expansion were explored.
It is well known that 3D culture can drastically change the proliferation, differentiation,
and paracrine activity of ASCs. In addition to 3D culture, the use of bioreactors that
apply external forces can also impact these cellular processes. The third aim (Chapter 4)
of this project investigated for the first time the effects of microcarrier composition (DAT
versus DCT) and how changes in dynamic culture parameters (oxygen tension or stirring
rate) impacted the adipogenic differentiation of hASCs directly on the microcarriers.

1.10.2

Hypothesis

It was hypothesized that tissue-specific microcarriers comprised exclusively of ECM
could be fabricated from a variety of connective tissue sources that were stable in longterm dynamic culture without chemical crosslinking. Further, it was hypothesized that the
phenotype of human ASCs would be altered through expansion under dynamic
conditions on the ECM-derived microcarriers, and that the differentiation of human ASCs
towards the adipogenic lineage on the microcarriers could be modulated by the substrate
composition, stirring rate and oxygen tension within the stirred culture system.

1.10.3

Specific Aims

AIM 1. To fabricate and characterize pure ECM-derived microcarriers from multiple
connective tissue sources and investigate their potential as platforms for the expansion of
tissue-specific stromal cell populations under dynamic conditions.
AIM 2. To fabricate and characterize DCT microcarriers and compare the effects of
human ASC expansion on the DAT or DCT microcarriers under dynamic conditions
within a stirred culture system on the ASC gene expression, protein expression, and
capacity to differentiate towards the adipogenic and chondrogenic lineages relative to
baseline conditions.
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AIM 3. To investigate the effects of microcarrier type (DAT versus DCT), stirring rate
and oxygen tension on the differentiation of human ASCs towards the adipogenic lineage
on the 3D microcarriers within a stirred culture system.
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Chapter 2
2 Development and characterization of tissue-specific
matrix-derived microcarriers using electrospraying
techniques
2.1 Abstract
Stirred bioreactor systems integrating microcarriers represent a promising approach for
therapeutic cell manufacturing. While various microcarriers are commercially available,
current options do not integrate the tissue-specific composition of the extracellular matrix
(ECM), which can play critical roles in directing cell function. The current study sought
to generate tissue-specific microcarriers comprised exclusively of ECM from multiple
tissue sources. More specifically, porcine decellularized dermis, porcine decellularized
myocardium and human decellularized adipose tissue were digested with a-amylase to
obtain ECM suspensions that could be electrosprayed to generate soft and compliant 3D
microcarriers that were stable over a range of concentrations without the need for
chemical crosslinking or other additives. Characterization studies confirmed that all three
microcarrier types had similar mechanical properties and were of a similar size range, but
that each had a distinct composition mimicking the native tissue source. Pilot in vivo
testing in immunocompetent mice confirmed that the microcarriers were well tolerated
and integrated into the host tissues, supporting the infiltration of host cells including
macrophages and endothelial cells. In vitro studies validated that the novel microcarriers
supported the attachment and growth of tissue-specific stromal cell populations within
spinner flasks, supporting their further development as cell culture and delivery
platforms.

2.2 Introduction
As research advances towards clinical application, there will be a substantial need for ex
vivo expansion platforms for many cell therapies under development, to obtain the tens of
millions to billions of cells predicted to be required for therapeutic efficacy in humans
[135]. Currently, cell expansion on tissue culture polystyrene (TCPS) is commonly used
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in pre-clinical studies, as the methods are straightforward and well-established. While
convenient for small-scale trials, there are notable limitations to this expansion approach
[240]. From a biological perspective, culturing cells under static conditions on TCPS
provides a rigid two-dimensional (2D) substrate that markedly differs from the complex
and dynamic three-dimensional (3D) cellular microenvironment found within tissues
[199], [241]. Importantly, there is an increasing body of evidence that the proliferation
and differentiation capacities of many cell types diminishes through expansion on TCPS
[242], which has been attributed to alterations in the cellular phenotype induced by
changes in both biochemical and biomechanical signaling in comparison to their native
milieu [243]. From a translational perspective, the biomanufacturing methods for
generating therapeutic cell populations need to be more scalable, supporting a shift
towards the use of bioreactor systems [171].
One promising strategy for therapeutic cell manufacturing involves culturing cells on 3D
microcarriers within stirred tank bioreactor systems [244]. Microcarriers can support
adherent cell populations cultured in suspension under dynamic conditions, and their high
surface area to volume ratio can enable cell growth to high densities [245]. A variety of
synthetic, semi-synthetic and naturally-derived microcarriers are commercially available
for mammalian cell culture applications, including dextran (Cytodex-1), polystyrene
coated with collagen (Corning), or crosslinked macroporous gelatin (Cultispher-S)
microcarriers [246]. Every formulation has strengths and limitations, and careful
consideration must be given when selecting the type of microcarrier to be used for a
specific application. Microcarriers based on polystyrene offer long-term stability in
culture, but similar to 2D TCPS, they provide an extremely stiff substrate and often
require modification with collagen to improve cellular interactions [247]. Collagen- or
gelatin-based microcarriers are designed to mimic the extracellular matrix (ECM), but
they lack the biological complexity and tissue-specific composition of the native ECM
and are typically chemically crosslinked, which may impact bioactivity [247].
Recognizing that the ECM can have tissue-specific cell-instructive effects in mediating
cellular processes such as adhesion, proliferation and differentiation [248], we previously
developed novel microcarriers using human decellularized adipose tissue (DAT) as an
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ECM source that were stable in long-term culture without chemical crosslinking or
requiring any additives [128]. To generate the microcarriers, we applied enzymatic
digestion of the DAT with a-amylase to generate an ECM suspension that could be
electrosprayed into liquid nitrogen to form spherical beads comprised exclusively of
ECM that were stable following lyophilization and a controlled rehydration process. The
soft and compliant microcarriers supported the attachment and proliferation of human
adipose-derived stromal cells (hASCs) under dynamic conditions within a spinner flask
system, with significantly enhanced cell yields obtained from the DAT microcarriers
relative to Cultispher-S controls after 4 weeks in culture [128].
The goal in the current study was to investigate whether the microcarrier fabrication
methods could be extended to generate tissue-specific microcarriers using other
decellularized tissues as ECM sources. More specifically, decellularized dermal tissue
(DDT) and decellularized myocardial tissue (DMT) were selected as soft tissues
commonly targeted in regenerative applications that would have distinct ECM structures
and compositions relative to one another and the DAT [108], [112], [249]. Initial studies
focused on characterizing the structure and mechanical properties of the DDT and DMT
microcarriers synthesized at a range of concentrations relative to DAT controls, and the
composition of the microcarriers was probed through biochemical assays and
immunohistochemical staining. Next, pilot in vivo studies were performed to investigate
host cell infiltration into the microcarriers implanted subcutaneously in an
immunocompetent mouse model. Finally, an in vitro validation study was conducted to
confirm that the new microcarriers could support the attachment and growth of tissuespecific stromal cell populations under dynamic conditions within a low-shear spinner
flask system.

2.3 Methods
2.3.1

Materials

Unless otherwise stated, all chemicals and reagents were purchased from Sigma Aldrich
Canada and were used as received.
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2.3.2

Tissue procurement and decellularization

For all tissue types, the decellularization protocols were performed at 37 ℃ under
constant agitation at 100 rpm on an orbital shaker. All decellularization solutions were
supplemented with 1 % antibiotic-antimycotic solution (ABAM) and 1 %
phenylmethanesulphonylfluoride (PMSF), with the exception of the enzymatic treatment
steps, where PMSF was excluded.
Fresh porcine skin was collected from the Mount Brydges abattoir and transported to the
lab on ice. The skin was sectioned into 4 cm2 pieces and the underlying hypodermis was
carefully removed using a scalpel. Next, the epidermis was separated from the dermis
following the methods described by Macdiarmid et al. [250]. Briefly, the samples were
soaked in 55 ℃ water for 2 min and then transferred into ice-cold cation-free Dulbecco's
phosphate buffered saline (D-PBS, Wisent Inc.) for 3 min, and finally, the epidermis was
gently extracted with a sharp razor. The prepared porcine dermis was then subjected to a
3-day decellularization protocol established by Reing et al. [251]. In brief, the dermal
tissue was first rinsed for 10 min in deionized water (dH2O) for a total of 3 washes and
then incubated in 0.25 % trypsin/ 0.1 % ethylenediaminetetraacetic acid (EDTA; Life
Technologies, Burlington, Canada) for 6 h. Following trypsin digestion, the samples
were rinsed with dH2O for 15 min three times, and then incubated in 70 % ethanol
overnight. The following day, the samples were transferred into 3 % H2O2 in dH2O for
15 min, followed by three 15-min rinses in dH2O. The samples were then incubated in a
detergent solution comprised of dH2O with 1 % Triton X-100, 8.9 mM
EDTA-tetrasodium salt, and 57 mM Tris base for 6 h, and the detergent solution was then
replaced before further incubation overnight. In the morning, the samples were rinsed
3 times for 15 min each in dH2O, followed by a final incubation in dH2O supplemented
with 0.1 % peracetic acid in a 4 % ethanol for 2 h. The resultant DDT was rinsed twice
with D-PBS for 15 min, followed by 3 additional washes in dH2O for 30 min each, prior
to being stored in 70 % ethanol at 4 ℃ until further use.
Fresh porcine hearts were collected from the Mount Brydges abattoir and transported to
the lab on ice. The left ventricle was extracted and decellularized using methods adapted
from Wainwright et al. [129], [252]. In brief, the left ventricle was excised, and the
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fibrous outermost layers of epicardium and endocardium were carefully removed to
maximize tissue exposure to the decellularization reagents. The tissue was then frozen at
- 80 °C in a hypotonic cell lysis buffer comprised of 10 mM Tris base and 5 mM EDTA
in dH2O (pH 8.0). This freeze-thaw cycle was repeated 4 times prior to mincing the
samples into ~ 5 mm3 pieces. The minced tissue was then exposed to 2 cycles of
chemical decellularization, each consisting of 6 h in 0.25 % Trypsin/ 0.1 % EDTA (Life
Technologies), 20 h in 4 % sodium deoxycholate in dH2O, and 20 h in 3 % Triton X-100
in dH2O, with 15 min washes in D-PBS between solution changes. The DMT was then
rinsed 3 times with dH2O prior to being stored in 70 % ethanol at 4 ℃ until further use.
Resected human adipose tissue was obtained with informed consent from routine breast
or abdominal reduction surgeries conducted at the University Hospital or St. Joseph’s
Health Care Center in London, ON, Canada, with human research ethics board approval
from Western University (HSREB # 105426). The fresh adipose tissue samples were
transported on ice in sterile D-PBS. DAT was prepared following our established 5-day
detergent-free decellularization protocol [100]. In brief, the samples were first subjected
to 3 freeze thaw cycles (- 80 ℃ to 37 ℃) in a hypotonic cell lysis buffer comprised of
10 mM Tris base and 5 mM EDTA in dH2O (pH 8.0). Next, the tissue was enzymatically
digested with 0.25 % Trypsin/ 0.1 % EDTA (Life Technologies) overnight for ~16 h.
Following this, the samples underwent polar solvent extraction in absolute isopropanol
for 48 h, changing the solution twice daily. The tissue was then rinsed 3 times for 30 min
each in a rinsing buffer comprised of dH2O with 137 mM NaCl, 2.68 mM KCl, 7 mM
Na2PO4, and 1.47 mM KH2PO4, followed by digestion for 6 h in 0.25 % Trypsin/ 0.1 %
EDTA (Life Technologies) and another 3 rinses in the rinsing buffer. The samples were
then incubated overnight in a digestion buffer comprised of 55 mM Na2PO4, 17 mM
KH2PO4, 4.9 mM MgSO4·7 H2O, 15 000 U DNase Type II (from bovine pancreas),
12.5 mg RNase Type III A (from bovine pancreas), and 2000 U Lipase Type VI-S (from
bovine pancreas) in dH2O, for 16 h. Next, the tissue was rinsed 3 times in rinsing buffer
and subjected to a final extraction in absolute isopropanol for 8 h. At the end of
processing, the DAT was rinsed a final 3 times in the rinsing buffer and stored in 70 %
ethanol at 4 ℃ until further use.
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2.3.3

Non-chemically crosslinked microcarrier fabrication

Large batches of ECM were prepared by pooling DDT and DMT from 3 different
animals, and DAT from 5 different donors. All decellularized tissues were rinsed
thoroughly with dH2O to remove residual 70 % ethanol and transferred fully-hydrated
into 50 mL conical tubes (filling a maximum of half the volume), which were frozen on
their sides at - 80 °C overnight. The tissues were lyophilized for a minimum of 48 h and
minced finely with scissors into ~1-2 mm2 pieces. The samples were then cryomilled
using a Retsch MM 400 mixer mill unit by submerging the milling chambers containing
the minced tissue and two 10-mm stainless steel milling balls in liquid nitrogen for 3 min,
followed by milling at 30 Hz for 3 min. The resultant decellularized tissue powders were
stored in glass vials in a desiccated chamber until further use.
Decellularized ECM suspensions were prepared following established methods in our
lab, adapted from the literature [130], [131]. Briefly, to prepare a stock 70 mg/mL ECM
suspension, 350 mg of milled ECM was placed in a 15 mL conical tube with 3.5 mg (1 %
(w/w)) α-amylase from Aspergillus oryzae and 10 mL of 0.22 M NaH2PO4 in dH2O
(pH 5.4) was added. The mixture digested for 72 h under continuous agitation at 300 rpm
and room temperature (RT). Following digestion, the ECM was rinsed by centrifuging at
1500 xg for 10 min and the supernatant was removed and replaced with 10 mL of 5 %
NaCl in dH2O. The samples were then agitated for 10 min at RT and re-centrifuged. The
rinsing in 5 % NaCl was repeated, followed by a rinse in dH2O.

After the final

centrifugation, the digested ECM pellet was resuspended in 0.2 M acetic acid in dH2O to
a total volume of 5 mL, and incubated under agitation overnight at 100 rpm and 37 °C.
The next day, the samples were homogenized (PowerGen Model 125 homogenizer,
Fisher Scientific, Ottawa, ON, Canada) to obtain a uniform suspension and stored at 4 °C
until further use.
Prior to electrospraying, the DDT, DMT, and DAT suspensions were warmed to 37 °C in
an incubator shaker overnight and diluted to 15, 25, and 35 mg/mL concentrations with
0.2 M acetic acid. The ECM suspensions were electrosprayed directly into a Dewar
containing liquid nitrogen. A 25G winged infusion set (BD Medical, Mississauga, ON,
Canada) was used, with the needle tip placed approximately 5 cm from the surface of the
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liquid nitrogen. A voltage of 18 kV was applied to the needle tip, and the extrusion rate
was set at 30 mL/h, controlled using a syringe pump (PHD 22/2000 infusion, Harvard
Apparatus, Holliston, MA, USA). Following electrospraying, the frozen microcarriers
were collected, transferred into 50 mL conical tubes, and immediately lyophilized
overnight. Once dried, the microcarriers were resuspended in 100 % ethanol, sieved with
a 1000 µm strainer to remove aggregates and stored in 100 % ethanol at 4 °C until further
use. To rehydrate the microcarriers for subsequent studies, a very gradual rehydration
process was followed using an ethanol series diluted in D-PBS (95 %, 90 %, 85 %, 80 %,
75 %, 70 %, 65 %, 60 %, 55 %, 50 %, 40 %, 30 %, 20 %, 10 %, 0 %). This process was
performed over a period of two days, incubating the samples under static conditions at
4 ℃ and allowing for complete settling of the microcarriers to occur at each dilution
stage.

2.3.4

Microcarrier size distribution

Rehydrated DDT, DMT, and DAT microcarriers were imaged using an EVOS XL Digital
Inverted Brightfield and Phase Contrast Microscope (Life Technologies), and the Feret’s
diameter was measured using ImageJ to determine the size distribution (n=100
microcarriers/trial, N=3 trials with different ECM batches for the 35 mg/mL
concentration and N=1 for the 15 and 25 mg/mL concentrations).

2.3.5

Scanning Electron Microscopy

The surface ultrastructure of the DDT, DMT, and DAT microcarriers was visualized by
scanning electron microscopy (SEM) using published protocols [253]. Briefly, the
microcarriers were lyophilized and coated with osmium prior to imaging with a LEO
1530 microscope (Zeiss, Germany) at an accelerating voltage of 2 kV and working
distance of 6 mm.

2.3.6

Mechanical Testing

The Young's moduli of the DDT, DMT, and DAT microcarriers fabricated with 15, 25,
and 35 mg/mL ECM concentrations were determined using a CellScale MicroTester
system (Waterloo, ON, Canada). For the testing, the micro-scale parallel-plate
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compression system was fitted with a 154 µm diameter cantilever. Briefly, individual
hydrated microcarrier samples were placed in a D-PBS fluid bath and the cantilever was
lowered until the upper compression plate made contact with the top of the microcarrier.
The microcarriers (n=6 microcarriers/trial, N=3 trials with different ECM batches) were
compressed to 50 % of their initial diameter for 3 preconditioning cycles at a strain rate
of 0.01 s-1, after which the data from 3 consecutive cycles was collected for each sample.
The Young’s moduli were calculated using nonlinear least squares curve fitting with a
published extended mechanics model for large elastic deformations of spherical
microparticles [254].

2.3.7

Biochemical assays

Biochemical assays were performed to compare the relative collagen content
(hydroxyproline assay), sulphated glycosoaminoglycan content (dimethylmethylene blue
(DMMB) assay), and elastin content (Fastin™ elastin assay) in the DDT, DMT and DAT
microcarriers synthesized with an ECM suspension concentration of 35 mg/mL.
For the hydroxyproline and DMMB assays, 10 mg samples of each microcarrier type
(n=3 samples/trial, N=3 trials with different ECM batches) were digested with 80 μg/mL
of papain in buffer comprised of dH2O with 35.3 mM ammonium acetate, 1.3 mM
EDTA, and 0.31 mg/mL of DL-dithiothreitol (pH 6.2) under agitation at 65 ℃ for 2 h.
For the DMMB assay, 10 μL samples of the digested microcarriers were transferred in
technical triplicates into a 96-well plate and 200 μL of a 1.6 % solution of DMMB in
dH2O supplemented with 1 % ethanol and 0.2 % formic acid was added and incubated at
RT for 5 min. The absorbance was read at 525 nm using a CLARIOstar®
spectrophotometer (BMG LABTECH Inc., Cary, NC, USA), and the sulphated GAG
content was determined through comparison to a chondroitin sulphate standard curve. For
the hydroxyproline assay, the digested microcarriers were hydrolyzed with 12 N
hydrochloric acid at 110 ℃ for 18 h and neutralized with 6 N sodium hydroxide. Equal
volumes of 0.05 N chloramine-T / 20 % 2-methoxyethanol (20 min incubation), 3.15 N
perchloric acid in dH2O (5 min incubation) and Ehrlich’s reagent (20 min incubation at
60 ℃) were sequentially added to the samples (diluted 1:30 in dH2O) within a 96-well
plate. After a 5 min incubation at 4 ℃ and a 20 min incubation at RT, the absorbance was
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measured at 560 nm using the CLARIOstar® spectrophotometer (BMG LABTECH Inc.),
and the hydroxyproline content was determined through comparison to a hydroxyproline
standard curve.
The Fastin™ elastin assay was used to assess the total elastin content following the
manufacturer’s instructions. In brief, 5-10 mg microcarrier samples (n=3 samples/trial,
N=3 trials with different ECM batches) were added to 1.5 mL centrifuge tubes and
750 μL of 0.25 M oxalic acid was added. The samples were incubated at 100 ℃ for
60 min to extract the elastin and then cooled to RT and centrifuged at 14,000 xg for
10 min. The supernatants were collected and retained for analysis. A second extraction
was performed, repeating these steps and the samples were pooled. Following the
extractions, precipitation of duplicate α-elastin standards and the test samples was
performed by adding an equal volume of elastin precipitating reagent, incubating for
15 min to precipitate the α-elastin and centrifuging for 10 min at 10,000 xg at RT. The
liquid contents were removed, 1 mL of dye reagent was added to the α-elastin pellets, and
the samples were incubated for 90 min at RT under agitation at 100 rpm. The samples
were then centrifuged at 10,000 xg for 10 min at RT to remove any unbound dye. The
bound dye was then dissociated using 250 μL of dye dissociation reagent, and the
samples were vortexed, incubated for 10 min at RT, and transferred into 96-well plates.
The absorbance was measured at 513 nm using a CLARIOstar® spectrophotometer
(BMG LABTECH Inc.) and the elastin content was determined through comparison to
the α-elastin standard curve.

2.3.8

Immunohistochemistry

To obtain a more comprehensive understanding of the complex ECM composition in the
DDT, DMT and DAT microcarriers fabricated with the 35 mg/mL ECM suspension,
immunostaining was performed with polyclonal rabbit anti-collagen I (Abcam, ab34710,
diluted 1:200), polyclonal rabbit anti-collagen IV (Abcam, ab6586, diluted 1:200),
polyclonal rabbit anti-collagen VI (Abcam, ab6588, diluted 1:150), polyclonal rabbit
anti-laminin (Abcam, ab11575, diluted 1:200), and polyclonal rabbit anti-fibronectin
(Abcam, ab6328, diluted 1:300), using native porcine myocardium, porcine skin, and
human adipose tissue samples as positive controls (Supplementary Figure A1).
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Microcarrier and control tissue samples (n=3 blocks/trial, N=3 trials with different ECM
batches) were embedded in Tissue-Tek® O.C.T.™ Compound (Electron Microscopy
Sciences) and cryosectioned (7 μm). Prior to staining, all slides were washed 3 x 2 min
with tris buffered saline (TBS) supplemented with 0.025 % Triton X-100 at RT, prior to
blocking in TBS supplemented with 10 % goat serum and 1 % BSA for 1 h at RT.
Blocked slides were then incubated with the primary antibody in a 1 % BSA solution in
TBS overnight at 4 ℃ in a humidity chamber. Following primary antibody incubation,
the slides were rinsed 3 x 2 min with TBS with 0.025 % Triton X-100. Dylight 650 goat
anti-rabbit secondary antibody (Abcam, ab96902) was diluted in TBS with 1 % BSA (2X
the dilution of the primary antibody) and applied to the sections. Slides were rinsed 3 x
3 min with TBS, mounted with Fluoroshield™ mounting medium (Abcam, ab104135)
and imaged using an EVOS FL® imaging system (Life Technologies).

2.3.9

Pilot in vivo study probing the host response to the implanted
microcarriers in immunocompetent mice

The pilot in vivo study followed the Canadian Council on Animal Care Guidelines and
was reviewed and approved by the Animal Care Committee at Western University
(Protocol # 2015-049). Prior to implantation, the DDT, DMT, and DAT microcarriers
were labelled with an Alexa Fluor® 350 NHS Ester (Succinimidyl Ester) (Thermo Fisher
Scientific, CAT # A10168) following the manufacturer’s instructions to aid in their
visualization within the tissue sections [255]. Male C57BL/6 mice of 12 weeks in age
(N=6 mice total) were anesthetized with isoflurane and given pre-operative doses of
bupivacaine and meloxicam. A small incision was made on each side of the dorsa and
two separate subcutaneous pockets were created using blunt-ended forceps. Next, 200 μL
of microcarriers were injected subcutaneously into the 2 implant regions through an 18G
needle, and the incisions were closed with surgical staples. The animals were euthanized
at 2-weeks post-implantation by CO2 overdose and the tissues surrounding the implant
sites were excised. The explants were embedded in O.C.T. Compound and stored
at - 20 ℃ prior to cryo-sectioning.
Immunofluorescence staining was used to probe host macrophage and endothelial cell
infiltration into the implanted microcarriers. The cryo-sectioned samples were rinsed and
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then blocked for 1 h at RT with TBS supplemented with 10 % goat serum and 1 %
TWEEN® 20. The samples were then stained overnight at 4 ℃ using anti-rabbit primary
antibodies for Iba1 to identify host macrophages [256] (Abcam, ab178846, diluted 1:200)
or CD31 to identify host endothelial cells (Abcam, ab28364, diluted 1:300). The samples
were then rinsed with TBS and incubated with an Alexa Fluor® 594 conjugated goat
anti-rabbit secondary antibody (Abcam, ab150080, diluted 1:400 for Iba1 and 1:600 for
CD31) for 1 h at RT. The slides were rinsed with TBS and then counterstained for 15 min
with SYTOX™ Orange (Life Technologies, diluted 1:1000 in TBS) to identify cell
nuclei, prior to rinsing and mounting in Fluoroshield™ mounting medium. The samples
were imaged using a EVOS FL® imaging system (Life Technologies).

2.3.10

In vitro validation that the microcarriers support the
attachment and growth of tissue-specific stromal cells under
dynamic conditions

Primary human dermal fibroblasts (HDFbs) were generously donated by Dr. Douglas
Hamilton at Western University. The HDFbs were cultured in complete medium
comprised of high glucose Dulbecco’s Modified Eagle’s medium (DMEM) (Wisent Inc.)
supplemented with 10 % fetal bovine serum (FBS) (Wisent Inc) and 1 %
penicillin-streptomycin (Life Technologies). Human ventricular cardiac fibroblasts
(NHCF-V) were purchased from Lonza and were cultured in Fibroblast Basal Medium
(FBM) supplemented with the FGM-3 SingleQuots Kit (Lonza, CAT # CC-4526).
Human ASCs were isolated from the fresh adipose tissue samples following published
methods [100] and cultured in complete medium comprised of DMEM:Ham’s F12
supplemented with 10 % FBS and 1 % penicillin-streptomycin.
Prior to seeding, the DDT, DMT, and DAT microcarriers were labeled with an Alexa
Fluor® 405 NHS Ester (Succinimidyl Ester) (Thermo Fisher Scientific, CAT # A30000)
following the manufacturer's instructions to aid in subsequent visualization via confocal
imaging [128]. The three different types of microcarriers were seeded with their
tissue-specific stromal cell types under dynamic conditions using a CELLSPIN flask
(INTEGRA Biosciences, USA). Before seeding, 100 mg (dry weight) of microcarriers
were measured for each 100 mL CELLSPIN flask and rehydrated following the

48

previously-described procedures. A previously-established 12-hour seeding regimen was
followed [227], and then the CELLSPIN flasks were stirred continuously at 25 rpm for
1 week. Half of the total media volume of 100 mL was changed every 2-3 days. Cellular
attachment on the microcarriers was visualized at time points of 24 h, 72 h and 1 week
using a Zeiss laser scanning microscope (LSM 800 with Airyscan, Germany) on samples
labeled with LIVE/DEAD® staining (Life Technologies) following the manufacturer’s
instructions (n=1 flask/trial, N=3 seeding trials).

2.3.11

Statistical Analyses

All values are reported as the mean ± standard deviation. Statistical analyses were
performed using linear mixed effects models with R statistics software (R core team
2017), using the “nlme” package for linear and nonlinear mixed effects models [257].
GraphPad Prism software version 6 (GraphPad, La Jolla, CA) was used to produce
graphs. Data were compared, correcting for multiple comparisons as described by
Hothorn et al. [258], and corrected p-values <0.05 were considered to be statistically
significant.

2.4 Results
2.4.1

Electrospraying methods can be applied to generate soft and
compliant microcarriers from multiple ECM sources that are
stable without chemical crosslinking

The primary objective of this study was to investigate whether we could apply
electrospraying methods to generate 3D microcarriers comprised exclusively of ECM
using a range of decellularized tissues as starting materials. In previous work, we first
established this new electrospraying methodology using ECM suspensions synthesized
with 50 mg/mL of a-amylase digested DAT [128]. In the current study, we successfully
used this same approach to fabricate microcarriers from decellularized porcine dermis,
decellularized porcine myocardium and decellularized human adipose tissue using ECM
suspension concentrations of 15, 25, and 35 mg/mL. These conditions were selected to
probe how the concentration impacted the microcarrier size, ultrastructure, and
mechanical properties. The 35 mg/mL concentration was selected as the upper limit as
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the DDT suspension was extremely viscous at higher concentrations, which made
electrospraying extremely challenging, and we wanted to compare the microcarriers
synthesized with the different ECM sources over the same range of concentrations.
Spherical microcarriers were generated under all conditions tested that were stable and
did not aggregate following rehydration in PBS. However, it was critical that the
lyophilized microcarriers were rehydrated very gradually through an ethanol series before
being transferred into PBS, otherwise rapid swelling caused a loss in structure and
potentially complete disintegration. In general, the microcarriers fabricated with the
highest ECM concentration were found to be more structurally robust during routine
handling (Figure 2.1A). The Feret’s diameter was measured for the rehydrated
microcarriers in PBS (Figure 2.1B). While there were no significant differences in the
average diameters between the microcarriers fabricated with the various ECM sources or
concentrations, the microcarriers fabricated with the 25 mg/mL ECM suspensions were
found to be the most consistent in size regardless of the starting ECM source, with
80-95 % of all microcarriers between 400-500 μm in size. In contrast, only 50-65 % of
the microcarriers were within this size range when synthesised with the 35 mg/mL ECM
suspensions. The broader size distributions observed at the highest concentrations were
attributed to the increased viscosity of the ECM suspensions causing greater variability
during electrospraying.
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Figure 2.1: Microcarriers could be fabricated at a range of concentrations from all
three ECM sources (DDT, DMT, DAT) that were stable following rehydration
without the need for chemical crosslinking. (A) Representative brightfield images of
the hydrated microcarriers fabricated with an ECM suspension concentration of
35 mg/mL. Scale bar = 500 μm. (B) Size distribution plots showing the Feret’s diameter
of the microcarriers following rehydration in PBS (n = 100 individual
microcarriers/batch, N = 1 batch for the 15 and 25 mg/mL concentrations and N = 3
batches for the 35 mg/mL concentration). Values reported represent the mean ± std dev.
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The microcarrier ultrastructure was assessed through SEM, which showed that all of the
microcarriers were comprised of complex networks of fibers of varying sizes (Figure
2.2; Supplementary Figure A2). Notably, the microcarriers fabricated from 15 mg/mL
ECM suspensions were more irregular in shape, while those synthesized with the
35 mg/mL ECM suspensions were qualitatively more spherical. In terms of overall
macroscopic appearance, the DDT microcarriers were more distinct, including more
globular regions and having spherical pores that were particularly noticeable at the
highest ECM concentration.

Figure 2.2: Scanning electron microscopy (SEM) revealed that all three
microcarrier types had a complex fibrous ultrastructure. The microcarriers fabricated
with the highest ECM suspension concentration (35 mg/mL) were consistently spherical,
while those fabricated at the lowest concentration (15 mg/mL) were more irregular in
shape. Scale bar = 100 μm.
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Compression testing was performed on the hydrated microcarriers to determine their
Young’s moduli (Figure 2.3A). In general, the microcarriers were soft and compliant,
having moduli in the range of 0.1 – 0.45 kPa, and were capable of being compressed up
to 50% repeatedly over 3 cycles without showing permanent deformation for all three
concentrations (Figure 2.3B). There was an increasing trend in the modulus as the
concentration increased, but this was only significant for the DAT (35 mg/mL as
compared to both lower concentrations) and the DDT (35 mg/mL as compared to
15 mg/mL). At the highest ECM suspension concentration, the DAT and DDT
microcarriers were significantly stiffer than the DMT microcarriers, although all the
materials were very soft.

Figure 2.3: The microcarriers were soft and resilient, withstanding repeated
compression up to 50% of their original diameter. (A) The average Young’s moduli of
the DDT, DMT, and DAT microcarriers determined through compression testing using a
CellScale MicroTester (n=6 microcarriers/trial, N=1 trial for the 15 and 25 mg/mL
concentrations and N = 3 trials for the 35 mg/mL concentration, prepared with different
ECM batches). (B) Representative force versus deformation curves for individual
microcarriers prepared with the 35 mg/mL ECM suspensions. Data from 3 cycles are
shown with compression at a strain rate of 0.01 s-1. * p<0.05, *** p<0.001.
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2.4.2

DDT, DMT and DAT microcarriers have a tissue-specific
composition

Biochemical assays were performed to quantitatively compare the ECM composition in
the 35 mg/mL microcarriers fabricated from the 3 ECM sources. The hydroxyproline
assay, which provides a measure of the total collagen content, suggested that the DAT
microcarriers contained significantly more collagen than the DDT and DMT
microcarriers (Figure 2.4A). In contrast, the DMMB and Fastin™ elastin assays revealed
that the DDT microcarriers contained significantly more sGAG and elastin as compared
to the DMT and DAT microcarriers (Figure 2.4B, C).

Figure 2.4: The DDT, DMT, and DAT microcarriers have distinct biochemical
compositions. (A) Hydroxyproline assay results showing significantly higher collagen
content in the DAT microcarriers compared to both DDT and DMT microcarriers. (B)
DMMB assay results showing that the DDT microcarriers contained significantly more
sGAG compared to the DMT and DAT microcarriers. (C) Fastin™ elastin assay results
showing that the DDT microcarriers contained significantly more elastin than the DMT
and DAT microcarriers. (n=3 samples/trial, N=3 trials with different ECM batches)
**p<0.01, ***p<0.001.
To further probe the ECM composition, immunohistochemistry was performed to assess
the presence and distribution of collagen I, collagen IV, collagen VI, fibronectin, and
laminin within the various types of microcarriers fabricated with the 35 mg/mL ECM
suspensions (Figure 2.5). The analysis demonstrated that the DDT, DMT and DAT
microcarriers showed strong positive staining for all collagen types and fibronectin.
Notably, laminin was not detected in any of the samples. Qualitatively, staining for
collagen type I suggested that the DAT contained a denser and more cohesive network of
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collagen fibers. In contrast, the collagen staining patterns suggested that the network in
the DMT microcarriers may be more fragmented.

Figure 2.5: The DDT, DMT and DAT microcarriers incorporated multiple types of
collagen and fibronectin. Representative immunohistochemical staining showing the
presence of collagen types I, IV, and VI, and fibronectin within the microcarriers
prepared with 35 mg/mL ECM suspensions. No positive staining for laminin was
detected in any of the samples. Scale bar = 400 μm.

2.4.3

Implanted ECM-derived microcarriers are well tolerated and
support host cell infiltration in an immunocompetent mouse
model

As the microcarriers have the potential to be applied as cell delivery vehicles, a pilot in
vivo study was performed to investigate the host response to the DDT, DMT, and DAT
microcarriers fabricated with the 35 mg/mL ECM suspensions at 2 weeks following
injection into subcutaneous pockets in immunocompetent C57BL/6 mice. The
microcarriers were pre-labelled with an amine-reactive Alex Fluor 350 dye to facilitate
visualization within the tissue sections [255]. To probe the innate immune response,
staining was performed for Iba1, as a pan-macrophage marker [92]. At 2 weeks, Iba1+
cells were visualized primarily at the interface of the implanted microcarriers and host
tissues (Figure 2.6). Qualitatively, there appeared to be enhanced macrophage infiltration
into the DDT and DMT microcarriers as compared to the DAT microcarriers. Notably,
Sytox orange staining of cell nuclei revealed that there was a high density of host cells
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throughout the microcarriers in all the groups, with the macrophages representing only a
very small fraction of the infiltrating cells at this timepoint. Overall, the DDT
microcarriers qualitatively appeared to contain the highest density of host cells.

Figure 2.6: The microcarriers supported extensive host cell infiltration, with Iba1+
macrophages dectected within the implant periphery at 14 days following
subcutaneous implantation in C57BL/6 mice. Representative images showing the
aggregated microcarriers (pre-labelled with an Alexa Fluor 350 succinimydyl ester; blue)
and Iba1+ macrophages (green), with nuclei counterstained with Sytox Orange (red)
shown in the merged images. White dashed lines denote the periphery of the implants, M
denotes the implanted microcarriers, and arrows highlight Iba1+ cells. In the DMT group,
the panniculus carnosus is present and also appears blue due to autofluorescence. Scale
bar = 100 μm.
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To further characterize the infiltrating host cell population, staining was also performed
for CD31 to identify host endothelial cells as a potential marker of early angiogenesis.
CD31+ cells could be visualized at the boundary and infiltrating into the implanted
microcarriers in all the groups at 2 weeks. Qualitatively, a higher density of CD31+ cells
was visualized in the host tissues adjacent to the implants in the DDT group.

Figure 2.7: Host CD31+ endothelial cells were visualized within the implant
periphery at 14 days following subcutaneous implantation in C57BL/6 mice.
Representative images showing the aggregated microcarriers (pre-labelled with an Alexa
Fluor 350 succinimydyl ester; blue) and CD31+ cells (green), with nuclei counterstained
with Sytox Orange (red) shown in the merged images. White dashed lines denote the
periphery of the implants, M denotes the implanted microcarriers, and arrows highlight
CD31+ cells. In the DMT group, the panniculus carnosus is present and also appears blue
due to autofluorescence. Scale bar = 100 μm.
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2.4.4

DDT, DMT and DAT microcarriers support the attachment
and growth of tissue-specific stromal cell populations within
spinner flask systems

Preliminary in vitro cell culture studies were performed as a final step to validate the
potential of the microcarriers as a cell culture platform for tissue-specific adherent cell
populations within stirred culture bioreactors. More specifically, the DDT, DMT and
DAT controls were seeded with tissue-specific stromal cell populations (e.g., human
dermal fibroblasts, human cardiac fibroblasts, and human ASCs, respectively), and
cultured under dynamic conditions within a low-shear spinner flask system over 1 week.
LIVE/DEAD® staining with visualization by confocal microscopy was performed at
24 h, 72 h and 1 week to qualitatively assess cell attachment and growth on the
microcarriers (Figure 2.8). At 24 h, a low density of cells was visualized heterogeneously
dispersed across the surface of the microcarriers in all groups. There was a qualitative
increase in the density of live cells on the microcarriers over time, suggesting that all
three platforms supported cell growth. Interestingly, while the DMT and DAT
microcarriers remained spherical throughout the 1-week culture period, the DDT
microcarriers showed signs of deformation and loss of their spherical shape starting as
early as 24 h post-seeding. The majority of cells remained alive for all conditions and
timepoints, however a small number of dead cells were observed at 72 h and 7 d on the
DDT microcarriers.
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Figure 2.8: The ECM-derived microcarriers support the attachment and growth of
tissue-specific stromal cell populations under dynamic culture conditions.
Representative LIVE/DEAD® staining visualized through confocal microscopy showing
the presence of calcein+ live cells (green) on the surface of the microcarriers (blue), with
a qualitative increase in the density observed over time. Arrows highlight EthD-1+ dead
cells (red) observed only in the DDT group. Macroscopic deformation of the DDT
microcarriers was observed starting as early as 24 h post-seeding. Scale bar = 100 µm.

2.5 Discussion
Stirred bioreactors represent a promising approach for generating cells for therapeutic
applications [171]. To support the expansion of adherent cell populations, 3D
microcarriers are typically applied within these systems [259]. Although a variety of
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microcarrier types are commercially-available, there are limitations to the existing
materials. When developing platforms for cell expansion, it is important to recognize the
critical impact that the cellular microenvironment has on cell attachment, proliferation,
and differentiation. Within tissues, cell function is mediated through interactions with the
ECM, which has a tissue-specific composition and structure [248]. Current microcarrier
technologies lack the biological complexity of the native ECM, and typically provide a
much stiffer substrate, which may be favorable for longevity, but can have detrimental
effects on cell phenotype and function [171], [260].
In the current study, we successfully demonstrated that electrospraying techniques could
be applied to generate tissue-specific microcarriers using multiple decellularized tissues
as starting materials. More specifically, we synthesized novel ECM-derived microcarriers
comprised exclusively of decellularized porcine dermis and myocardium, and also
demonstrated that the previously-established DAT platform could be extended to
fabricate

microcarriers

using

ECM

suspension

concentrations

ranging

from

15-35 mg/mL. The microcarriers were stable following a controlled rehydration process
without chemical crosslinking, which may be beneficial for in vitro cell attachment [261],
as well as in vivo performance including cellular infiltration, scaffold remodeling and
implant vascularization [262].
In general, the microcarriers synthesized with the highest ECM concentration were more
structurally robust and had a more consistent spherical shape. Interestingly, the size range
was similar for all three sources without having to alter the electrospraying parameters.
However, the microcarriers fabricated with the 35 mg/mL ECM suspensions had a
broader size range distribution, which is likely related to the increased viscosity of these
suspensions [263]. Many commercially-available microcarriers also have varying
diameters, with Cultispher-S, Cytodex 1™, and FACT III microcarriers reported to have
hydrated diameters ranging from 130-380 µm, 147-248 µm, and 125-212 µm,
respectively [264], [265]. Other studies have shown that microcarriers with an average
size range between 350-500 µm are favorable for supporting the attachment and
expansion of various cell types including MSCs [266], [267]. If a narrower size
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distribution was desired, it would be possible to employ sieving to select the
microcarriers within the target range.
SEM imaging revealed that all the microcarriers were comprised of a complex network of
interconnected fibers. Notably, macroscopic differences were observed in the DDT
microcarriers, consistent with the observed variations in the ECM composition. All the
microcarriers were porous, with the DDT microcarriers having more spherical pores.
Qualitatively, the pores were small, which would likely limit cellular infiltration at early
timepoints. However, our previous study with the DAT microcarriers fabricated with
50 mg/mL ECM suspensions showed evidence of cell infiltration based on DAPI staining
of sectioned microcarriers after 4 weeks of culture within spinner flasks [128], supporting
that the cells can remodel the microcarriers over time. The results from the current in
vivo study also support this, with extensive host cell infiltration observed into all
3 microcarrier types at 2 weeks post-implantation.
In addition to composition, the mechanical properties of biomaterial substrates can also
play an important role in directing cell functions including attachment, proliferation and
differentiation [268], [269]. While there can be species variability, Young’s moduli
reported in the literature for human dermis, ventricular and adipose tissues are in the
range of 4.5-8 kPa [57], [270], 10-15 kPa [271], and 3-4 kPa [100] respectively, which is
an order of magnitude higher than the values measured for the microcarriers in the
current study. This marked reduction in the moduli is likely attributed to the multiple
processing steps required to generate the microcarriers, including the combination of
decellularization, cryomilling and α-amylase digestion, which result in a markedly
different ECM organization as compared to what would be found in the native tissues.
The DMT microcarriers were significantly less stiff than the DDT and DAT microcarriers
at the 35 mg/mL concentration, and unlike the other two sources, showed no significant
differences in the moduli between concentrations. Although this may be related to the
tissue-specific ECM composition, the decellularization protocols used to generate the
starting materials may have also contributed to these differences, as each tissue type
required a customized protocol to ensure effective cellular removal [100], [251], [252].
While Triton X-100 is generally regarded as being more mild in terms of its effects on the
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structure and composition of ECM proteins [272], ionic detergents including the sodium
deoxycholate that was used to generate the DMT have been reported to disrupt tissue
structures and denature proteins [97]. Notably, the IHC staining for collagen suggested
that the DMT microcarriers had a less cohesive internal structure as compared to the
DDT and DAT microcarriers, which is consistent with the mechanical testing data.
The biochemical characterization results support that the microcarriers had tissue-specific
compositions. While the DAT microcarriers were more collagen rich, the DDT
microcarriers contained significantly more sGAG and elastin. Overall, the trends in terms
of the relative sGAG and elastin contents between the ECM sources are consistent with
what would be expected for the different tissue types based on values reported in the
literature [252], [273]–[275].

IHC analyses confirmed that all of the microcarriers

contained a variety of collagens, including collagen type I, which would be expected to
contribute

to

the

microcarrier

structure

[276],

as

well

as

the

basement

membrane-associated collagens type IV and VI, which may have bioactive effects [277].
All microcarrier types stained strongly positive for fibronectin, which may be favorable
for promoting cell attachment and proliferation [39]. Interestingly, laminin was not
detected in any samples, although it was observed in the positive controls. These findings
are consistent with previous work with myocardial ECM-derived foams, which showed
positive staining for laminin in foams fabricated with decellularized myocardium that had
been minced and digested with a-amylase, but not in those samples that had been
cryomilled prior to enzymatic digestion [129], suggesting that the milling process may
have affected the protein structure. In the current project, cryomilling was necessary to
generate a more homogeneous ECM suspension that was required to avoid issues with
needle clogging during electrospraying.
Given that they are comprised exclusively of ECM, the microcarriers have the potential
to be applied as injectable cell delivery platforms. As such, pilot in vivo studies were
performed to investigate implant integration and host cell infiltration. In general, the
implants were well tolerated and there were no adverse reactions in any of the mice.
Histological evaluation of the pre-labeled microcarriers showed that they could be
visually detected at 2-weeks post-implantation and appeared to have aggregated together
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into larger tissue-like structures that were well integrated with the host tissues. The
microcarriers contained a high density of host cells at 2 weeks, indicating they were
strongly supportive of host cell infiltration. Notably, the degradation products of
ECM-derived scaffolds can function as chemoattractants for stem and progenitor cells
both in vitro and in vivo [81], which may have contributed to the observed cell
infiltration in all groups. As macrophages are known to play an important role in the
remodeling of ECM-derived biomaterials [278], staining for Iba1 was performed and
revealed a low density of macrophages at the interface with the host tissues. The
qualitatively higher density of macrophages within the DDT and DMT microcarriers
relative to the DAT microcarriers could be attributed to variations in the ECM
composition, or potentially to variable low levels of intracellular debris that may remain
within the scaffolds following decellularization [279]. In general, the macrophages
comprised only a small fraction of the infiltrating cells, and future studies should assess
additional markers to probe the presence and distribution of other immune cell
populations, such as T cells, neutrophils, and monocytes, as well as other host cell types
including fibroblasts. CD31 staining revealed that there were host endothelial cells
infiltrating the implants, which is a positive sign in terms of integration. The qualitatively
enhanced presence of CD31+ cells in the DDT implant periphery may be related to the
higher concentration of sGAGs in this group, which are known to have pro-angiogenic
effects [280], or potentially to the higher elastin content, as elastin-derived peptides have
also been reported to stimulate endothelial cell migration [281]. Future studies should
probe additional markers of angiogenesis to investigate whether there are further
differences between the groups over time. In addition, it would be interesting to explore
the host response when the microcarriers are delivered in combination with cells.
Finally, the in vitro study validated that all microcarrier types could support the
attachment and growth of tissue-specific stromal cells under dynamic conditions within
spinner flasks. The stirring rate of 25 rpm was selected for these studies based on our
previous work with the human ASCs on DAT microcarriers [128]. One notable
observation was that the DDT microcarriers rapidly lost their spherical shape following
cell seeding, which may have been attributed to the higher sGAG and elastin content
resulting in a more deformable matrix [282]. However, it is also possible that the dermal
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fibroblasts were more contractile than the ASCs or cardiac fibroblasts. A limitation of
this study is that only qualitative methods were applied to provide an initial indication of
the potential of the microcarriers as cell expansion platforms. Future studies should
expand on this foundation by investigating the cellular response on the various
microcarriers in greater depth, using more quantitative approaches and dynamic culture
conditions carefully selected to promote the expansion of each specific cell type.

2.6 Conclusions
In conclusion, this study demonstrates that tissue-specific ECM-derived microcarriers can
be generated via electrospraying techniques using a range of different decellularized
tissues as ECM sources. More specifically, dermal, myocardial and adipose-derived
microcarriers were fabricated using ECM suspensions prepared over a range of
concentrations that were stable without the need for chemical crosslinking or other
additives, demonstrating the versatility of the a-amylase digestion method and
electrospraying process. While the microcarriers fabricated from the different sources had
similar soft and compliant mechanical properties and were of a similar size range, their
biochemical composition varied as would be expected for each source. The preliminary
in vivo and in vitro studies yielded promising results in terms of the cell-supportive
characteristics of all three microcarrier types, justifying their further investigation as
tissue-specific platforms for cell culture and delivery. Building from the current study, it
would be interesting to assess whether the tissue-specific ECM could direct the
lineage-specific differentiation of stem or progenitor cell populations within the spinner
flask systems, including exploring how the dynamic culture conditions could be tuned to
augment proliferation and/or differentiation. Overall, this work demonstrates the
flexibility of our electrospraying approach to microcarrier synthesis and showcases the
potential of generating a broad range of tissue-specific microcarriers comprised
exclusively of ECM that could be applied as off-the-shelf cell culture substrates or
potentially in vivo delivery platforms.
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Chapter 3
3 Probing the effects of matrix-derived microcarrier
composition on human adipose-derived stromal cells
expanded within spinner flasks
3.1 Abstract
Recognizing the multilineage potential of human adipose-derived stromal cells (hASCs)
and the tissue-specific, cell-instructive capacity of the extracellular matrix (ECM), the
focus of this study was to compare the effects of dynamic culture under proliferation
conditions on 3D microcarriers comprised of decellularized adipose tissue (DAT) or
decellularized cartilage tissue (DCT) on the phenotype and function of hASCs. Following
validation of an effective protocol for decellularizing porcine auricular cartilage,
electrospraying fabrication techniques previously established using the DAT were
extended to generate soft and compliant DCT microcarriers that were stable in culture
without chemical crosslinking. Characterization studies confirmed that the DAT and
DCT microcarriers produced were of a similar size range and had matching Young’s
moduli but were compositionally distinct. Assessment of hASC expansion on the
microcarriers over 14 days of culture within spinner flasks indicated that there was a
significantly higher cell density on the DCT microcarriers at 7 and 14 days, which was
likely attributed to an enhancement in initial cell attachment. A qPCR array was used to
probe the effects of dynamic culture on the ECM-derived microcarriers on mesenchymal
stem cell-associated gene expression, which showed there were no significant differences
in the gene expression patterns between the two microcarrier groups. However,
comparison to baseline conditions of the hASCs prior to microcarrier seeding suggested
that culturing on the DCT microcarriers may have predisposed the cells towards the
chondrogenic lineage. Global analysis of protein expression in cell lysates collected after
14 days of dynamic culture on the DAT and DCT microcarriers in comparison to baseline
controls using liquid chromatography-tandem mass spectrometry (LC-MS/MS) indicated
that ~83 % of the 4851 proteins identified were shared in all conditions. Notably,
label-free quantification revealed that a number of proteins associated with extracellular
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matrix organization and cell adhesion were significantly changed by 3D culture on the
microcarriers relative to the baseline conditions. In comparing the DAT and DCT groups,
more proteins were identified that were significantly upregulated in the DCT group,
including a variety of proteins associated with cartilage development and the extracellular
matrix of elastic cartilage. Luminex assays were performed to quantify the levels of
expression of a range of immunomodulatory and angiogenic factors in conditioned media
samples collected from the two microcarrier groups, which showed similar profiles with
the exception of significantly higher levels of IL-8 and PDGFAA measured in the DCT
group. Finally, differentiation studies confirmed that the adipogenic and chondrogenic
differentiation capacities of the hASCs expanded on the microcarriers over 14 days were
similar to the baseline controls, although low levels of chondrogenic gene expression
were observed in all groups.

3.2 Introduction
Mesenchymal stromal cells (MSCs) are widely studied in tissue engineering and
regenerative medicine due to their capacity to differentiate towards the adipogenic,
chondrogenic and osteogenic lineages, as well as to produce a broad range of growth
factors and cytokines that can promote regeneration through paracrine-mediated
mechanisms [151]. As of June 2020, over 1100 clinical trials were registered worldwide
using MSCs for a range of disease treatments [283]. Although there has been substantial
progress in MSC research, scaling up the production of MSCs in a reproducible way
remains an important challenge to overcome for commercialization and late-stage clinical
trials [133]. MSCs are often expanded on tissue culture polystyrene (TCPS), which can
induce changes in the cellular phenotype including a reduced proliferation capacity and a
loss of in vitro multipotency [283], [284]. A potential method to circumvent the
challenges of in vitro expansion on TCPS is to utilize spinner flask bioreactors
incorporating three-dimensional (3D) microcarrier scaffolds to support the attachment
and expansion of MSCs [242].
Within tissues, the extracellular matrix (ECM) provides structural support and regulates
cell survival, shape, proliferation, differentiation, and migration [8]. The properties of the
ECM are unique to each tissue source [4], [285], supporting the rationale for applying a
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tissue-specific approach in the design of biomaterials for cell expansion and delivery.
Previously, we developed novel microcarriers comprised exclusively of decellularized
adipose tissue (DAT) and investigated their application as an expansion platform for
human adipose-derived stromal cells (hASCs) [128]. Notably, hASC proliferation was
significantly enhanced on the DAT microcarriers as compared to commercially-available
Cultispher-S microcarriers within a 3D spinner flask culture system. Further, there were
indications that the trilineage differentiation capacity of the hASCs expanded on the DAT
microcarriers was also augmented relative to the Cultispher-S microcarrier group, despite
the cells having undergone a significantly higher population fold change.
Recognizing that tissue-specific ECM can provide cell-instructive cues that may
modulate cell attachment and proliferation, as well as direct MSC differentiation towards
the adipogenic and chondrogenic lineages [92], the current study sought to build our
previous work by comparing hASCs expanded on our unique ECM-derived microcarriers
fabricated from DAT or decellularized cartilage tissue (DCT). Porcine auricular cartilage
was selected as an accessible and abundant ECM source, and a cartilage decellularization
protocol was established by adapting methods from the literature [272]. Subsequently,
electrospraying techniques were applied to fabricate soft and compliant microcarriers
using ECM suspensions generated from a-amylase-digested DAT or DCT. To
specifically probe the effects of ECM composition, the ECM suspension concentrations
used were selected to generate DAT and DCT microcarriers of a similar size with
matching Young’s moduli to control for possible biomechanical effects [96], [286].
Following the establishment of the new DCT microcarrier platform, in-depth in vitro
studies were performed to compare the effects of culturing hASCs on the DAT or DCT
microcarriers under proliferation conditions within spinner flasks for two weeks, with
comparison to baseline controls of the hASC populations prior to microcarrier seeding. It
was hypothesized that the ECM source used would influence hASC attachment and
proliferation, as well as modulate paracrine factor secretion and mediate their
downstream capacity to differentiate towards the adipogenic and chondrogenic lineages.
Moving beyond the characterization of small subsets of pre-selected markers, we sought
to apply unbiased approaches to characterize changes in gene and protein expression in
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the hASCs expanded on the microcarriers under dynamic conditions. In particular,
high-throughput mass spectrometry (MS) techniques were harnessed as a powerful
method to explore how the culture microenvironments affected global protein expression
[287], to develop a deeper understanding of the potential of applying tissue-specific
ECM-derived microcarriers as platforms for pro-regenerative cell expansion for varying
therapeutic applications.

3.3 Methods
3.3.1

Materials

Unless otherwise indicated, all chemical reagents for this work were obtained from
Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada) and were used as received.

3.3.2

Adipose tissue procurement and processing

Resected human adipose tissue was obtained with informed consent from routine breast
or abdominal reduction surgeries conducted at the University Hospital in London, ON,
Canada, with approval of the Human Research Ethics Board at Western University
(HSREB# 105426). Fresh adipose tissue samples were transported on ice in sterile
cation-free phosphate buffered saline (PBS, Wisent Bioproducts) supplemented with 2 %
bovine serum albumin (BSA, Bio-shop) and used for either hASC isolation or
decellularized following published protocols [100]. For decellularization, in brief, the
tissue was treated with a 5-day detergent-free extraction protocol involving freeze-thaw
cell lysis in hypotonic buffer, multiple extractions in isopropanol to remove lipids, and
enzymatic digestion with trypsin-EDTA, as well as DNase, RNase, and lipase. DAT was
pooled from a minimum of 5 donors and lyophilized for 48 h. Following lyophilization,
the DAT was finely minced (1-2 mm3 pieces) and cryomilled using established methods
[128], and stored in a desiccator at room temperature (RT) until further use.
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3.3.3

Cartilage tissue procurement and processing

Fresh porcine ears were obtained from the Mount Brydges abattoir for use as an auricular
cartilage source. The dermis was removed and the tissue was cryomilled following
established methods [128]. The milled cartilage was decellularized by adapting methods
from Xu et al. used for decellularizing porcine annulus fibrosus [272], including
alterations to the processing times, modifications to the mechanical processing steps and
a lower concentration of Triton X-100 for the detergent extractions. All steps were
performed at 37 ˚C under agitation at 200 rpm, with 1.5 g of milled tissue to start and
50 mL volumes for all solutions. All decellularization solutions were supplemented with
1 % antibiotic-antimycotic solution (ABAM) and 1 % phenylmethanesulphonylfluoride
(PMSF). To change solutions, the samples were centrifuged for 10 min at 1200 xg to
collect the milled tissues and the supernatants were replaced. In brief, the tissue was
subjected to three freeze-thaw cycles in 10 mM Tris base and 5 mM
ethylenediaminetetraacetic acid (EDTA) in deionized water (dH2O) (pH 8.0), before
undergoing a high salt detergent extraction with 50 mM Tris base, 1.5 M KCl, 5 mM
EDTA and 1% Triton X-100 in dH2O for 24 h, changing the solution twice per day.
Subsequently, the tissue was rinsed three times in phosphate buffered saline (PBS) for
30 min, followed by digestion in Sorenson’s phosphate buffer solution (SPB) with
12.5 mg RNase Type III A (from bovine pancreas) and 15,000 U DNase Type II (from
bovine pancreas) for 2 h. After digestion, the tissue was placed in 50 mM Tris buffer with
1 % Triton X-100 for 24 h, replacing the solution twice per day. Following this, the
resultant DCT was rinsed 3 times for 30 min in dH2O, frozen at -80 ℃, and lyophilized
for 24 h. The DCT from 5 donors was pooled, cryomilled, and stored in a desiccator at
RT until further processing.

3.3.4

Non-chemically crosslinked DAT and DCT microcarrier
fabrication

The milled DAT and DCT were subsequently digested with α-amylase and homogenized
to generate 50 mg/mL ECM suspensions, following previously-established methods
[128]. To prepare for electrospraying, the suspensions were diluted with 0.2 M acetic acid
to 35 mg/mL and 30 mg/mL for the DAT and DCT respectively. These concentrations
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were selected based on preliminary testing that indicated they would generate
microcarriers with matching mechanical properties to be able to more specifically probe
the effects of ECM composition on the cellular response. The suspensions were loaded
into 10 mL syringes and secured in a syringe pump set to 0.5 mL/min. The positive probe
was attached to the tip of a 25G winged infusion set (BD Medical, Mississauga, ON,
Canada). A voltage of 18 kV was applied to the needle tip, and the extrusion rate was set
at 30 mL/h, controlled using a syringe pump (PHD 22/2000 infusion, Harvard Apparatus,
Holliston, MA, USA). The frozen microcarriers were collected and lyophilized. Next, the
dried microcarriers were resuspended in 100 % ethanol, sieved to remove aggregates, and
stored in 100 % ethanol at 4 °C. Prior to further testing, the microcarriers were subjected
to a controlled rehydration process through a very gradual ethanol series in sterile PBS,
as previously described [128].

3.3.5
3.3.5.1

Characterization of the DAT and DCT microcarriers
Scanning electron microscopy (SEM)

The surface ultrastructure of the DAT and DCT microcarriers were visualized using
SEM. Lyophilized microcarriers were mounted onto stubs with conductive carbon tape
and coated with 5 nm of osmium before visualization with a LEO 1530 scanning electron
microscopy at an accelerating voltage of 1 kV.

3.3.5.2

Mechanical testing

The Young’s moduli of the DAT and DCT microcarriers were determined using a
CellScale MicroTester system (Waterloo, ON, Canada). In brief, the microcarriers were
tested using a micro-scale parallel-plate compression configuration fitted with a 154 μm
diameter cantilever. The microcarriers were placed in a PBS fluid bath at 37 ℃ and the
cantilever was lowered until the upper compression plate made contact with the
microcarrier. The microcarriers were compressed for 20 s to 50 % of their total diameter,
held for 5 s, and released for 20 s (n=6 individual microcarriers/trial, N=4 trials with
different ECM batches). A total of 6 compression cycles were performed. A modified
Hertzian half-space contact mechanics model for spheres with large elastic deformations
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was applied and the Young’s moduli were determined by nonlinear least squares curve
fitting [254].

3.3.5.3

Biochemical assays

For the dimethylmethylene blue (DMMB) and hydroxyproline assays, approximately
10 mg of DAT and DCT microcarriers were weighed and digested with 80 μg/mL of
papain in digestion buffer comprised of 35.3 mM ammonium acetate, 1.3 mM EDTA,
and 0.31 mg/mL of DL-dithiothreitol in dH2O (pH 6.2) (n=3 samples/trial, N=3 trials
with different ECM batches). The samples were incubated for 2 h at 65 ℃ under
agitation at 1000 rpm.
For the DMMB assay, 10 μL aliquots of the digested scaffolds were transferred in
technical triplicates into a 96-well plate and 200 μL of a 1.6 % solution of DMMB dye in
dH2O supplemented with 1 % ethanol and 0.2 % formic acid was added. The absorbance
was read at 525 nm and was recorded using a CLARIOstar® spectrophotometer (BMG
LABTECH Inc., Cary, NC, USA), including a chondroitin sulphate standard curve.
For the hydroxyproline assay, digested samples were hydrolyzed with 12 N hydrochloric
acid at 110 ℃ for 18 h and neutralized with 6 N NaOH. Equal volumes of 0.05 N
chloramine-T/20 % 2-methoxyethanol (20 min incubation), 3.15 N perchloric acid (5 min
incubation) and Ehrlich’s reagent (20 min incubation at 60 ℃) were sequentially added to
the digested scaffolds (diluted 1:30 in dH2O) within a 96-well plate. After a 5 min
incubation at 4 ℃ and a 20 min incubation at RT, the absorbance was measured at
560 nm using the CLARIOstar® spectrophotometer, including a hydroxyproline standard
curve.
The Fastin™ elastin assay was used to assess total elastin content following the
manufacturer’s instructions. In brief, 5-10 mg of microcarriers (n=3 samples/trial, N=3
trials with different ECM batches) were added to 1.5 mL centrifuge tubes and 750 μL of
0.25 M oxalic acid was added. The samples were incubated at 100 ℃ for 60 min to
extract the elastin. Samples were cooled to RT and centrifuged at 9,600 xg for 10 min.
The supernatant was collected and retained for analysis. A second extraction was
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performed, repeating these steps and the samples were pooled. Following the extractions,
precipitation of both α-elastin standards and the test samples was performed, and the
samples were centrifuged to pellet the elastin content. Next, the dye regent was added to
form a complex with the precipitated elastin and incubated for 90 min at RT. The samples
were centrifuged at 10,000 xg for 10 min and the remaining unbound dye was removed.
The bound dye was then dissociated and transferred into a 96-well plate. The absorbance
was measured at 513 nm using the CLARIOstar® spectrophotometer.

3.3.6

hASC seeding and dynamic culture

Human ASCs were cultured in proliferation medium comprised of Dulbecco’s Modified
Eagle’s medium:Ham’s F12 nutrient mixture (DMEM:Ham’s F12) supplemented with
10 % fetal bovine serum (FBS) (Wisent Inc., US origin), and 100 U/mL penicillin and
0.1 mg/mL streptomycin (1% pen-strep) (Life Technologies). Passage 2 hASCs were
used for all in vitro culture experiments.
On the day before seeding, DAT or DCT microcarriers (100 mg dry weight) were
resuspended in 25 mL of proliferation medium in a 100 mL CELLSPIN flask (INTEGRA
Biosciences, AG, Switzerland) and incubated overnight (37 ℃, 5 % CO2). Passage 2
hASCs were trypsin-released from the TCPS flasks and added to the spinner culture
system in 25 mL of proliferation medium to achieve a density of 25,000 hASCs/mg
microcarriers (dry weight). To facilitate cell attachment, a 12-h intermittent stirring
regimen previously established in the lab was performed [227]. The CELLSPIN flasks
containing 100 mL of proliferation medium were stirred continuously at 25 rpm for
2 weeks, with half media changes performed every 5-7 days.

3.3.7

hASC proliferation studies

Human ASC proliferation on the DAT and DCT microcarriers was assessed over
2 weeks, with triplicate samples taken at time points of 24 h, 72 h, 1 week, and 2 weeks.
This study was repeated with a total of 6 donors (n=3 samples per donor, N=6; donor
information for all studies is available in Supplementary Table B1). At each time point,
the samples were rinsed 2 times with PBS, frozen with dry ice, and lyophilized. To
quantify the cell density on the microcarriers, the samples were analyzed with the
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PicoGreen® assay (Thermo Fisher Scientific) to measure the total double-stranded DNA
(dsDNA) content. In preparation, the samples were processed with the DNeasy Blood &
Tissue Kit (Qiagen) following the manufacturer’s instructions. In brief, 10 mg of sample
was digested using proteinase K (20 mg/mL, > 318 mU/mL) for 1 h at 56 ℃ under
agitation at 1000 rpm. Next, 200 μL of absolute ethanol was added to each digest, and the
entire sample was loaded into a DNeasy Mini spin column and centrifuged at 6000 xg for
1 min. The flow-through was discarded and two washes were then performed. Finally, the
dsDNA was eluted with 200 μL of Buffer AE provided with the kit. The PicoGreen®
assay was then used to quantify the total dsDNA content in each sample, following the
manufacturer’s instructions. A known number of cells was used to generate a standard
curve for each cell donor to report the data in terms of the cell number per mg of
microcarriers.
To compliment the quantitative data, samples of the cell-seeded microcarriers were
stained at each time point with a Live/Dead® assay kit (Life Technologies) and imaged
with a Zeiss LSM confocal microscope (Germany).

3.3.8

Human mesenchymal stem cell PCR array

A human mesenchymal stem cell qPCR array (STEMCELL™ Technologies) was used to
investigate the effects of dynamic culture on the expression of 90 genes (Supplementary
Table B1) associated with MSCs or their differentiation towards the adipogenic,
chondrogenic and osteogenic lineages. A complete list of genes included in the panel is
provided in Supplementary Table B2. Triplicate samples of the hASC-seeded DAT and
DCT microcarriers were taken at 24 h, 72 h, 1 week and 2 weeks after dynamic seeding
for RNA extraction. Baseline RNA was also extracted from the hASCs cultured on TCPS
prior to seeding. The RNA was extracted for all samples using PureZOL™ (Bio-Rad,
Mississauga, Canada) and purified using the Aurum™ Total RNA Fatty and Fibrous
Tissue Kit (Bio-Rad). The triplicate samples of RNA were pooled, and the study was
repeated with a total of 4 cell donors (n=3 pooled, N=4 cell donors). The Human
Mesenchymal Stem Cell qPCR Array was performed and analyzed following the
manufacturer’s instructions. Genes that were not consistently amplified in any group
were removed from further analysis. Expression was normalized to a panel of
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housekeeping genes using the 2!∆#! method. Based on this, 53 genes for DAT versus
baseline (Supplementary Table B3) and 51 genes for DCT versus baseline
(Supplementary Table B4) were compared with multiple t-tests and adjusted for multiple
comparisons with a false discovery rate correction set to 15 %.

3.3.9

Label-free mass spectrometry

Label-free mass spectrometry analyses were conducted to compare the hASC proteome
following 2 weeks of expansion on the DAT or DCT microcarriers relative to baseline
samples of the hASCs prior to microcarrier seeding. Fluorescence activated cell sorting
(FACs) was performed to isolate a highly purified cell population and avoid potential
confounding effects of scaffold debris on the proteomic analyses. Triplicate samples were
collected from each group per trial and after extraction were pooled for FACs, and the
study was repeated with a total of 3 cell donors (n=3 pooled samples were used for a
single sort, N=3). Following 2 weeks of expansion within the spinner flasks, the
hASC-seeded DAT and DCT microcarriers were digested using 4 mg/mL collagenase
Type IV (Thermo Fisher Scientific) in DMEM:Ham’s F12 under agitation at 100 rpm and
37 ℃ for 60 min, with periodic pipetting every 15 min. Next, an equal volume of
proliferation medium was added, and the cells were filtered through a 40 μm filter,
followed by rinsing the filter with an additional 10 mL of complete medium. The
extracted cells were counted with a hemocytometer using trypan blue. Baseline hASCs
were trypsin-released and similarly counted. The samples from all groups were then
centrifuged at 500 x g for 5 min and washed once with D-PBS. After re-centrifuging, the
cells were stained with 10 μM calcein-AM (Thermo Fisher Scientific) for 30 min at
37 ℃. An equal volume of proliferation medium was then added, and the samples were
re-centrifuged. The cell pellet was resuspended in D-PBS with 10 % FBS and the
samples were incubated at 37 ℃ for 30 min. Finally, the cells were centrifuged and
resuspended in 300 μL of D-PBS supplemented with 5 % FBS. Live cells were then
sorted on a FACS Aria III cell sorter (gating strategies shown in Supplementary Figure
B1) and cell lysates were prepared for mass spectrometry.
To prepare the lysates, the FACs-purified viable hASCs were lysed using a lysis buffer
comprised of 8 M urea, 50 mM ammonium bicarbonate (ABC), 10 mM dithiothreitol
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(DTT) and 2 % SDS in dH2O using tip-probe sonication (10 X 0.5 s pulses; Level 1)
(Sonic Dismembrator Model 100, Fisher Scientific). Protein was quantified using Ionic
Detergent Compatibility Reagent for Pierce™ 660 nm Protein Assay Reagent (Thermo
Fisher). Approximately 25 μg of protein was reduced in 10 mM DTT for 30 min at RT,
alkylated in 100 mM iodoacetamide for 30 min at RT in the dark, and precipitated in
chloroform/methanol/water (1:4:3). On-pellet in-solution protein digestion was
performed in 100 µL of 50 mM ABC (pH 8) by adding Trypsin/LysC (Promega, 1:50
ratio) to precipitated hASC proteins. Human ASC proteins were incubated at 37 °C
overnight (~18 h) in a ThermoMixer C (Eppendorf) at 900 rpm. An additional volume of
LysC (Promega, 1:100 ratio) was added for ~3 h before acidifying to pH 3-4 with 10 %
formic acid (FA). Mobile phase A was made of 99 % dH2O/0.1 % FA, and 99 %
acetonitrile/0.1 % FA was used for mobile phase B. Approximately 500 ng of peptides
per sample were initially loaded onto an ACQUITY UPLC M-Class Symmetry C18 Trap
Column, 5 µm, 180 µm x 20 mm and trapped for 4 min at a flow rate of 10 µl/min at
99 % A/1 % B. Peptides were separated on an ACQUITY UPLC M-Class Peptide BEH
C18 Column (130 Å, 1.7 µm, 75 µm X 250 mm) operating at a flow rate of 300 nL/min
at 35 °C, using a non-linear gradient consisting of 1-7 % B over 18 min, 7-19 % B over
86.5 min and 19-30 % B over 30 min before increasing to 95 % B and washing. Settings
for data acquisition on Q Exactive Plus are outlined in Supplementary Table B5.
MS raw files were searched in MaxQuant (1.5.8.3) using the Human Uniprot database
(reviewed only, updated November 2020 with 40,550 entries). Missed cleavages were set
to 3 and I=L. Cysteine carbamidomethylation was set as a fixed modification. Oxidation
(M), N-terminal acetylation (protein), and deamidation (NQ) were set as variable
modifications (max. number of modifications per peptide = 5) and all other setting were
left as default. Precursor mass deviation was left at 20 ppm and 4.5 ppm for first and
main search, respectively. Fragment mass deviation was left at 20 ppm. Protein and
peptide FDR was set to 0.01 (1 %) and the decoy database was set to revert. The
match-between-runs feature was utilized across all sample types to maximize proteome
coverage and quantitation. Datasets were loaded into Perseus (1.6.14) and proteins
identified by site; reverse and potential contaminants were removed. Protein
identifications with quantitative values in ≥3 of 9 samples were retained for downstream
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analysis. Missing values were imputed using a width of 0.3 and down shift of 1.8 to
enable statistical comparisons. Enrichment analyses were performed using Metascape.org
using default settings. Data analysis and visualization was performed in a Python 3.7
environment.

3.3.10

Luminex assay

To complement the proteomic analysis of the cell lysates, customized Luminex assays
(R&D systems) were performed to compare the levels of a variety of pro-angiogenic and
immunomodulatory proteins in conditioned media samples collected from the hASCs
expanded on the DAT versus DCT microcarriers. The specific analytes included in the
customized Luminex arrays were:
Panel 1: monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth
factor (VEGF), hepatocyte growth factor (HGF), leptin, platelet derived growth
factor-AA (PDGFAA), angiogenin, angipoietin-1, placental growth factor (PIGF).
Panel

2:

tumour

necrosis

factor-alpha

(TNF-α),

interleukin-1

beta

(IL-1β),

interleukin-4, -8, -10, and -13 (IL-4, -6, -8, -10, -13).
The conditioned media samples were collected after 2 weeks in dynamic culture, where
the media had been conditioned for a total of 7 days. At 2 weeks, media samples were
centrifuged at 1200 xg to remove debris and frozen at - 80 °C. Complete media samples
incubated without cells were also collected as controls. The assays were then performed
according to the manufacturer’s instructions, with the samples analyzed in technical
duplicates and the study was repeated with a total of 3 hASC donors (n=2, N=3). In brief,
conditioned media samples were diluted 1:1 using the dilution buffer provided with the
kit. In a 96-well plate, 50 µL of the diluted samples were incubated with 50 µL of
premixed microparticle cocktail. The plates were washed using a magnetic plate
separator, and further incubated with 50 µL/well of premixed biotin antibodies. After an
additional washing step, a final incubation with 50 µL/well of Phycoerythrin
(PE)-conjugated streptavidin was performed. The plates were analyzed using a Luminex
MAGPix Analyzer. The background signal from the complete medium was subtracted
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from each sample measurement. To normalize the data, cell counts were acquired by
enzymatically releasing the hASCs from the microcarriers using 2 mg/mL collagenase
Type I (Worthington) in Kreb’s Ringer bicarbonate buffer supplemented with 20 mg/mL
BSA, 3 mM glucose, and 25 mM HEPES under agitation at 100 rpm and 37 ℃ for
45 min, with periodic pipetting every 15 min. Hemocytometer counting using trypan blue
was performed and the results were normalized to mass of cytokine (ng)/106 cells.

3.3.11

hASC differentiation studies

The final experiments focused on comparing the effects of 2 weeks of expansion on the
DAT or DCT microcarriers on the capacity of the hASCs to differentiate towards the
adipogenic or chondrogenic lineages relative to baseline samples of the ASCs prior to
microcarrier seeding. After 2 weeks of dynamic culture in the spinner flasks, the hASCs
were enzymatically released from the microcarriers as described in the previous section.
The baseline ASC samples were isolated using trypsin, and all samples were counted
with a hemocytometer using trypan blue.

3.3.11.1 Adipogenic differentiation
For the adipogenic differentiation studies, the hASCs were seeded at a density of
30,000 cells/cm2 on 6-well plates. After 24 h, the hASCs were rinsed once with PBS and
induced with adipogenic differentiation medium comprised of DMEM:Ham’s F12
supplemented with 33 μm biotin, 17 μm pantothenate, 10 μg/mL transferrin, 100 nM
hydrocortisone, 66 nM human insulin, 1 nM triiodothyronine, and 1 % pen-strep, with
0.25 nM isobutylmethylxanthine (IBMX) and 1 μg/mL troglitazone supplemented for the
first 3 days [100]. Non-induced controls were maintained in proliferation medium. After
7 days

of

culture,

adipogenesis

was

quantitatively

assessed

using

the

glycerol-3-phosphate dehydrogenase (GPDH) Enzyme Activity Measurement Kit
(Kamiya Biomedical Inc.), with normalization to the total intracellular protein content
measured using the BioRad Protein Assay, according to established methods (n=3
wells/trial, N=3 trials with different cell donors) [100]. In addition, oil red O staining was
performed to visualize intracellular lipid accumulation (n=3 wells, N=3 trials with
different donors) [227].
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3.3.11.2 Chondrogenic differentiation
For the chondrogenic studies, the hASCs were cultured in 3D aggregates at a density of
250,000 cells/aggregate, following previously published methods [128]. The aggregates
were cultured in proliferation medium for 48 h and then transferred into chondrogenic
differentiation medium comprised of DMEM:Ham’s F12 supplemented with 10 % FBS,
50 μg/mL ascorbic acid, 6.25 μg/mL human insulin, 100 nM dexamethasone, 10 ng/mL
transforming growth factor-beta 1 (TGF-β1), and 1 % pen-strep for an additional 28-days.
Non-induced controls were maintained in proliferation medium for the full culture period.
Chondrogenic differentiation was assessed through qualitative toluidine blue staining
(n=2-3 pellets/trial, N=3 trials with different cell donors). In brief, the aggregates were
embedded in OCT and cryosectioned (7 μm). For the staining, the sections were fixed for
10 min at – 20 ℃ in acetone, followed by three rinses for 2 min each in dH2O, and then
incubated in 0.15 mg/mL toluidine blue in 50 mM sodium acetate for 5 minutes. The
slides were then rinsed with tap water until the water was clear and placed at 37 ℃ to
completely dry. The samples were then mounted with Permount™ Mounting Medium
(Fisher) and imaged using an EVOS® XL CORE bright field microscope (Life
Technologies).

3.3.11.3 Quantitative RT-PCR analysis
Real-time RT-qPCR analyses were also conducted to assess the expression of key
lineage-specific gene markers (Table 4.4) for both the adipogenic (n=3 wells, N=3 cell
donors) and chondrogenic lineages (n=2-3 pellets, N=3 cell donors) in the dynamic
culture groups in comparison to the baseline controls at 7 and 28 days post-induction
respectively.
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Table 3.1 Human gene-specific primers
Lineage
Adipogenesis

Chondrogenesis

a

Gene
PPARγ
CEBPα
LPL
PLIN
ADIPOQ
LEP
GAPDHa
IPO8a
SOX9
COLL 1
COMP
ACAN
COLL 10
RPL13Aa
GUSBa

Description
Peroxisome proliferator-activated receptor gamma
CCAAT/enhancer-binding protein alpha
Lipoprotein lipase
Perilipin
Adiponectin
Leptin
Glyceraldehdye-3-phosphate dehydrogenase
Importin 8
SRY-box transcription factor 9
Collagen 1
Cartilage oligomeric matrix protein
Aggrecan
Collagen 10
Ribosomal protein L13a
Glucuronidase beta

Product No.
NM_138712
NM_004364
M15856
NM_002666.5
NM_004797.3
NM_000230
NM_002046
NM_006390.3
NM_000346
NM_000088
NM_000095
NM_001135.3
NM_000493
NM_012423.3
NC_000007

Housekeeping genes selected for each lineage using the BioRad reference gene panel

RNA was extracted for all samples using PureZOL™ (Bio-Rad, Mississauga, Canada)
and purified using the Aurum™ Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad).
cDNA was synthesized from 500 ng of input RNA using the iScript™ Reverse
Transcription Supermix kit (Bio-Rad) following the manufacturer’s instructions. For
RT-qPCR, samples were prepared using SsoFast™ EvaGreen® Supermix (Bio-Rad;
10 ng cDNA/well). Amplifications were carried out using a CFX384 Touch™ Real-Time
PCR Detection System (Bio-Rad) as follows: initial incubation at 95 ℃ for 2 min,
followed by 40 cycles of 95 ℃ for 5 s and 58.5 ℃ for adipogenic genes or 60 ℃ for
chondrogenic genes for 30 s. The data was analyzed by the comparative Ct method, with
normalization to the geometric mean of two stable housekeeping genes for each lineage.

3.3.12

Statistical Methods

With the exception of the analysis performed on the array data as described above,
statistical analyses were performed using linear effects models with R statistics software
(R core team 2017), using the “nlme” package for linear and nonlinear mixed effects
models [257]. Data were compared, correcting for multiple comparisons as described by
Hothorn et al. [258]. Corrected p-values <0.05 were considered to be statistically
significant. GraphPad Prism software version 6 (GraphPad, La Jolla, CA) was used to
produce the graphs.
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3.4 Results
3.4.1

Microcarrier characterization

As a first step in this study, methods were established to decellularize porcine auricular
cartilage, and it was verified that the developed protocol effectively extracted cellular
content from the tissues, while conserving the total collagen and sulphated
glycosaminoglycan content (Supplementary Figure B2). Next, the previously-established
electrospraying techniques used to fabricate DAT microcarriers [128] were extended to
synthesize DCT microcarriers that were comprised exclusively of ECM and were stable
without chemical crosslinking. Both the DAT and DCT microcarriers were easily handled
with serological pipettes and maintained their macroscopic integrity and geometry under
routine handling. Size distribution analysis of the DAT and DCT microcarriers hydrated
in PBS confirmed that they were of a similar size, with an average diameter of
468.9 ± 163.8 μm and 478.9 ± 191.9 μm respectively.
SEM imaging revealed that the ECM-derived microcarriers had a rough surface
topography and numerous pores, however there were noticeable differences between the
ultrastructure of the DAT and DCT microcarriers that were likely due to compositional
differences (Figure 3.1 A). More specifically, the DAT microcarriers included a complex
network of thin fibers interspersed with some thicker fiber bundles and small sheet-like
structures. In contrast, the DCT microcarriers were primarily comprised of larger sheetlike structures connected by a smaller number of branching fibers, which resulted in
qualitatively larger pores relative to the DAT microcarriers.
Compressive testing performed using a CellScale MicroTester under simulated
physiological conditions confirmed that the DAT microcarriers fabricated with a
35 mg/mL ECM suspension had a similar Young’s modulus to the DCT microcarriers
fabricated with a 30 mg/mL ECM suspension concentration. More specifically, the
Young modulus measured for the DAT microcarriers was 0.57 ± 0.07 kPa, compared to
0.66 ± 0.10 kPa for the DCT microcarriers (Figure 3.1B). Both microcarrier types were
soft and compliant, and returned to their original geometry after they were compressed to
50 % of their original diameter repeatedly over 6 cycles (Figure 3.1 C, D).

80

Figure 3.1: Soft and compliant DAT and DCT microcarriers were fabricated via
electrospraying that had similar mechanical properties but distinct biochemical
compositions. (A) SEM images showing the differing surface ultrastructure of the DAT
and DCT microcarriers fabricated with 35 mg/mL and 30 mg/mL ECM suspensions
respectively. Scale bar = 10 μm. (B) The average Young’s moduli of the DAT and DCT
microcarriers determined through compression testing using a CellScale MicroTester
(n=6 microcarriers/trial, N = 4 trials with different ECM batches). Representative force
versus deformation curves for (C) 35 mg/mL DAT microcarriers and (D) 30 mg/mL DCT
microcarriers. Data from 3 cycles are shown with compression at a strain rate of 0.01 s-1.
(E) Hydroxyproline assay results showing no significant difference between the groups
(n=3 samples/trial, N=3 trials with different ECM batches). (F) DMMB assay results
showing that the DCT microcarriers had significantly more sGAG compared to the DAT
microcarriers (n=3 samples/trial, N=3 trials with different ECM batches) (*p<0.05). (G)
Fastin™ elastin assay results showing that the DCT microcarriers had significantly more
elastin than the DAT microcarriers (n=3 samples/trial, N=3 trials with different ECM
batches). Data were analyzed with linear mixed effects models (* p<0.05).
Biochemical analysis of the total collagen content with the hydroxyproline assay revealed
no significant difference in the levels of collagen for both microcarrier types (Figure
3.1E). However, the DMMB and Fastin™ elastin assays indicated that the DCT
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microcarriers contained significantly more sulphated glycosaminoglycans (sGAGs) and
elastin content compared to the DAT microcarriers (Figure 3.1F, G).

3.4.2

hASC proliferation on DAT and DCT microcarriers under
dynamic conditions

Confocal imaging showed that the initial attachment of the hASCs appeared qualitatively
greater on the DCT microcarriers compared to the DAT microcarriers (Figure 3.2A). The
hASCs grew uniformly across the surface of both microcarrier types, with surface
confluence observed at 2 weeks. While both microcarrier types remained structurally
intact, some aggregation was observed in the final week of culture. Gentle pipetting to
disrupt large aggregates ensured that all microcarriers remained in suspension.
The cell density on the DAT and DCT microcarriers was assessed using the PicoGreen®
assay to quantify the total dsDNA content, which was correlated to the number of cells
using a cell standard curve (Figure 3.2B). At both the 1- and 2-week timepoints, the cell
density was significantly higher on the DCT microcarriers as compared to the DAT.
However, when the results were normalized to the cell density at 24 h, it was found that
the average population fold change was similar between the DAT and DCT groups,
suggesting that the difference in the cell density observed at the later timepoints was
likely related to differences in initial cell attachment rather than alterations in the growth
rate (Figure 3.2C).
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Figure 3.2: DAT and DCT microcarriers supported the attachment and growth of
hASCs within the stirred culture bioreactor over a 2-week time period. (A)
Live/Dead® staining was used to visualize hASC attachment on the microcarriers over the
2-week culture period. Viable calcein+ cells are shown in green; no EthD-1+ dead cells
were visualized on the microcarriers at any timepoint. Scale bars = 50 μm. (B) dsDNA
content was assessed with the PicoGreen® assay to quantify the cell content on the
microcarriers at various timepoints. A significantly greater number of cells were detected
on the DCT microcarriers as compared to the DAT microcarriers at 1 and 2 weeks (n=3
replicate samples/trial, N=6 trials with different cell donors). Data were analyzed with
linear mixed effects models (* p<0.05). (C) Cell density data normalized to the 24 h
timepoint showing similar population fold changes on the DAT and DCT microcarriers
over the 2-week expansion.
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3.4.3

Characterization of human ASCs with qPCR array

A human mesenchymal stem cell qPCR array was used to probe the effects of dynamic
culture on the ECM-derived microcarriers on the gene expression levels of 90 different
MSC-associated markers in the hASCs at the end of 2 weeks of dynamic culture relative
to baseline hASCs prior to microcarrier seeding. Differentially expressed genes were
selected using a false discovery rate of 15%, and a complete list of comparisons is shown
in Supplementary Tables B2 and B3. No significant differences were observed when
comparing the hASCs cultured on the DAT versus DCT microcarriers. However, there
were a total of 36 genes that were significantly different on the DAT microcarriers
relative to the baseline samples, and 16 genes that were significantly different on the
DCT microcarriers relative to baseline. In analyzing the data, we focused on comparing
the expression levels of genes categorized as (i) differentiation markers, (ii) cell surface
receptors and (iii) secreted factors and cytokines (Figure 3.3). Interestingly, when
looking at the differentiation markers, all three master transcription factors associated
with MSC tri-lineage differentiation (e.g., PPARγ, RUNX2, SOX9) were enhanced on the
DAT microcarriers relative to baseline conditions, suggesting that the cells were not
predisposed towards one specific lineage. In contrast, SOX9 was the only transcription
factor upregulated on the DCT microcarriers in comparison to baseline conditions, in
addition to several other markers associated with chondrogenic differentiation including
Notch1 [288], CSPG4 [289], and the hypertrophic marker COL10A1 [290], suggesting
that the hASCs expanded on the DCT microcarriers may be more pre-disposed towards
the chondrogenic lineage. When looking at the genes within the cell surface receptors
category, gene expression of the integrin av subunit, ITGAV, was enhanced on the DAT
microcarriers [291], while the hyaluronan receptor CD44 [292] was expressed at higher
levels in both microcarrier groups. In addition to altered levels of these cell-ECM
receptors, several genes associated with ECM remodeling showed significantly increased
expression following dynamic culture on the microcarriers, including TGFβ1&3 [293]
and MMP2 [294]. Interestingly, HGF, a pleiotropic factor associated with both
angiogenesis and immunomodulatory function in hASCs [295] that can have anti-fibrotic
effects was also upregulated on the DAT microcarriers.
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Figure 3.3: MSC-associated gene expression was modulated by dynamic culture on
the DAT or DCT microcarriers. Human MSC qPCR Array results showing the fold
change in gene expression of hASCs cultured dynamically on the (A) DAT microcarriers
or (B) DCT microcarriers for 2 weeks relative to baseline hASCs prior to microcarrier
seeding. Green bars represent transcripts enriched in the DAT or DCT groups, and red
bars represent transcripts enriched in the baseline conditions. All data were analyzed by
multiple t-tests and were controlled for multiple comparisons using a false discovery
correction of 15% (n = 3 pooled samples, N = 4 donors).
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3.4.4

Proteomic analysis of hASCs cultured dynamically on the
DAT or DCT microcarriers

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to provide a
global assessment of the changes in the hASC proteome after 2 weeks of dynamic culture
on the DAT or DCT microcarriers compared to lysates collected from baseline cells, just
prior to microcarrier seeding (TCP). A total of 4030 unique proteins were commonly
identified in all three groups, suggesting that there was a high degree of similarity in the
cells under all culture conditions (Figure 3.4A). Unsupervised classification of the data
via principal component analysis (PCA) revealed that the 3D culture groups (DAT &
DCT) were segregated from the baseline TCP conditions, with a 27.85 % difference in
component 1 (Figure 3.4B). However, component 2, with a magnitude of 19.53 %,
indicated that there were also differences between the hASCs cultured on the DAT and
DCT microcarriers, with greater cell donor variability observed for the DAT group.
Focusing on the hASCs in the 3D conditions compared to baseline, label-free
quantification revealed that 95 proteins were significantly upregulated, and 30 proteins
were significantly downregulated in both the DAT and DCT groups relative to the
baseline hASCs on TCP (Figure 3.4C). These significant proteins were further classified
using the gene ontology biological processes (GOBP) database, which identified that
there were significant changes in some annotations only in the 3D groups, including
proteins associated with extracellular matrix organization and cell-substrate adhesion
(Figure 3.4D). In addition, there were significant changes in proteins in other
annotations, including supramolecular fiber organization and angiogenesis, in all three of
the groups. Further probing a selected subset of the proteins associated with ECM
organization and cell adhesion, Figure 3.4E presents the fold change in the hASCs in the
DAT and DCT groups relative to the baseline conditions. Numerous ECM components
including various collagens, laminin subunit beta 1 (LAMB1), lumican, decorin, and
fibulin 1 (FBLN1) were significantly upregulated in the DAT and DCT groups. In
addition, proteins associated with collagen biosynthesis and ECM remodeling including
prolyl-3-hydroxylase 1 (LEPRE1), prolyl-3-hydroxylase 3 (LEPREL2) [17], matrix
metalloproteinase (MMP) 2 and 14, TGF-β1, cathepsin K (CTSK), HtrA serine peptidase
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1 (HTRA1) [296], and fibroblast activation protein (FAP) [297] were significantly
upregulated in the hASCs following dynamic culture on the ECM-derived microcarriers.
Interestingly, expression of integrin subunit alpha 1 (ITGA1) was significantly
downregulated in the hASCs cultured on the microcarriers, while dystroglycan precursor
(DAG1), which can act as a cell adhesion receptor [296], was significantly upregulated.
Focusing on the differences in the hASCs cultured on the DAT versus DCT
microcarriers, Figure 3.4F shows a volcano plot highlighting that significantly more
proteins were upregulated in the DCT group in comparison to the DAT group.
Interestingly, many of these proteins were associated with cartilage development and the
extracellular matrix of elastic cartilage, including aggrecan (ACAN) [298], elastin
microfibril interfacer 1 (EMILIN1) [299], chondroadherin (CHAD) [299], matrilin-3
(MATN3) [300], collagen type 8 alpha chain 1 (COL8A1) [301], prolargin (PRELP),
tenascin (TNC) and asporin (ASPN) [37], similar to the gene array findings that
suggested that culturing on the DCT microcarriers may have predisposed the hASCs
towards the chondrogenic lineage. One of the few proteins enhanced on the DAT
microcarriers was CD36, which is a marker of adipose progenitor cells [302]. Volcano
plots highlighting the proteins significantly upregulated in the DAT or DCT groups in
comparison to the TCPS group can be found in Supplementary Figure B3 and
Supplementary Figure B4. Confirming that the FACS isolation method yielded highly
purified cell populations and that the presence of residual scaffold debris was not
contributing to the enhanced presence of cartilage-specific proteins in the DCT group,
similar protein intensities were measured for a range of ECM and cellular proteins in both
ECM-derived microcarrier groups relative to the baseline TCP samples (Supplementary
Figure B1).
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Figure 3.4: The hASC proteome was altered by dynamic culture on the DAT or
DCT microcarriers. Human ASCs were extracted from DAT or DCT microcarriers after
2 weeks of dynamic culture within the spinner flasks, as well as from baseline samples
prior to microcarrier seeding, and purified using FACS. (A) LC-MS/MS was used to
characterize >4000 proteins in the hASC lysates collected from the 3D conditions (DAT
or DCT) and the baseline hASCs prior to dynamic culture (TCP), showing a high degree
of overlap between all conditions. (B) Principal component analysis demonstrates distinct
proteomic signatures between hASC isolated from different culture conditions. (C)
Human ASCs isolated from 3D culture conditions demonstrated a significant enrichment
of 95 proteins compared to baseline hASCs. On the other hand, 30 proteins were
significantly enriched in the lysates of baseline hASCs compared to 3D-cultured hASCs.
(D) Differential proteins were significantly associated with GO Biological Processes
annotations, including cell-substrate adhesion and ECM remodeling. (E) Selected
proteins associated with cell-substrate adhesion and ECM remodeling significantly
altered by 3D dynamic culture compared to baseline hASCs. (F) Proteomic differences
were observed between hASCs cultured on DCT vs DAT. A total of 54 proteins were
significantly enriched in the lysates of hASCs grown on DCT microcarriers, including
numerous proteins associated with chondrogenesis, whereas 6 proteins were significantly
enriched in the lysates of hASCs grown on DAT microcarriers.
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3.4.5

Cell secretome analysis

To complement the LC-MS/MS characterization of the cell lysates, customized Luminex
assays were performed to quantify the levels of a range of pro-angiogenic, and
immunomodulatory factors reported to be secreted by hASCs in conditioned media
samples collected from the cells cultured within the spinner flasks on the DAT or DCT
microcarriers (Figure 3.5). Consistent with the LC-MS/MS findings, there was a high
degree of similarity in the protein expression levels between the groups. More
specifically, the only significant differences observed were higher expression of IL-8 and
PDGFAA in the hASCs expanded on the DCT microcarriers.

Figure 3.5: Dynamic culture on DAT and DCT microcarriers had a similar
abundance of a range of pro-angiogenic and immunomodulatory factors detected
within conditioned media. Protein levels in media from ASCs dynamically cultured on
DAT or DCT microcarriers (media was conditioned for 7 days, with the samples
collected at 2-weeks post-seeding) were quantified using Luminex® magnetic bead
assays. Results are reported relative to total viable cell numbers counted with a
hemocytometer with trypan blue staining after extraction from the microcarriers. Data
were analyzed with linear mixed effects models; * p<0.05.
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3.4.6

Assessment of adipogenic differentiation capacity postexpansion on the microcarriers

Human ASCs were extracted from the DAT and DCT microcarriers after 2 weeks of
dynamic culture and plated on TCPS to probe their capacity to differentiate towards the
adipogenic lineage relative to baseline controls of the cells prior to microcarrier seeding.
To quantitatively assess adipogenic differentiation, GPDH enzyme activity was measured
at 7 days post-induction and showed that the levels of GPDH activity were similar in all
induced groups (Figure 3.6A), with each induced group showing significantly higher
levels than their non-induced controls. To further characterize the response, adipogenic
gene expression was assessed through RT-qPCR at 7 days post-induction. All genes
showed similar trends to the GPDH data, with no significant differences in the levels of
expression for any of the genes in the induced groups. There was a trend for higher levels
in the induced conditions than the non-induced controls for all groups, although
significant differences were only observed for CEBPα due to cell donor variability in the
relative expression levels (Figure 3.6B). The GPDH and RT-qPCR results were
confirmed with oil red O staining, which showed the presence of differentiating cells
containing intracellular lipid droplets in all of the induced groups (Figure 3.6C).
Qualitatively, there were more cells containing intracellular lipid observed within the
induced hASCs that had been cultured on the microcarriers relative to the baseline
conditions, suggesting that microcarrier expansion may have had a positive effect on the
capacity of the cells to differentiate towards the adipogenic lineage.
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Figure 3.6: The adipogenic differentiation capacity of hASCs was maintained after 2
weeks of dynamic culture on the DAT and DCT microcarriers. The hASCs were
enzymatically extracted from the microcarriers after 2 weeks of culture in proliferation
medium within the spinner culture system and cultured on TCPS for an additional 7 days
in adipogenic differentiation medium (induced) or proliferation medium (non-induced)
(A) Adipogenic differentiation was assessed at 7 days post-induction by measuring
glyercol-3-phosphate dehydrogenase (GPDH) activity. All groups in induced medium
had significantly greater GPDH activity compared to their non-induced counterparts (n=3
wells per trial, N=3 trials with different cell donors) (***p<0.001). (B) Adipogenic
differentiation at 7 days post-induction was assessed by RT-qPCR and data is presented
relative to DCT non-induced conditions. CEBPα expression was significantly enhanced
for the DAT and DCT induced groups compared to their non-induced controls (n=3 wells
per trial, N=3 trials with different cell donors) (*p<0.05). (C) Oil red O staining for lipid
accumulation in the induced and non-induced hASCs plated on TCPS after 7 days in
culture. Qualitatively, there was more lipid accumulation visualized in the induced
groups compared to the non-induced groups. Additionally, more lipid accumulation was
visualized in the DAT and DCT expanded hASC groups compared to the baseline hASC
group. Scale bar = 100 μm.
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3.4.7

Assessment of chondrogenic differentiation capacity postexpansion on the microcarriers

The chondrogenic differentiation capacity of the hASCs expanded on the DAT or DCT
microcarriers for 2 weeks was also compared to the baseline populations prior to
microcarrier seeding, by extracting the cells from the microcarriers and culturing them in
3D aggregates for 28 days in chondrogenic differentiation medium or proliferation
medium as a control. RT-qPCR was used to quantitatively assess chondrogenic
differentiation. No significant differences were found in any of the markers between the
culture groups or between the induced and non-induced controls, suggesting that there
may have been limited chondrogenic differentiation under the conditions in the current
study (Figure 3.7)
Consistent with this interpretation, there was inconsistent expression of the mature
cartilage markers COL2 and ACAN, with no expression observed in some of the groups
for some cell donors. However, toluidine blue staining did show qualitatively more
intense purple/blue staining for GAGs in the induced samples compared to the noninduced controls, suggesting that there was at least a low level of differentiation (Figure
3.7B). Notably, the staining also demonstrated that the DAT and DCT pellets were larger
than the baseline samples, which is likely attributed to the incorporation of ECM
fragments from the digested microcarriers. Moreover, the qualitatively more intense
staining visualized in the samples extracted from the DCT microcarriers as compared to
the DAT microcarriers may have been related at least in part to the higher sGAG content
in the DCT microcarriers.
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Figure 3.7: Analysis of chondrogenic gene expression suggested there was a low level
of differentiation in all groups under the conditions in the current study. The ASCs
were enzymatically extracted from the microcarriers after 2 weeks of culture in
proliferation medium within the stirred bioreactor system and cultured as 3D pellets for
an additional 28 days in chondrogenic differentiation medium (induced) or proliferation
medium (non-induced). (A) Chondrogenic differentiation at 28 days post-induction was
assessed by RT-qPCR. There were no statistically significant differences in the
expression levels for the hASCs expanded on the DAT and DCT in comparison to the
baseline hASCs (n=3 pellets/trial, N=3 trials with different cell donors). (B) Toluidine
blue staining for GAG in the induced and non-induced pellet cultures at day 28.
Qualitatively, there was more intense blue/purple staining in the induced samples as
compared to the non-induced controls. The DAT and DCT pellets were visibly larger due
to the incorporation of ECM debris from the microcarriers generated during enzymatic
cell extraction. The microcarrier-sourced ECM may have contributed to the positive
staining for GAG in the non-induced pellets in the DCT group, as well as the
qualitatively more intense staining in the induced DCT group relative to the DAT and
baseline samples. Scale bar = 100 μm.
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3.5 Discussion
The 3D microenvironment plays an important role in mediating cell function both in vitro
and in vivo and ECM-derived biomaterials have the potential to be cell-instructive
platforms that can direct cellular functions including proliferation, differentiation, and
paracrine activity [92]. Building on these concepts, the primary aim of the present study
was to investigate the effects of ECM composition on hASCs expanded on our novel
ECM-derived microcarriers under proliferation conditions within spinner flasks. The
DAT and DCT microcarriers were biomechanically similar but biochemically distinct,
with the DCT microcarriers containing significantly more sGAG and elastin, as expected
based on the starting tissue source [303]. Within the ECM, GAGs have multiple roles
including providing structural support, while elastin confers stretch, flexibility, and
strength to tissues [31], [304], [305]. These factors likely contributed to the lower
concentration of DCT required to match the mechanical properties of the DAT
microcarriers.
Importantly, both microcarrier types supported cellular attachment and growth over
2 weeks in culture within the spinner flasks. In contrast to previous studies that have
shown cell adhesion is limited within intact decellularized cartilage due to the dense
ECM network and anti-adhesive properties of proteoglycans [107], [306], [307], initial
cell attachment was qualitatively higher on the DCT microcarriers as compared to the
DAT microcarriers. Further, the findings suggested this contributed to the significantly
higher cell densities observed in the DCT group at 7 and 14 days. Differences in the
surface structure or topography [308], or potentially differences in the ECM composition,
may have altered early adhesion to the microcarriers. Notably, the PCR array indicated
that CD44 expression was upregulated in both microcarrier groups, and the higher sGAG
content within the DCT microcarriers may have been favorable for promoting cell-ECM
interactions via this receptor [309].
Under proliferation conditions, MSCs express low levels of the master transcription
factors PPARγ, RUNX2, and SOX9, which cross-regulate each other to maintain the
undifferentiated state [180]. The PCR array data also suggested that culturing on the DCT
microcarriers may have predisposed the hASCs towards the chondrogenic lineage, based
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on exclusive upregulation of SOX9, along with higher levels of expression of other
chondrogenic markers. These findings were corroborated by the proteomics data, which
showed that a number of proteins associated with cartilage development and the ECM of
elastic cartilage were upregulated in the hASCs expanded on the DCT microcarriers as
compared to the DAT microcarriers. For example, ACAN, the main proteoglycan found
within cartilage, was enhanced on the DCT microcarriers. A study performed by
Sutherland et al. reported similar chondro-inductive effects of integrating decellularized
or devitalized cartilage particles in pellet cultures of rat bone marrow-derived MSCs,
with ECM incorporation enhancing expression of aggrecan and collagen II under
proliferation conditions [310]. Other matrix proteins enhanced in the hASCs on the DCT
microcarriers included CHAD, implicated in the early chondrogenesis of MSCs [311] and
MATN3, an ECM component

essential for cartilage development [312], [313].

Interestingly, MATN3 has been shown to have potent chondrogenic effects on hASC
spheroids [313]. In addition, markers associated with elastic cartilage ECM were also
enhanced in the hASCs cultured on the DCT microcarriers, including FBN1, FBN2, and
EMLIN1 [299], [314], which may suggest that the auricular cartilage source could be
promoting differentiation towards an elastic chondrocyte phenotype. In the future, it
would be interesting to compare the effects of culturing on DCT microcarriers fabricated
from other cartilage sources, including hyaline or fibro-cartilage tissues, to assess
whether the cartilage type would alter the cartilage ECM expression profile.
Our findings in terms of the lack of upregulation of adipogenic markers in the hASCs
cultured on the DAT microcarriers are in contrast to our previous work with
microcarriers fabricated from pepsin-digested DAT, which indicated that the
microcarriers had adipo-inductive effects on adipogenic gene expression and GPDH
enzyme activity, with low levels of intracellular lipid accumulation observed under
proliferation conditions [202]. Possible reasons for these differences include variations
in: (i) the microcarrier composition and structure due to the varying enzymatic digestion
and microcarrier synthesis methods used, (ii) the stirring rate (15 rpm versus 25 rpm in
the current study), and (iii) the culture period (3-4 weeks versus 2 weeks). Future work
should explore the effects of the dynamic culture conditions in more detail, to see if
similar pro-adipogenic effects may be observed at later timepoints. Having a platform for
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hASC expansion that does not pre-dispose the cells towards a specific lineage may be
favorable for some applications, while for others it may be desirable to try to harness the
combined effects of the ECM and the dynamic culture microenvironment to direct
lineage-specific differentiation.
In addition to the differentiation markers, the PCR array and proteomics data indicated
that dynamic culture on the ECM-derived microcarriers altered the expression of a range
of markers associated with cell adhesion and ECM remodeling relative to baseline hASCs
prior to microcarrier seeding. These differences may be attributed to the ECM substrate
and/or to the dynamic culture conditions [315], and the inability to decouple these effects
is a limitation of the current study design. In terms of cell adhesion molecules, the
proteomics data indicated that the expression of the integrin α1 subunit (ITGA1) and
endoglin (CD105) were both reduced in the hASCs cultured dynamically on the
microcarriers. Our results align with a previous study by Frith et al., which showed
decreased CD105 expression in human bone marrow-derived MSCs cultured in
aggregates within rotating wall vessels and spinner flasks [232]. Similarly, flow
cytometry data indicated there was a trend for reduced expression of CD105 and CD29
(integrin b1) in our previous study characterizing the hASCs expanded on the DAT
microcarriers over 3 weeks within spinner flasks [128]. Interestingly, Mina et al. showed
reduced ITGA1 expression in human umbilical vein endothelial cells (HUVECs) when
cultured under low shear conditions within a microfluidic device within collagen gels
compared to static conditions [316], which suggests that the dynamic culture conditions
may be the key mediating factor. Upregulated markers associated with ECM remodeling
in the microcarrier groups include members of the TGF-β super family, which play
important roles in tissue repair and remodeling [293], as well as proteases including
MMPs [294], cathepsin K, HTRA1, and FAP involved in ECM degradation [317]. The
proteomics data also indicated that the small leucine-rich proteoglycans (SLRPs) decorin
and lumican were both upregulated in the dynamic culture groups. Decorin and lumican
have demonstrated roles in collagen fibrillogenesis [318], [319], although decorin can
also affect multiple cellular functions including differentiation, proliferation, migration,
and cell spreading [320]. In general, our findings are consistent with the fact that
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culturing MSCs on ECM substrates promotes scaffold remodeling, which may be further
augmented by the effects of fluid shear stress experienced by the cells within the spinner
culture system [321], [322].
It is becoming well recognized that the regenerative function of hASCs in vivo is mainly
attributed to their paracrine effects, rather than through long-term engraftment and
differentiation [40]. These secreted paracrine factors allow MSCs to guide tissue
regeneration by exerting immunomodulatory effects and stimulating angiogenesis [323].
Overall, the secretory profile of the hASCs on the DAT and DCT microcarriers was
highly similar, with the exception that IL-8 and PDGFAA were significantly higher in the
conditioned media from the DCT group. Our studies controlled for substrate stiffness, but
there were more cells present on the DCT microcarriers after 2 weeks of culture, and
variations in cell-cell interactions could have altered paracrine factor production [40],
[324]. In addition, while the starting mechanical properties of the microcarriers were
similar, they may have changed differentially over time, as the cells remodeled and
contracted the matrices. Notably, substrate elasticity has been shown to impact IL-8
secretion, with stiffer matrices enhancing its production by MSCs [325], [326], so it
would be interesting to compare the mechanical properties of the cell-seeded
microcarriers at the end of the culture period.
It is well recognized that the differentiation potential of MSCs decreases through
passaging and expansion on 2D TCPS [302], [327]. Based on previous studies, it is
possible that both compliant substrates [328] and dynamic culture can modulate the
capacity of MSCs to differentiate [329]. Interestingly, the PCR array indicated that gene
expression of nerve growth factor receptor (NGFR) was enhanced in both microcarrier
groups after 2 weeks in dynamic culture in comparison to baseline, which has previously
been associated with higher clonogenic and differentiation potential in hASCs [330]. In
general, the findings in the current study indicate that the adipogenic and chondrogenic
differentiation capacities of the hASCs in both microcarrier groups were similar to the
cells at baseline, despite the cells having undergone expansion. One notable difference in
the adipogenic study was that dynamic culture on the microcarriers qualitatively appeared
to have a positive effect on lipid accumulation at 7 days post-induction of differentiation,
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which should be explored further in future work. In the chondrogenic studies, a low level
of differentiation was observed in all groups. While the current data suggests that the
DCT microcarriers may have chondro-inductive effects on the hASCs during expansion,
the exploration of alternative cell sources for this lineage may be warranted. For example,
numerous studies have shown that human bone marrow-derived MSCs have a higher
chondrogenic differentiation capacity than donor-matched hASCs [331]–[334].
Alternatively, induced pluripotent stem cells (iPSCs) may be another promising cell
source based on previous work showing enhanced sGAG production, with lower levels of
hypertrophic marker expression, as compared to human bone marrow-derived MSCs
[335]. Moreover, it would be worthwhile to explore changes in gene expression over time
in future work, to gain a better understanding of the differentiation process, as variations
between the groups may be observed at earlier or later timepoints [336], [337].

3.6 Conclusion
In conclusion, this study demonstrates the promising application of our novel
ECM-derived microcarriers as 3D dynamic hASC expansion platforms and the flexibility
of our fabrication process to be applied to an additional ECM source. The studies in the
current paper confirmed hASCs could be dynamically expanded with similar population
fold changes on both DAT and DCT microcarriers. Additionally, dynamic culture
irrespective of ECM source altered the expression of genes and proteins associated with
cell adhesion and ECM remodeling in comparison to hASCs prior to dynamic culture.
Further, the qPCR array and proteomics data suggested that culturing on the DCT
microcarriers may have predisposed the hASCs towards the chondrogenic lineage,
supporting the further investigation of this platform specifically for cartilage regeneration
strategies. Future studies should explore how altering conditions such as the oxygen
tension, stirring rate and culture period within the dynamic culture system influences cell
behaviour by studying the immunophenotype, proliferation, differentiation, and paracrine
secretion compared to hASCs expanded on TCPS. Further, it would be interesting to see
if these culture parameters could help to direct the differentiation of hASCs cultured in
inductive media on the microcarriers within the spinner flask bioreactors. Given that the
microcarriers are cell-supportive and naturally-derived, in vivo testing should also be
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performed to explore their potential as cell delivery vehicles towards the future
development and translation of autologous or allogeneic cell-based therapies.
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Chapter 4
4 The effect of microcarrier composition and dynamic
culture conditions on the adipogenic differentiation of
human adipose derived-stromal cells within spinner flasks
4.1 Abstract
Building on previous work, the goal of this study was to investigate the adipogenic
differentiation of human adipose-derived stromal cells (hASCs) cultured within spinner
flasks on 3-D microcarriers derived from the extracellular matrix (ECM). Recognizing
that both the tissue-specific ECM composition and the dynamic culture conditions may
impact hASC differentiation, the hASC response was compared on microcarriers
comprised of human decellularized adipose tissue (DAT) and porcine decellularized
cartilage tissue (DCT) under varying stirring rates and oxygen tensions. The hASCs were
expanded on the DAT or DCT microcarriers for 2 weeks under proliferation conditions,
and subsequently induced by culturing in adipogenic differentiation medium for an
additional 7 days. Initial studies focused on comparing the effects of the stirring rate by
culturing under 20 rpm or 40 rpm post-induction. Adipogenic gene expression was not
significantly affected by the stirring rate. However, analysis of glycerol-3-phosphatedehydrogenase (GPDH) enzyme activity and intracellular lipid accumulation indicated
that hASC adipogenesis was enhanced on the DAT microcarriers under the 20 rpm
stirring condition. Subsequently, the effects of oxygen tension (~20 % versus 2 % O2)
were explored in samples cultured at 20 rpm. Interestingly, the oxygen tension did not
affect adipogenic gene expression or GPDH enzyme activity, with similar levels observed
in the induced DAT and DCT groups. However, for two out of three of the cell donors
assessed, there was qualitatively enhanced intracellular lipid accumulation in the induced
DAT microcarrier group cultured under ~20 % O2, suggesting that further studies
including a larger number of donors and additional timepoints may be warranted to assess
differences between the groups.
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4.2 Introduction
Currently a variety of bench-scale ex-vivo cell expansion bioreactors are being explored
with the goal of maintaining the proliferative and differentiation capacities of stem or
progenitor cell populations in order to facilitate scale-up and application in clinical cell
therapies [171]. These bioreactors aim to overcome the limitations of expanding cells on
two-dimensional (2D) tissue culture polystyrene (TCPS), which can diminish the
regenerative capacity of these cells. Stirred bioreactor systems are advantageous as they
are easy to setup, allow for homogenous culture conditions with even distribution of
oxygen and nutrients, and parameters such as substrate, stirring rate, and oxygen tension
can be tuned to refine the culture conditions [192]–[196], [215]. Additionally,
microcarriers or other three-dimensional (3D) bioscaffolds can be suspended in these
mixed bioreactor systems to support adherent cell populations and the growth of
mesenchymal stromal cells (MSCs) has been reported to be as high as 20-fold greater
relative to TCPS [338], [339]. Importantly, the multilineage differentiation capacity of
MSCs expanded within these systems can also be maintained relative to pre-expanded
MSCs [52], [267], [340].
Recognizing that both the tissue-specific extracellular matrix (ECM) composition and the
dynamic culture conditions may impact human adipose-derived stromal cell (hASC)
differentiation, in the current study, the hASC response was compared on microcarriers
comprised of human decellularized adipose tissue (DAT) and porcine decellularized
cartilage tissue (DCT) within spinner flasks under varying stirring rates and oxygen
tensions. In previous studies using an array of DAT scaffold formats, including 3D
scaffolds, microcarriers, foams, and hydrogel composites, the adipose-derived ECM has
been shown to have pro-adipogenic effects on hASCs, promoting adipogenic gene and
protein expression, as well as low levels of intracellular lipid accumulation, under
proliferation conditions that would normally suppress adipogenesis [100], [124], [130],
[202]. In contrast, other studies have reported that decellularized cartilage can have
chondro-inductive effects on MSC populations [298]. However, very few studies to date
have performed a head-to-head comparison of ECM-derived scaffolds from varying
tissue sources that have similar structural and biomechanical properties, to be able to
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conclude that the ECM composition has tissue-specific effects in directing MSC
differentiation [92].

As such, the primary hypothesis for this work was that the

adipogenic differentiation of hASCs would be enhanced on the DAT microcarriers
relative to DCT microcarriers, which were designed to be of a similar size range and have
matching mechanical properties.
In terms of the effects of the dynamic culture conditions, the stirring rate selected within
the spinner flask systems will affect the shear forces experienced by the cells, which can
alter their capacity to differentiate [236], [341], [342]. Previous work suggests that fluid
shear stress can have a detrimental effect on the adipogenic differentiation of MSC
populations [231]. Additionally, ASCs reside in a low oxygen environment (3-11 %) in
vivo, and these conditions can be recapitulated in vitro and have the potential to modulate
differentiation [233]. To date, previous studies comparing the effects of 2 and 5 %
oxygen tension on the adipogenic differentiation of hASCs on TCPS have shown that the
differentiation capacity of the cells is reduced compared to cells cultured under
atmospheric conditions [239]. Taken together, the secondary hypothesis for this study is
that the adipogenic differentiation of the hASCs on the DAT microcarriers can be further
enhanced by culturing at a lower stirring rate (20 rpm versus 40 rpm) and under ~20 %
O2 as compared to 2 % O2.

4.3 Methods
4.3.1

Materials

Unless otherwise indicated, all chemical reagents for this work were obtained from
Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada).

4.3.2

Adipose tissue procurement and processing

Human adipose tissue was obtained with informed consent from abdominoplasty or
mammaplasty surgeries conducted at the University Hospital in London, ON, Canada,
with human Research Ethics Board approval from Western University (HSREB#
105426). Fresh adipose tissue was transported on ice in sterile cation-free phosphate
buffered saline (PBS, Wisent Bioproducts) supplemented with 2 % bovine serum albumin
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(BSA, Bio-shop). Human ASC isolations were performed following established methods
within 2 h of collection or frozen at -80 ℃ in a hypotonic solution for downstream
decellularization [100].

Human adipose tissue was decellularized using a 5-day

detergent-free protocol, as described in detail in Section 2.3.2 [100]. Lyophilized DAT
was pooled from 5 donors, minced finely into 1-2 mm3 pieces and cryomilled using
established methods [128] and stored in a desiccator at room temperature (RT) until
further use.

4.3.3

Cartilage tissue procurement and processing

Porcine ears were obtained from the local abattoir and the dermis was removed to obtain
the auricular cartilage. The cartilage was frozen, lyophilized, and cryomilled prior to
decellularization following methods adapted from Xu et al. [272], as described in detail
in Section 3.3.3. Lyophilized DCT was pooled from 5 donors, cryomilled, and stored in a
dessicator at RT until further processing.

4.3.4

Non-chemically crosslinked DAT and DCT microcarrier
fabrication

The milled DAT and DCT were subsequently digested with α-amylase and used to
generate homogenous suspensions following previously-published protocols [128]. As
described in Chapter 3, the DAT suspension was diluted to 35 mg/mL and the DCT
suspension was diluted to 30 mg/mL, to generate tissue-specific microcarriers that had
matching compressive properties. Electrospraying was performed following the detailed
methods in Section 2.3.3, and the resultant microcarriers were gradually rehydrated
through an ethanol series with sterile PBS prior to seeding, as also described in detail in
Section 2.3.3.

4.3.5

ASC seeding, and dynamic culture

Human ASCs were cultured in proliferation medium comprised of Dulbecco’s Modified
Eagle’s medium:Ham’s F12 nutrient mixture (DMEM:Ham’s F12) supplemented with
10 % fetal bovine serum (FBS) (Wisent Bioproducts), and 100 U/mL penicillin and
0.1 mg/mL streptomyocyin (1 % pen-strep) (Life Technologies) [100]. Passage 2 hASCs
were used for all in vitro culture experiments. As described in detail in Section 3.3.6, the
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day before seeding the microcarriers were equilibrated within CELLSPIN flasks in
25 mL of proliferation medium and incubated overnight (37 ℃, 5 % CO2). On the day of
seeding, passage 2 hASCs were trypsin-released from tissue culture polystyrene TCPS
flasks and added to the spinner flask to achieve a density of 25,000 hASCs/mg
microcarriers (dry weight) in 50 mL of media. A previously established 12-h seeding
regimen was followed and the media was topped up to the final working volume of
100 mL. Half of the medium was changed every 5-7 days. The microcarriers were
expanded for 2 weeks at 25 rpm and 37 ℃ and 5 % CO2 in a NuAire CO2 incubator prior
to inducing the spinner flasks for adipogenic differentiation.

4.3.6

Adipogenic differentiation

After the 2-week expansion phase, the microcarriers were rinsed with PBS and divided
into two spinner flasks: one flask was maintained in proliferation medium as a control
and the other was induced with adipogenic differentiation medium comprised of
DMEM:Ham’s F12 supplemented with 33 μm biotin, 17 μm pantothenate, 10 μg/mL
transferrin, 100 nM hydrocortisone, 66 nM human insulin, 1 nM triiodothyronine, and
1% pen-strep, with 0.25 nM isobutylmethylxanthine (IBMX) and 1 μg/mL troglitazone
for the first 3 days [100]. Two studies were performed: (i) to compare the effects of
stirring rate (20 versus 40 rpm) under atmospheric conditions (95 % air/5 % CO2) and (ii)
to compare the effects of oxygen tension (~20 % versus 2 %) using a stirring rate of
20 rpm on the adipogenic differentiation of hASCs on the DAT and DCT microcarriers
within the spinner flasks. For the 2 % oxygen conditions, a Whitley HypOxystation®
H35 was used (2 % O2/93 % N2/5 % CO2). Donor information for all studies can be
found in Supplementary Table C1.

4.3.7

Quantitative RT-PCR analysis

Real-time RT-PCR analysis was conducted to assess the expression of key lineagespecific gene markers for adipogenic differentiation at 7 days after the induction of
adipogenic differentiation. As described in detail Section 3.3.11.3, RNA was extracted
for all samples using PureZOL™ (Bio-Rad, Mississauga, Canada) and purified using the
Aurum™ Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad) following the
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manufacturer’s instructions. cDNA was synthesized using the iScript™ Reverse
Transcription Supermix kit (Bio-Rad) and for RT-qPCR, the samples were prepared
using SsoFast™ EvaGreen® (Bio-Rad; 10 ng cDNA/well). Amplifications were carried
out using a CFX384 Touch™ Real-Time PCR Detection System (Bio-Rad), as previously
described. The data was analyzed by comparative Ct methods using two stable
housekeeping genes (n=3 samples of microcarriers/trial, N=3 trials with different hASC
donors). Human gene-specific primers (Invitrogen) were designed and are presented in
Table 4.4.
Table 4.4 Human gene-specific primers
Lineage
Adipogenesis

a

Gene
PPARγ
CEBPα
LPL
PLIN
ADIPOQ
LEP
GAPDHa
IPO8a

Description
Peroxisome proliferator-activated receptor gamma
CCAAT/enhancer-binding protein alpha
Lipoprotein lipase
Perilipin
Adiponectin
Leptin
Glyceraldehdye-3-phosphate dehydrogenase
Importin 8

Product No.
NM_138712
NM_004364
M15856
NM_002666.5
NM_004797.3
NM_000230
NM_002046
NM_006390.3

Housekeeping genes selected for each lineage using the BioRad reference gene panel

4.3.8

GPDH Activity Assay

After 7 days of culture in either adipogenic or proliferation medium, the adipogenic
differentiation of the hASCs cultured dynamically on the DAT or DCT microcarriers was
quantitatively assessed using the glycerol-3-phosphate dehydrogenase (GPDH) Activity
Measurement Kit (Kamiya Biomedical Inc., Cat. # KT-010, Seattle, WA, USA), with
normalization to the total intracellular protein content measured using the BioRad Protein
Assay according to established methods (n=3 samples of microcarriers/trial, N=3 trials
with different hASC donors) [100].

4.3.9

Visualization of intracellular lipid accumulation

The lipophilic fluorophore BODIPY™ 493/503 (ThermoFisher Scientific) was used to
assess intracellular lipid accumulation in both the induced and non-induced controls as a
qualitative indicator of adipogenesis at 7 days following the induction of differentiation.
Samples of the hASC-seeded microcarriers were rinsed twice with D-PBS prior to being
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stained for 30 min with BODIPY™ (diluted 1:500 in PBS) at 37 ℃ (N=3 trials with
different hASC donors). The microcarriers were rinsed with PBS and fixed with 4 %
paraformaldehyde (PFA) for 15 min at RT. After rinsing twice with PBS, the
microcarriers were stored in D-PBS at 4 ℃ prior to imaging with a Zeiss LSM confocal
microscope (Germany).

4.3.10

Statistical Methods

Statistical analyses for all data were performed using linear and nonlinear mixed effects
models with R statistics software (R core team 2017), using the “nlme” package for linear
and nonlinear mixed effects models [257]. Data were compared, correcting for multiple
comparisons as described by Hothorn et al. [258]. Corrected p-values <0.05 were
considered to be statistically significant. GraphPad Prism software version 6 (GraphPad,
La Jolla CA) was used to produce the GPDH graphs and the heat maps were produced
through the Broad Institute Morpheus software [343].

4.4 Results
4.4.1

Adipogenic gene expression analysis comparing 20 versus
40 rpm stirring conditions

The first set of studies focused on assessing the effects of stirring rate on the adipogenic
differentiation of hASCs cultured on the DAT or DCT microcarriers within spinner
flasks. RT-qPCR analysis was used to assess the gene expression levels of PPARγ and
CEBPα as the key transcription factors that regulate adipogenesis, as well as LPL, PLIN1,
and ADIPOQ as mid- to late-stage markers of adipogenic differentiation. Human ASCs
were seeded at low density and cultured on the DAT or DCT microcarriers for 2 weeks at
25 rpm to promote cell expansion, and then the stirring rate was adjusted to 20 or 40 rpm
and the cells were induced using adipogenic differentiation medium for 7 days. A
separate set of samples was maintained in proliferation medium as non-induced controls.
Relative gene expression is presented in the heatmap using the non-induced DCT group
cultured at 40 rpm as the calibrator (Figure 4.1). While there was donor variability in the
magnitude of the response, similar gene expression patterns were observed for all three
cell donors, with higher expression of all markers in the samples that had been cultured in
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adipogenic differentiation medium for 7 days. No statistical differences were observed
between the induced or non-induced conditions, in addition to no significant differences
between the groups within each media condition.

Figure 4.1: hASCs cultured within the spinner flasks on DAT or DCT microcarriers
at either 20 or 40 rpm showed similar patterns of adipogenic gene expression.
Human ASCs were expanded on the DAT and DCT microcarriers for 2 weeks and either
induced in adipogenic differentiation medium (induced) or maintained in proliferation
medium as a control (non-induced) for an additional 7 days of culture. Data were
analyzed using the delta delta Ct method with normalization to the geometric mean of the
stable housekeeping genes GAPDH and IPO8, using the DCT 40 rpm non-induced
samples as the calibrator. Data is presented in a heatmap, with each row being scaled
independently. (n=3 samples of microcarriers/trial, N=3 trials with different hASC
donors).
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4.4.2

The effects of culturing at 20 versus 40 rpm on adipogenic
enzyme activity and intracellular lipid accumulation

GPDH enzyme activity was used to further assess hASC adipogenic differentiation on the
DAT or DCT microcarriers cultured in the spinner flasks at either 20 or 40 rpm (Figure
4.2A). Interestingly, GPDH activity was significantly affected by the stirring rate, with
the DAT 20 rpm induced conditions showing significantly enhanced GPDH enzyme
activity as compared to the DAT and DCT 40 rpm induced conditions, as well as the
DCT 20 rpm induced condition. Additionally, the DAT 20 rpm and 40 rpm induced
conditions showed significantly more GPDH activity compared to their respective
non-induced conditions. These results were further confirmed by staining for neutral
lipids using BODIPY™. Qualitatively, the hASCs cultured on the DAT microcarriers at
20 rpm in adipogenic differentiation medium had more intracellular lipid accumulation
compared to all other conditions, with the cells having a multilocular phenotype (Figure
4.2B). This trend was consistent across all three cell donors. Based on the GPDH activity
and intracellular lipid accumulation, the 20-rpm stirring rate was selected for the next set
of studies probing the effects of oxygen tension.
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Figure 4.2: Adipogenesis measured through GPDH enzyme activity and lipid
accumulation was enhanced on the DAT microcarriers at 20 rpm (A) GPDH enzyme
activity levels were significantly higher for hASCs cultured on DAT microcarriers at
20 rpm compared to all other induced groups (n=3 microcarrier samples/trial, N=3 trials
with different hASC donors). Additionally, DAT 20 rpm and 40 rpm induced conditions
had significantly greater GPDH enzyme activity compared to their respective noninduced conditions (***p<0.001, **p<0.01, *p<0.05). (B) Intracellular lipid
accumulation corroborated the GPDH results, showing qualitatively more lipid droplets
within the 20 rpm DAT condition compared to all other groups. Scale bar = 40 μm.
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4.4.3

Adipogenic gene expression analysis comparing the effects
of culturing under ~20 % versus 2 % O2

In the second set of studies, following the 2-week expansion phase, the media was
replaced with adipogenic differentiation medium or fresh proliferation medium as a
control, and the samples were cultured for an additional 7 days at 20 rpm under ~20 % O2
or 2 % O2 to probe the effects of oxygen tension on the adipogenic differentiation of the
hASCs on the DAT or DCT microcarriers. Relative gene expression is presented in the
heatmap using the non-induced DCT group cultured under 2 % O2 as the calibrator
(Figure 4.3). There were no significant differences observed, including between the
induced and non-induced conditions, likely due to the donor variability in the magnitude
of the response. However, similar patterns were observed for all three donors, showing a
trend for higher expression in the induced as compared to the non-induced conditions.
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Figure 4.3: hASCs cultured within the spinner flasks on DAT or DCT microcarriers
at either ~20 % or 2 % O2 showed similar patterns of adipogenic gene expression.
Human ASCs were expanded on the DAT and DCT microcarriers for 2 weeks and either
induced in adipogenic differentiation medium (induced) or maintained in proliferation
media (non-induced) for an additional 7 days of culture. Data were analyzed using the
delta delta Ct method with normalization to the geometric mean of the stable
housekeeping genes GAPDH and IPO8, using the non-induced DCT 2 % O2 group as the
calibrator. Data is presented in a heatmap, with each row being scaled independently.
(n=3 samples of microcarriers/trial, N=3 trials with different hASC donors).
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4.4.4

The effects of culturing at ~20 % versus 2 % O2 on
adipogenic enzyme activity and intracellular lipid
accumulation

Similar to the gene expression findings, the GPDH enzyme activity levels were not
significantly affected by the oxygen tensions explored under the conditions in the current
study (Figure 4.4A). Notably, there was marked donor variability observed in the GPDH
levels, and further studies using a larger number of donors may be warranted. Staining of
intracellular lipid using BODIPY™ revealed that for 2 out of 3 of the cell donors, the
hASCs cultured in adipogenic differentiation medium on the DAT microcarriers under
~20 % O2 had qualitatively enhanced lipid accumulation compared to all other conditions
(Figure 4.4B). In general, for these two donors, qualitatively higher levels of lipid were
observed on the induced DAT microcarriers as compared to the induced DCT
microcarriers. Interestingly, lipid accumulation was also observed in the non-induced
samples, at qualitatively higher levels in the DAT groups as compared to the DCT,
suggesting a possible donor-dependent adipo-inductive effect of the DAT. For the third
cell donor, there was more comparable lipid accumulation across all the groups under the
induced conditions (Supplementary Figure C1).
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Figure 4.4: Lipid accumulation was qualitatively enhanced under 20 % O2, but
oxygen tension did not affect GPDH enzyme activity. (A) No significant differences
were observed in GPDH activity between any of the groups for ~20 % versus 2 % oxygen
conditions (n=3 samples of microcarriers/trial, N=3 trials with different hASC donors).
(B) Qualitatively enhanced intracellular lipid accumulation was observed in the induced
DAT microcarrier group cultured under ~20 % O2.
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4.5 Discussion
Recapitulating the native cellular microenvironment through the combination of
biomaterials and dynamic culture is an attractive approach to improve tissue regeneration
strategies. Recognizing the importance of the ECM in directing cellular function, this
study investigated the impact of both the ECM composition and dynamic culture
parameters on the adipogenic differentiation of hASCs cultured on ECM-derived
microcarriers within spinner flasks. More specifically, building on the investigation of the
DAT versus DCT microcarriers as an hASC expansion platform in the previous chapter,
the current study explored these two microcarrier types as an in vitro differentiation
platform. In addition to testing the hypothesis that hASC adipogenesis would be
enhanced on the tissue-specific, adipose-derived microcarriers, a secondary goal was to
probe the effects of stirring rate and oxygen tension on the adipogenic differentiation of
the hASCs on the microcarriers.
Dynamic culture has been shown to have advantages in the field of biomaterials
research, by providing better nutrient delivery for cells in 3-D matrices and thus
enhancing general cell survival [6]. When assessing the differentiation capacity of hASCs
in dynamic culture, chondrogenesis and osteogenesis have been the primary areas of
study [6], [340], [344]–[346]. Limited research has been conducted on the effects of
dynamic culture on the adipogenic differentiation of MSCs. A study by Gerlach et al.
used a hollow fiber bioreactor to expand hASCs for 2 weeks prior to a 6-week culture
period in adipogenic differentiation medium compared to hASCs grown on 2D TCPS
[342]. Interestingly, the hASCs cultured in the bioreactor appeared to have more
unilocular morphologies consistent with mature adipocytes compared to the hASCs in 2D
culture [342]. Another study by O’Donnell et al. used a perfusion bioreactor system to
dynamically culture hASCs within gelatin methacrylate hydrogels in either adipogenic or
proliferation media. A perfusion rate of 5 μL/min was used for 28 days, and static 3D and
monolayer controls were included [231]. Notably the gene expression levels of the
adipogenic markers ADIPOQ, FABP4, PLIN1, and LPL were decreased in the samples
cultured under dynamic conditions as compared to both the monolayer and static 3D
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controls [231], suggesting that perfusion had a negative effect on adipogenic
differentiation.
In our current study, the microcarriers were stirred at 25 rpm for 2 weeks and at the time
of induction, the stirring rate was adjusted to either 20 rpm or 40 rpm. By changing the
stirring rate, the shear forces experienced by the hASCs would be altered. A study
performed by Ismadi et al. used Particle Image Velocimetry (PIV) to study the stresses
and vorticity associated with the flow within a spinner flask and a linear correlation
between stirring rate and shear stress magnitude was reported [347]. Although a similar
relationship may be expected in the current study, differences in the microcarrier
properties and specific spinner culture systems used could influence the results. As such,
it would be worthwhile in future work to develop computational models to more
accurately predict the shear forces experienced within our system.
After 7 days of culture in differentiation medium, adipogenic gene expression, GPDH
enzyme activity, and BODIPY™ staining of intracellular lipid were used to assess hASC
adipogenic differentiation levels. In comparing the results of the stirring rate and oxygen
tension trials, the data clearly supports that the adipogenic differentiation of the hASCs
was enhanced when the cells were cultured at 20 rpm on the DAT microcarriers as
compared to the DCT microcarriers based on analysis of intracellular lipid accumulation,
which is the most definitive marker of adipocytes. Despite the short culture period
following induction, a high level of lipid accumulation was observed in the hASCs on the
DAT microcarriers cultured in adipogenic differentiation media, with the cells having a
multilocular phenotype that is consistent with immature adipocytes in the process of
differentiation [348]. These findings strengthen the interpretation that DAT scaffolds
provide a pro-adipogenic microenvironment for hASCs [100], [202], [253], and support
the rationale of applying tissue-specific ECM in the development of platforms for MSC
differentiation.
Interestingly, stirring rate did not have an impact on adipogenic gene expression on either
the DAT or DCT microcarriers cultured in adipogenic differentiation medium. However,
when the hASCs were cultured on the DAT microcarriers at 20 rpm, the GPDH enzyme
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activity was significantly increased, and intracellular lipid accumulation was qualitatively
enhanced. In a study performed by Choi et al. fluid shear stress of 1 Pa was applied at a
frequency of 1 Hz for 1 h on day 0, day 3 (indicating early stage of differentiation
induction), and day 5 (indicating the maturation period) in cultures of the pre-adipocyte
3T3-L1 cell line cultured in adipogenic medium [349]. The relative triglyceride content
was quantified and was significantly reduced when the shear was applied at day 5
compared to all other timepoints, which was corroborated with oil red O staining showing
reduced lipid accumulation in this group. These findings suggest that fluid shear stress
can have a negative impact on the maturation of pre-adipocytes into adipocytes, which
may be relevant in the context of MSC research. Building from the current work, it would
be interesting to analyze adipogenic marker expression at additional timepoints to see if
there are greater differences in marker expression during the early or later stages of
differentiation.
The second phase of the study focused on characterizing the effects of oxygen tension on
the adipogenic differentiation of the hASCs on the microcarriers, by comparing the
response when cultured under ~20 % versus 2 % O2. In vivo, adipocytes reside in an
environment with 3-11 % O2, thus it is of interest to study the effects of more
physiological oxygen tension levels within in vitro culture systems [236]. While no
significant differences were observed in adipogenic gene expression or GPDH enzyme
activity between the induced DAT versus DCT microcarriers cultured under ~20 % or
2% O2, for 2 out of the 3 donors studied, qualitatively more intracellular lipid
accumulation was observed in the induced hASCs cultured on the DAT microcarriers
under ~20 % O2 as compared to 2 % O2, as well as both of the DCT microcarrier groups,
suggesting that the combination of the DAT and the higher oxygen tension was favorable
for adipocyte maturation. Other studies have reported that hASCs cultured under 2 or
5 % O2 on TCPS show reduced PPARγ, LPL, and FABP4 expression, after 21 days in
culture, consistent with impaired adipogenesis [237], [239]. Schiller et al. also reported
reduced GPDH enzyme activity under 5 % oxygen tension, although this was not
significant until 21 days post-induction [239]. In general, these findings support
extending our studies to include later timepoints, as well as additional donors.
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Interestingly, it was observed that the DAT microcarriers had adipo-inductive effects on
the hASCs, with lipid accumulation occurring in the non-induced controls maintained in
proliferation medium that would normally suppress adipogenesis [350]. We have
previously shown that intact DAT scaffolds and our first-generation DAT microcarriers
fabricated from pepsin-digested DAT were similarly adipo-inductive, as demonstrated
through increased GPDH activity compared to hASCs grown on TCPS, as well as low
levels of lipid accumulation under non-induced conditions [100], [227]. However, the
magnitude of this effect was notably donor dependent, as can be observed by comparing
the non-induced controls in the stirring rate and oxygen tension trials. Donor variability
in terms of the adipogenic differentiation capacity of hASCs is well recognized, with
factors including age, body mass index (BMI), sex, health status, and tissue depot
affecting the cellular response [189], [351]. As such, further studies specifically exploring
the adipo-inductive effects of the DAT microcarriers including a larger number of donors
are warranted.
A limitation of the study design is that it would be expected that the cell density would be
higher on the DCT microcarriers as compared to the DAT microcarriers at the end of the
2-week expansion phase prior to the induction of differentiation. Adipogenic
differentiation has been shown to be enhanced when MSCs are cultured at high densities
in both 2D and 3D settings. A study by Ang et al. demonstrated macromolecular
crowding in 3D cultures of bone marrow-derived MSCs enhanced adipogenic
differentiation after 14 days in culture [352]. Previous work done in our lab has also
shown that higher cell densities are favorable for the adipogenic differentiation of hASCs
within methacrylated chondroitin sulphate (MCS)-DAT composite hydrogels based on
GPDH activity and oil red O staining [124]. As such, it is possible that the differences
between the DAT and DCT groups would have been greater if the cell density on the
microcarriers was the same at the time of adipogenic induction.

4.6 Conclusions
In conclusion, recognizing the effect of tissue-specific ECM on hASC differentiation, the
hASC response was compared on microcarriers comprised of human DAT and DCT
under varying stirring rates and oxygen tensions. Adipogenic gene expression was not
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significantly affected by the stirring rate or oxygen tension. However, analysis of GPDH
enzyme activity and intracellular lipid accumulation indicated that hASC adipogenesis
was enhanced on the DAT microcarriers under the 20-rpm stirring condition. It would be
recommended that these studies be expanded in the future to include a larger number of
donors, as well as additional timepoints. However, these studies demonstrate the potential
of applying the ECM-derived microcarriers as a dynamic culture platform for the in vitro
differentiation of hASCs towards the adipogenic lineage. The findings generally support
the use of tissue-specific ECM-derived substrates for directing the lineage-specific
differentiation of hASCs and emphasize that the spinner flask culture parameters can also
have a marked effect on hASC differentiation. It would be interesting to study the in vivo
effects of these pre-differentiated adipogenic hASCs when delivered subcutaneously into
pre-clinical mouse or rat models, potentially in combination with MCS hydrogels to
assess the effects on fat formation. This work could be extended to explore the effects of
other ECM sources such as cartilage tissue on the differentiation of induced pluripotent
stem cells or bone marrow-derived stem cells.
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Chapter 5
5 General discussion and conclusions
5.1 General discussion
Cell behaviour is known to be mediated by the extracellular matrix (ECM), a complex
and dynamic network of macromolecules present within all tissues, that is tissue-specific
in terms of its composition and ultrastructure [3], [4]. The ECM provides cues required
for cell survival, proliferation, and differentiation and growing evidence suggests that the
ECM can have distinct tissue-specific effects on stem or progenitor cell proliferation
and/or differentiation [5]. Recognizing the role that the ECM plays in directing cell
function, there is a need to develop three-dimensional (3D) in vitro culture platforms that
can reflect the complexity of the ECM. These biomimetic models may provide a better
understanding of the importance of these cell-ECM interactions and allow for the
development of strategies that harness the innate potential of the ECM to direct cell
function.
Bioreactors are often employed in 3D in vitro cell culture models to provide a dynamic
environment that overcomes static culture limitations with nutrient delivery and waste
removal, which typically occurs within the inner scaffold regions (> 100 - 200 µm from
the surface) [6], [353]. There are numerous bioreactor types, ranging from simple
systems such as spinner flasks to more complex perfusion reactors. Stirred bioreactor
systems allow for homogenous culture conditions with even distribution of oxygen and
nutrients [193]–[196]. Additionally, microcarriers or other 3D bioscaffolds can be
suspended in these mixed bioreactor systems and have shown improvements in the
expansion of mesenchymal stromal cells (MSCs), as well as improved differentiation
towards the adipogenic, chondrogenic, and osteogenic lineages [197]–[203].
Since their development in 1967, microcarriers have been fabricated from a variety of
natural and synthetic materials both within laboratories and commercial settings. When
developing microcarriers for cell expansion, it is important to recognize the critical
impact the cellular microenvironment has on cell attachment, proliferation, and
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Commercially-available microcarriers have been fabricated from a wide-range of
materials such as gelatin, collagen, dextran, or polystyrene, however they lack the
biological complexity of the native ECM, and typically provide a much stiffer substrate
[171]. Although, these materials may be favourable for longevity, substrate elasticity is
known to have effects on cell spreading and shape, which can influence proliferation and
lineage commitment and overall may have detrimental effects on their efficacy for cell
therapies [354], [355].
To address the limitations of current microcarriers, we previously developed novel
microcarriers using human decellularized adipose tissue (DAT) as an ECM source that
were stable in long-term culture without chemical crosslinking or requiring any additives
[128]. Understanding the tissue-specific cell-instructive effects of the ECM in mediating
cellular processes [248], the current work aimed to extend these fabrication methods to
other ECM sources including decellularized dermis, myocardium, and cartilage. A wide
range of studies have reported that tissue-specific ECM-derived scaffolds can promote
the lineage-specific differentiation of stem or progenitor cell populations in vitro [90],
[91]. Our group has shown that a variety of DAT-based scaffolds provide both an adipoconductive and adipo-inductive microenvironment for human adipose-derived stromal
cells (hASCs) by enhancing in vitro differentiation in adipogenic differentiation medium
as well as in proliferation medium, which normally inhibits adipogenesis [100], [128],
[130], [202], [253], [356]. In one study, we found that hASCs cultured on DAT-based
microcarriers compared to gelatin microcarriers cultured in adipogenic differentiation
medium showed enhanced adipogenic gene expression, lipid biosynthetic glycerol-3phosphate-dehydrogenase (GPDH) enzyme activity, and intracellular lipid accumulation
[202]. Further, elevated levels of intracellular lipid accumulation, adipogenic gene and
protein expression were also observed in the non-induced DAT group maintained in
proliferation medium, demonstrating the inductive effects of our DAT platform [202]. In
the context of dermal wound healing, a study by Liu et al. utilized sections of
decellularized porcine dermal tissue seeded with allogeneic murine ASCs and
demonstrated increased in vivo wound closure and re-epithelization at 7 days in a
C57/BL6 mouse cutaneous wound model compared to unseeded scaffolds and
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chondroitin sulphate hydrogels, suggesting that dermal-derived ECM can also have
cell-instructive effects [357]. Furthermore, a study performed by Duan et al. encapsulated
human embryonic stem cells (ESCs) as embryoid bodies into hydrogels containing
varying percentages of porcine heart ECM and observed that higher percentages of ECM
correlated with increased cardiac marker expression [90]. Inductive effects have also
been shown using decellularized cartilage for the culture of stem or progenitor cell
populations [298], [310]. Sutherland et al. integrated decellularized or devitalized
cartilage particles in pellet cultures of rat bone marrow-derived MSCs and the gene
expression of aggrecan and collagen II under proliferation conditions was enhanced
relative to pellet culture without ECM [310].
To fabricate our non-chemically crosslinked ECM-derived microcarriers, we utilize a
unique method of cryomilling, α-amylase digestion and homogenization to generate an
ECM suspension that is easy to electrospray and can be adapted to various starting ECM
sources. Within the biomaterials field, pepsin is the most common enzyme used to digest
ECM, resulting in soluble peptide fragments that can be used to create hydrogels through
thermally-induced gelation or crosslinked into stable constructs [358]–[360]. However,
recent findings have suggested that the choice of ECM processing methods can highly
modify ECM physical and bioactive properties, ultimately affecting the cellular response
[123], [358], [361]. An interesting study by Kusuma et al. compared pepsin digestion,
urea extraction, and acetic acid homogenization methods to fabricate ECM-derived
coatings from decellularized ECM secreted by placental MSCs [358]. Each method
retained proteins of varying molecular weights, resulting in a unique cell response, with
pepsin digestion enhancing metabolic activity, urea extracted ECM enhancing
osteogenesis, and acetic acid homogenization producing negligible bioactive effects
compared to tissue culture polystyrene (TCPS) [358]. Other studies have suggested
pepsin digestion results in ECM hydrogels that are mechanically weak and may not be
stable long-term, and thus this approach is not suitable for the electrospraying of
microcarriers comprised exclusively of ECM [126], [362]. In our digestion approach,
collagen fibrils are preserved providing stability to our materials, as opposed to the
non-specific proteolytic cleavage that occurs when using pepsin [131]. Stability and
bioactivity of the materials generated with this approach has been demonstrated through
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the fabrication of 3-D foams from α-amylase digested DAT and decellularized
myocardial tissue (DMT), which showed tissue-specific inductive effects on directing the
lineage-specific differentiation of hASCs [129], [130].
The decellularization methods utilized to generate ECM-derived scaffolds are an
important first step in the fabrication of these materials. The goal of tissue
decellularization is to remove the immunogenic cellular components while conserving the
complex composition and ultrastructure of the ECM, although it is important to recognize
decellularization will invariably alter these to some degree [82], [102]. All three of our
newly fabricated microcarriers retained relative amounts of collagens, sulphated
glycosaminoglycans (sGAGs), and elastin consistent with the expected trends found
within the native tissues [252], [273]–[275]. Furthermore, our newly-developed cartilage
decellularization protocol conserved 63 % of sGAGs and in comparison to the literature
is comparable or better than most protocols reported, which have been associated with
40-80 % of sGAG loss [122], [123], [363]. Another important consideration when using
decellularized tissues as a starting material for synthesizing other ECM scaffold formats
is maintaining the integrity of the collagen network to be able to make robust materials.
Our DMT microcarriers were found to have a less cohesive internal structure through
immunohistochemistry, which could have been a result of our decellularization methods
utilizing sodium deoxycholate that is known to potentially disrupt tissue structures and
denature proteins [97]. It may be worth investigating microcarriers fabricated from a
more concentrated DMT suspension in order to improve both mechanical properties and
internal structure.
Further building from the understanding of the cell-instructive properties of ECM-derived
bioscaffolds, the work presented in this thesis aimed to investigate the potential of
microcarriers as both (i) cell expansion platforms, and (ii) cell differentiation platforms.
Under proliferative conditions, MSCs are typically not committed to any particular
lineage, expressing low levels of PPARγ, RUNX2, and SOX9, which cross-regulate one
other to maintain the undifferentiated state

[180]. Within our platform, DCT

microcarriers promoted the expression of SOX9 and a number of proteins associated with
cartilage development and the ECM of elastic cartilage. As previously mentioned, this is
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consistent with work that has shown an inductive effect of decellularized cartilage [298],
[310]. An interesting finding in Chapter 3 was the lack of upregulation of adipogenic
markers in the hASCs cultured on the DAT microcarriers after 2 weeks in dynamic
culture at 25 rpm. This is in contrast to our previous work mentioned earlier, which
showed the microcarriers generated with pepsin-digested DAT had an adipo-inductive
effect after 3-4 weeks in culture at 15 rpm [202]. However, with further investigation in
Chapter 4, it was found that after the initial 2-week culture phase and adjusting the speed
to 20 rpm for an additional week, donor-dependent adipo-inductive effects were
observed. This reiterates the influence of culture parameters on the response of hASCs.
Depending on the specific application, it may be favourable to have a platform that does
not predispose the cells towards a specific lineage, while on the other hand, in other
strategies it may be desirable to harness the combined effects of the ECM and dynamic
culture to drive lineage-specific differentiation.
It is well recognized that cells sense and respond to the ECM by remodeling the
environment, further demonstrating the dynamic interrelationship between cells and their
surroundings [4]. Culturing MSCs in vitro on ECM substrates has been shown to promote
scaffold remodeling and this may further be augmented by the effects of fluid shear stress
experienced by the cells within the spinner culture system [321], [322]. Our PCR and
proteomics findings indicate that the dynamic culture of hASCs on both the DAT and
DCT microcarriers altered the expression of a range of markers associated with cell
adhesion and ECM remodeling relative to hASCs at baseline prior to dynamic seeding. In
terms of cell adhesion molecules, integrin α1 subunit (ITGA1) and endoglin (CD105)
were both reduced in hASCs dynamically cultured on the microcarriers. This is consistent
with previous studies by our lab that showed reduced expression of CD105 through flow
cytometry in hASCs cultured for 3 weeks on DAT microcarriers in spinner flasks [128],
along with the work of Firth et al. who showed similar findings with human bone
marrow-derived MSCs cultured as aggregates for 7 days in spinner flasks or rotating wall
vessels [232]. Furthermore, the expression of ITGA1 has also been reduced under shear
conditions as shown by Mina et al., where human umbilical vein endothelial cells
(HUVECs) were cultured within a microfluidic device within collagen gels under low
shear conditions for 48 h [316]. A number of markers associated with ECM remodeling
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were upregulated in the microcarrier groups in the current study, including members of
the TGF-β family, which have important roles in remodeling and tissue repair [293], and
proteases involved in matrix degradation such as matrix metalloproteinases (MMPs)
[294], cathepsin K, HtrA serine peptidase 1 (HTRA1) and fibroblast activation protein
(FAP) [317]. Further characterization of ECM remodeling could be assessed by
investigating both the biochemical and biomechanical properties of the cell-seeded
microcarriers at the end of the dynamic culture. Additionally, investigating cell
infiltration into the microcarriers through histology at timepoints beyond 2-weeks could
be performed.
Given that the microcarriers are exclusively comprised of ECM and the in vitro work
performed in this thesis yielded promising results in terms of the cell-supportive
characteristics of the various microcarriers, there is potential for their use as injectable
cell delivery platforms. Preliminary in vivo studies were performed and decellularized
dermal tissue (DDT), DMT, and DAT microcarriers were well tolerated within C57/BL6
mice, supporting cell infiltration, with a low density of macrophages found at the
interface with the host tissue and CD31 positive staining revealing endothelial cell
infiltration. Next steps would be to further characterize the host response to the materials
in an immunocompetent model before investigating their potential in combination with
cells. While the size of the microcarriers supported cell attachment and expansion, further
steps would be needed to investigate the effects of injecting the cell-seeded microcarriers
on cell survival, as this would ideally be their form of delivery.

5.2 Future work
The body of work presented in this thesis demonstrates the versatility of our α-amylase
digestion and electrospraying techniques to fabricate microcarriers from a range of
decellularized tissues as ECM sources that are stable without the need for chemical
crosslinking or additives. Furthermore, these microcarriers supported cell attachment and
expansion within spinner flask bioreactors. Future studies could investigate different
starting ECM sources for microcarrier fabrication. In our studies, the DCT microcarriers
were fabricated from auricular cartilage, and markers associated with elastic cartilage
ECM were promoted, such as fibrillin-1 and 2 and elastin microfibril interfacer 1
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(EMLIN1). Building from this, it would be interesting to compare the effects of culturing
on DCT microcarriers fabricated from other cartilage sources, including hyaline or fibrocartilage tissues to assess whether the cartilage type causes changes to the cartilage ECM
expression profile.
Furthermore, results indicated that DCT microcarriers may have predisposed the hASCs
towards the chondrogenic lineage after 2 weeks in dynamic culture, however when
looking at the chondrogenic differentiation of the hASCs extracted from these
microcarriers, no differences were observed. It is possible differences between the DAT
and DCT microcarrier groups would be observed by using another cell source such as
induced pluripotent stem cells (iPSCs) or bone marrow-derived MSCs, which have been
shown to have an improved capacity to differentiate towards the chondrogenic lineage as
compared to ASCs [331]–[335]. These studies could be performed either with cells
extracted from the microcarriers after dynamic culture or with the cells directly on the
microcarriers.
Preliminary in vitro and in vivo testing supported the use of DDT, DMT, and DAT
microcarriers for cell culture platforms and subsequent delivery. Future studies should
expand on this foundation by investigating the cellular response on the DDT and DMT
microcarriers in greater depth, using more quantitative approaches, similar to the more
in-depth studies performed on the DAT and DCT microcarriers. It would also be
interesting to assess whether the tissue-specific ECM could direct the lineage-specific
differentiation of stem or progenitor cell populations within the spinner flask systems.
Furthermore, the proliferation and differentiation of hASCs or other progenitor cell types
could be further augmented by refining the culture parameters by exploring the effects of
oxygen tension, stirring rate and culture period for all of the microcarrier types presented
in this thesis. After refining the culture parameters further to promote differentiation, it
would be interesting to study the in vivo effects of these pre-differentiated hASCs or
progenitor cells when delivered subcutaneously into pre-clinical mouse or rat models,
potentially in combination with methacrylated chondroitin sulphate (MCS) hydrogels to
assess the effects on tissue formation.
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Computational modeling is a powerful tool that can provide insight into various
phenomena. Within our spinner flasks systems, it would be beneficial to have a better
understanding of the shear force distribution, as well as at the forces applied at the
microcarrier surface, to better understand what the cells are experiencing. Additionally, it
would be helpful to understand how the magnitude of these forces changes with increased
or decreased stirring rate.

5.3 Significance
Tying everything together, electrospraying techniques were successfully and easily
adapted to generate tissue-specific microcarriers using 3 new ECM sources –
decellularized dermis, myocardium, and cartilage, which were stable in long-term culture
without chemical crosslinking or requiring structural reinforcement with other materials.
These findings suggest our unique methods could readily be adapted to any tissue that
can be decellularized. Further, our decellularized microcarriers have great potential to be
used as off-the-shelf cell culture and delivery platforms, as they can be stored in the
lyophilized state and rehydrated as needed.
The newly-synthesized DCT microcarriers in addition to the DAT microcarriers
supported the attachment and expansion of hASCs within spinner flasks. The proteomics
work provided an unbiased approach to assess the effects of the combination of
ECM-derived microcarriers and dynamic culture on hASCs. It was interesting to observe
that after 2 weeks in dynamic culture it was suggested that the DAT microcarriers did not
predispose the hASCs towards the adipogenic lineage. In contrast, the gene expression
and proteomics results suggested that culturing on the DCT microcarriers may have
predisposed the hASCs towards the chondrogenic lineage. Overall, the DCT work
supports the further investigation of the ECM-derived microcarriers as tissue-specific
expansion platforms for regenerative cell populations depending on the target application.
Although adipogenic gene expression was not significantly altered in our final studies,
interestingly GPDH enzyme activity and lipid accumulation were enhanced under the
20-rpm stirring condition. The expansion of these studies to include more cell donors and
additional timepoints would help to elucidate the effects of stirring rate and oxygen
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tension. In general, the findings support the use of tissue-specific ECM-derived substrates
for directing lineage-specific differentiation and emphasize that the spinner flask culture
parameters can also be tuned augment hASC differentiation.
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Appendices
Appendix A: Supplementary Data

Supplementary Figure A1: Representative images of tissue-positive controls for the
immunohistochemical staining of the ECM components. Native porcine dermis,
porcine myocardium and human adipose tissue were used as controls and showed the
expected expression of all markers. Scale bar = 200 μm.
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Supplementary Figure A2: Higher magnification SEM images showing the
ultrastructure of the DAT, DLV, and DDT microcarriers synthesized with varying
ECM suspension concentrations. Scale bar = 20 μm.
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Appendix B: Supplementary Data
Supplementary Table B1: Donor list for all studies
Donor Gender Age BMI Anatomical location
1

Female 50

56

abdomen

2

Female 26

26.8

abdomen

3

Female 39

29.9

abdomen

4

Female 49

28.5

breast

5

Female 47

26.8

breast

6

Female 37

28.8

breast

7

Female 40

29

abdomen
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Supplementary Table B2: Complete list of the genes included on the human
mesenchymal stem cell qPCR array (STEMCELL™ Technologies)
Genes of Interest
PPARG
RHOA
CEBPA
CEBPB
HAT1
ITGAX
MMP13
CSPG4
SP7
BGLAP

COL1A1
FGF10
HDAC1
PTK2
SMURF2
RUNX2
BMP4
TGFB1
MSX2
BMP2

PRRX1
CTNNB1
EGF
HGF
ICAM1
IGF1
IL1B
IL6
ITGB1
MMP2

NES
NUDT6
PTPRC
TNF
VEGFA
VIM
SMAD4
HIC1
TWIST2
ANPEP

CASP3
CD44
ENG
FUT4
FZD9
ITGA6
ITGAV
MCAM
NGFR
NT5E

PDGFRB
THY1
VCAM1
COL10A1
FGF18
DLX2
DLX5
PDGFRA
FGF2
LIF

GDF5
LEPR
KAT2B
SOX9
ACAN
ALPL
SMURF1
TBX5
FGF9
TGFB3

BMP6
MSX1
KITLG
SLC17A5
JAG1
NOTCH1
GDF15
ERBB2
BDNF
CD200

COL2A1
IBSP
BMP7
KDR
IFNG
IL10
VWF
PROM1
SOX2
TERT

Housekeeping
Genes
GAPDH
RN18S1
ACTB
UBC
TBP
Positive Control
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Supplementary Table B3: Complete summary of Human MSC qPCR Array results for
the hASCs expanded on the DAT microcarriers for 2 weeks versus baseline comparison.
Genes significantly upregulated relative to the baseline condition are shown in green, and
those significantly downregulated are shown in red.
Gene

Fold
Change

Numerator
DF

Denominator
DF

F Value

P Value

False Discovery

NGFR

26.424

1

3

6.046

0.091

0.133

HGF

10.555

1

2

15.700

0.058

0.115

SOX9

8.515

1

3

8.926

0.058

0.115

NES

6.095

1

3

11.445

0.043

0.115

GDF5

5.869

1

3

20.803

0.020

0.115

NUDT6

5.402

1

3

8.788

0.059

0.115

NOTCH1

4.739

1

2

17.143

0.054

0.115

CSPG4

4.647

1

2

10.319

0.085

0.127

FUT4

4.520

1

3

12.647

0.038

0.115

RUNX2

4.067

1

3

10.739

0.047

0.115

TBX5

3.663

1

3

7.416

0.072

0.115

CD44

3.595

1

3

21.872

0.018

0.115

HIC1

3.403

1

3

9.068

0.057

0.115

PPARG

3.327

1

3

11.237

0.044

0.115

MMP2

3.294

1

3

14.211

0.033

0.115

CEBPB

3.115

1

3

5.453

0.102

0.140

PRRX1

2.698

1

3

37.232

0.009

0.115

PDGFRA

2.659

1

3

8.017

0.066

0.115

SLC17A5

2.530

1

3

17.528

0.025

0.115

ANPEP

2.484

1

3

32.975

0.010

0.115

ALPL

2.336

1

3

13.901

0.034

0.115

HAT1

2.304

1

2

12.241

0.073

0.115

THY1

2.037

1

3

144.950

0.001

0.063

KITLG

2.027

1

2

13.236

0.068

0.115

TGFB1

1.984

1

3

7.620

0.070

0.115

PTK2

1.927

1

3

8.309

0.063

0.115

ITGAV

1.741

1

3

12.033

0.040

0.115

TGFB3

1.709

1

3

9.018

0.058

0.115

ERBB2

1.657

1

3

11.219

0.044

0.115

CTNNB1

1.367

1

3

9.111

0.057

0.115
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SMAD4

0.675

1

2

8.933

0.096

0.136

CASP3

0.635

1

2

16.860

0.055

0.115

CD200

0.583

1

3

15.115

0.030

0.115

JAG1

0.474

1

2

19.812

0.047

0.115

BMP6

0.398

1

3

7.232

0.074

0.115

LEPR

0.208

1

3

12.007

0.040

0.115

FGF9

0.112

1

3

7.927

0.067

0.115

VIM

4.279

1

3

3.814

0.146

0.181

KAT2B

2.649

1

2

6.443

0.126

0.165

SMURF1

2.145

1

3

4.129

0.135

0.172

IL6

2.022

1

3

2.984

0.183

0.211

MSX2

1.951

1

3

2.092

0.244

0.265

IGF1

1.859

1

2

6.531

0.125

0.165

NT5E

1.439

1

2

5.105

0.152

0.185

TWIST2

1.159

1

2

0.381

0.600

0.600

VEGFA

1.129

1

2

0.405

0.590

0.600

HDAC1

1.121

1

3

2.921

0.186

0.211

CEBPA

0.844

1

2

2.335

0.266

0.283

ACAN

0.543

1

2

4.623

0.165

0.195

MCAM

0.500

1

2

2.673

0.244

0.265

IL1B

0.150

1

2

1.299

0.372

0.388
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Supplementary Table B4: Complete summary of Human MSC qPCR Array results for
the hASCs expanded on the DCT microcarriers for 2 weeks versus baseline comparison.
Genes significantly upregulated relative to the baseline condition are shown in green, and
those significantly downregulated are shown in red.
Gene

Fold
Change

Numerator
DF

Denominator
DF

F Value

P Value

False Discovery

NGFR

44.747

1

3

58.823

0.005

0.102

COL10A1

13.481

1

3

21.226

0.019

0.123

NES

12.671

1

3

78.205

0.003

0.102

CSPG4

12.350

1

2

31.760

0.030

0.123

SOX9

11.645

1

3

47.083

0.006

0.102

LIF

5.350

1

2

121.603

0.008

0.102

MMP2

4.645

1

3

24.033

0.016

0.123

NOTCH1

3.796

1

3

14.290

0.032

0.123

PDGFRB

3.367

1

2

31.556

0.030

0.123

CD44

2.939

1

3

16.068

0.028

0.123

TGFB3

2.498

1

2

45.846

0.021

0.123

ANPEP

2.050

1

3

23.109

0.017

0.123

ENG

0.525

1

2

24.005

0.039

0.134

CD200

0.401

1

3

34.957

0.010

0.102

BMP6

0.300

1

3

12.016

0.040

0.134

LEPR

0.211

1

3

15.004

0.030

0.123

HGF

13.716

1

2

3.289

0.211

0.273

NUDT6

7.177

1

3

1.896

0.262

0.286

FUT4

7.138

1

2

3.013

0.225

0.282

RUNX2

5.231

1

3

3.851

0.145

0.230

VIM

4.239

1

3

2.271

0.229

0.282

HAT1

4.226

1

2

2.714

0.241

0.284

SLC17A5

3.737

1

3

5.978

0.092

0.193

PPARG

3.417

1

3

4.474

0.125

0.221

HIC1

3.212

1

3

1.879

0.264

0.286

PRRX1

3.067

1

3

4.107

0.136

0.225

CEBPB

2.960

1

3

2.781

0.194

0.262

TBX5

2.888

1

3

7.465

0.072

0.193

ALPL

2.738

1

2

3.691

0.195

0.262

ICAM1

2.738

1

2

3.611

0.198

0.262
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PDGFRA

2.510

1

3

5.302

0.105

0.206

KAT2B

2.388

1

3

7.504

0.071

0.193

GDF5

2.331

1

2

9.084

0.095

0.193

ITGAV

2.266

1

2

2.570

0.250

0.286

THY1

2.263

1

2

6.178

0.131

0.224

PTK2

2.199

1

3

1.929

0.259

0.286

ERBB2

2.085

1

3

5.991

0.092

0.193

IL6

2.040

1

2

1.845

0.307

0.307

TGFB1

1.863

1

2

6.996

0.118

0.221

CTNNB1

1.725

1

3

4.472

0.125

0.221

SMURF1

1.693

1

3

3.186

0.172

0.247

MSX1

1.565

1

2

10.839

0.081

0.193

RHOA

1.563

1

2

2.757

0.239

0.284

KITLG

1.526

1

2

2.174

0.278

0.292

IGF1

1.444

1

3

3.655

0.152

0.230

GDF15

1.125

1

2

1.934

0.299

0.305

COL1A1

0.951

1

2

2.138

0.281

0.292

HDAC1

0.859

1

2

5.251

0.149

0.230

JAG1

0.633

1

3

6.456

0.085

0.193

BDNF

0.629

1

3

8.891

0.059

0.182

SMAD4

0.624

1

2

12.003

0.074

0.193

NT5E

0.605

1

2

4.484

0.168

0.247

CEBPA

0.175

1

2

11.187

0.079

0.193
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Supplementary Figure B1: Gating strategy used to separate live cells from debris
through fluorescence-activated cell sorting. For all panels, cells were identified by
FSC-A and SSC-A parameters, single cells were selected for, and live cells were
identified using calcein. Calcein+ cells are green, calcein- cells are red. Calcein+ single
cell fractions are shown for (A) baseline hASCs cultured on TCPS prior to dynamic
expansion, (B) Unlabeled hASCs, (C) hASCs expanded on DAT microcarriers and (D)
hASCs expanded on DCT microcarriers. Abbreviations: FSC-A: forward scatter area;
SSC-A: side scatter area; SSC-H: side scatter height; FSC-H: forward scatter height;
FSC-W: forward scatter width.
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Supplementary Table B5: Mass Spectrometry Parameters.
Parameters

QE Plus Orbitrap

Mass Range (m/z)
Isolation Window (m/z)
MS Resolution
MSMS Resolution
MS Injection Time (ms)
AGC Target (MS)
AGC (Target MSn)
Preview Scan
Threshold (counts)
Underfill Ratio
Data Dependent Acquisition
Dynamic Exclusion (s)
Exclusion Mass Width (m/z)
Exclude Isotopes/Monoisotopic
Precursor Selection
Fragmentation Type
Normalized Collison Energy
Lock Mass (445.120025m/z)
Charge State Rejection
Default Charge State

400-1450
3.0
35K @ 200 m/z
17.5K
250
1E6
2E5
n/a
50K
3%
Top 15
30
n/a
Enabled
HCD
23
Best
Unassigned and +1
+2
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Supplementary Figure B2: Validation of the decellularization protocol for porcine
auricular cartilage. (A) DAPI staining (blue) of native porcine auricular cartilage prior
to decellularization compared to (B) DAPI staining of milled decellularized cartilage
showing no detectable nuclei present at the end of processing. Scale bar = 100 μm. (C)
PicoGreen® analysis showing a significant reduction in dsDNA content in the DCT
compared to the native tissues (n=3 samples/trial, N=3 trials with different ECM batches)
(**p<0.01). (D) Hydroxyproline assay results showing a significant increase in collagen
content in the DCT compared to the native tissues (n=3 samples/trial, N=3 trials with
different ECM batches) (*p<0.05). (E) DMMB assay results showing no significant
differences in sGAG content between the DCT and native tissues (n=3 samples/trial, N=3
trials with different ECM batches).
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Supplementary Figure B3: Proteomic differences were observed between hASCs
cultured on DAT vs TCPS prior to dynamic culture. A total of 138 proteins were
significantly enriched in the lysates of hASCs grown on DAT microcarriers, whereas 51
proteins were significantly downregulated.
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Supplementary Figure B4: Proteomic differences were observed between hASCs
cultured on DCT vs TCPS prior to dynamic culture. A total of 180 proteins were
significantly enriched in the lysates of hASCs grown on DCT microcarriers, whereas 57
proteins were significantly downregulated.
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Appendix C: Supplementary Data
Supplementary Table C1: Donor list for all studies
Donor
1
2

Gender
Female
Female

Age
26
39

BMI
26.8
29.9

Anatomical location
abdomen
abdomen

Study
20 % v 2 % O2
20 % v 2 % O2

3

Female

34

38.9

breast

Both

4
5
6
7
8

Female
Female
Female
Female
Female

51
50
52
39
38

28.5
23.9
37.5
38.9
31.2

abdomen
abdomen
abdomen
abdomen
breast

20 rpm v 40 rpm
20 rpm v 40 rpm
20 rpm v 40 rpm
20 rpm v 40 rpm
20 rpm v 40 rpm

Assay
GPDH, PCR, BODIPY main body
GPDH, PCR, BODIPY supplemental
GPDH (20 % v 2 % O2), PCR (20 % v 2 %
O2), BODIPY (20 rpm v 40 rpm)
GPDH
GPDH and PCR
GPDH
PCR
PCR
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Supplementary Figure C1: Lipid accumulation was more comparable across the
conditions for one of the three cell donors in the oxygen study. Intracellular lipid
accumulation shown through BODIPY™ was dependent on the donor. Scale bar = 20
μm.
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